approach,library_id,link_type,claim_1_text,claim_2_text,reasoning,claim_id_1,claim_id_2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Both claims concern lithium but at different levels: Claim 1 describes a clinical subgroup (full responders) and the research value of studying them, while Claim 2 describes cellular/molecular mechanisms of lithium action. They address the same topic without repeating, supporting, or contradicting each other, so they are variant perspectives.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,ec67c767-39fb-4ccb-be89-27fd2a97ae56
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 argues that full responders form a distinct and valuable cohort for study, while claim 2 proposes specific mechanisms by which lithium acts. They are related and complementary but do not duplicate, contradict, or serve as direct logical premises for one another.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Both claims concern lithium treatment response but make different, non-conflicting points: claim 1 asserts that full lithium responders are a distinct, valuable group to study; claim 2 reports that genetic predisposition to major depression is associated with poorer lithium response in bipolar disorder. They are related by topic but not duplicate, contradictory, or a direct premise.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,2d5e05cd-d871-42cb-b864-4c444cd9994c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Claim 2 reports a specific empirical association (low major-depression genetic loading predicts ~1.5× better long-term lithium outcomes). That finding is an example of the kind of specific effect/predictor that studying full lithium responders (Claim 1) could uncover, so Claim 2 functions as supporting evidence/premise for Claim 1 rather than a duplicate, variant, or contradiction.",97c81d6e-e353-4dd4-9a45-2c12671217e8,84d6eec7-ac14-4f03-aff5-95b68ad5a314
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Both claims concern lithium responsiveness in bipolar disorder but make different points: Claim 1 argues that full responders form a valuable, distinct group for study; Claim 2 identifies a specific clinical phenotype (predominant manic features) associated with better lithium response. They are related in topic but not duplicates, not contradictory, and Claim 2 is not a direct logical premise for Claim 1.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,4429ac65-e370-4a8f-8b4f-25845d777d97
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Both claims concern lithium treatment response in bipolar disorder but address different aspects: Claim 1 argues that full responders form a distinct, valuable group to study lithium-specific effects, while Claim 2 identifies psychiatric comorbid genetic traits as reducing likelihood of optimal lithium response. They are related and complementary but neither duplicates, directly contradicts, nor serves as a clear logical premise for the other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Both claims concern lithium's effects but address different points: Claim 1 argues that studying full responders is valuable for uncovering lithium-specific effects in those who benefit, while Claim 2 asserts a mechanistic distinction between lithium's antidepressant actions and mechanisms of long-term bipolar response. They are related but neither duplicates, contradicts, nor logically entails the other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,97bdd2dc-de39-4a2f-a3b2-d374fbd202e0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims concern lithium treatment but address different points: Claim 1 argues that full lithium responders form a distinct group valuable for research, while Claim 2 is a clinical recommendation that lithium remain first-line for most bipolar patients. They relate by topic but neither duplicates, directly supports as a premise, nor contradicts the other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium treatment in bipolar disorder but state different, non-conflicting points: claim 1 asserts that full lithium responders are a distinct, valuable study population; claim 2 asserts lithium monotherapy is superior to valproate for preventing relapses. They address different aspects (population/value of study vs comparative efficacy) and neither duplicates, contradicts, nor serves as a direct premise for the other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims concern lithium treatment in bipolar disorder but make different, non-overlapping assertions: Claim 1 states that full lithium responders form a distinct population valuable for study; Claim 2 asserts lithium is superior to carbamazepine for preventing recurrences in BD I and for preventing suicide across bipolar disorder. They do not duplicate, contradict, or serve as premises for one another, but address the same general topic in different ways.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium treatment in bipolar disorder but address different points: claim 1 focuses on the value of studying full responders as a distinct subgroup, while claim 2 asserts lithium's overall efficacy. They are related topical variants, not duplicates, premises, or contradictions.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium treatment in bipolar disorder but address different aspects. Claim 1 argues that full lithium responders are a distinct, valuable population for study; Claim 2 makes a comparative efficacy claim (lithium superior to anticonvulsants for preventing mania). They are related by topic but do not duplicate, contradict, or serve as premises for each other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium treatment for bipolar disorder but make different, non-conflicting points: Claim 1 describes full responders as a distinct, valuable research population; Claim 2 asserts lithium's broad, unique clinical superiority. They are topically related but neither entails, contradicts, nor serves as a direct premise for the other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern effects of lithium treatment but at different levels: Claim 1 is a methodological/clinical statement about the value of studying full responders, while Claim 2 reports a specific neuroanatomical effect of lithium after 8 weeks in bipolar patients. They relate by topic without duplicating, contradicting, or providing a direct premise-conclusion relationship.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern effects of lithium treatment but address different levels: Claim 1 argues that studying full responders is valuable for uncovering lithium-specific effects (a methodological/population point), while Claim 2 reports specific molecular pathways correlated with lithium-induced structural brain changes. They are related by topic but neither duplicates, directly premises, nor contradicts the other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Claim 1 asserts that studying full lithium responders is valuable for uncovering specific effects of lithium. Claim 2 describes a specific mechanistic finding (sphingomyelin pathway associated with symptom improvement mediated by mediodorsal thalamus volume changes) that could be the kind of specific effect discovered by studying such responders. Thus Claim 1 serves as a methodological/empirical premise supporting the plausibility and value of studies producing Claim 2.,84d6eec7-ac14-4f03-aff5-95b68ad5a314,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims concern lithium's effects but address different aspects: Claim 1 argues that studying full responders is valuable as a distinct clinical group, while Claim 2 reports mechanistic findings that lithium engages neurotrophic pathways. Claim 1 does not directly state or logically entail Claim 2, nor do they contradict or duplicate each other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern effects of lithium treatment, but they address different aspects: claim 1 is a methodological/clinical assertion about the value of studying full responders as a distinct population, while claim 2 reports a specific biological finding (structural brain changes correlating with gene expression in neurotrophic/cell‑modeling pathways). They do not duplicate, contradict, or logically entail one another.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.",Claim 1 asserts that studying full lithium responders is a valuable way to uncover lithium-specific effects. Claim 2 proposes a specific lithium-related mechanism (up-regulation of GRIN2A) that such studies could reveal. Thus Claim 1 serves as a premise/rationale supporting the investigation and plausibility of Claim 2.,84d6eec7-ac14-4f03-aff5-95b68ad5a314,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims concern effects of lithium but address different aspects: Claim 1 argues that studying full lithium responders is valuable as a distinct clinical population, while Claim 2 reports lithium's regulation of immune-related pathways. They are related topically but do not restate, support, or contradict each other, so they are variants.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern lithium but address different levels and purposes: Claim 1 argues that studying full clinical responders is valuable for uncovering lithium's specific effects, while Claim 2 states specific cellular mechanisms of lithium. They are related and compatible but neither duplicates, directly contradicts, nor logically entails the other.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but address different aspects: Claim 1 argues for the research value of studying full clinical responders, while Claim 2 proposes specific intracellular mechanisms (GSK3 and IMPase) underlying lithium's effects. They neither duplicate, contradict, nor serve as direct premises for one another.",84d6eec7-ac14-4f03-aff5-95b68ad5a314,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Full responders to lithium represent a unique clinical population whose study has inherent value for uncovering specific effects of lithium treatment in individuals who clearly benefit from it.,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern lithium but at different levels: Claim 1 addresses a clinical population and the value of studying full responders, while Claim 2 asserts a specific molecular mechanism (lithium enhancing autophagy via an mTOR-independent, IP3-related pathway). They do not duplicate or contradict one another, nor is one a direct logical premise of the other, so they are related but different (variant).",84d6eec7-ac14-4f03-aff5-95b68ad5a314,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 1 describes cellular/molecular actions of lithium (modulating signaling nodes such as GSK3, CREB, Na+-K+ ATPase and shifting basal vs stimulated activity) that provide a mechanistic foundation for Claim 2’s assertion that lithium dampens excessive network activity and thereby stabilizes neurons, enhances plasticity/resilience, and affects chronobiology. The claims are complementary (mechanism → therapeutic effects), not duplicate or contradictory.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Both claims concern lithium but at different levels: Claim 1 describes cellular/molecular effects of lithium, while Claim 2 reports a clinical genetic association with lithium treatment response in bipolar disorder. They address related subject matter without contradicting or directly supporting one another, nor is either claim a direct logical premise of the other.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,2d5e05cd-d871-42cb-b864-4c444cd9994c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Both claims concern lithium but at different levels: Claim 1 describes lithium's cellular signaling effects, while Claim 2 addresses a clinical trial outcome (tamoxifen + lithium vs lithium alone). They discuss the same topic without contradicting or providing a direct logical premise for one another.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,2b69a477-3fa3-4a96-9a36-77b58dda0554
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium but at different levels: Claim 1 describes cellular/molecular effects, Claim 2 states clinical efficacy in bipolar disorder. They are related by topic but neither duplicates, contradicts, nor serves as a direct logical premise for the other.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium but at different levels: claim 1 describes cellular/molecular effects, while claim 2 is a clinical efficacy comparison for bipolar disorder. They address related topics (lithium's actions vs clinical outcomes) without contradicting or providing a direct logical premise for one another.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both statements concern lithium but at different levels: Claim 1 describes cellular/molecular effects (mechanisms involving GSK3, CREB, Na+-K+ ATPase), while Claim 2 asserts clinical efficacy and comparative superiority in bipolar disorder. The mechanistic claim does not by itself establish or refute the clinical superiority claim, nor are they duplicates or contradictions, so they are related but distinct (variant).",ec67c767-39fb-4ccb-be89-27fd2a97ae56,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern effects of lithium but at different levels: Claim 1 describes cellular signaling mechanisms (GSK3, CREB, Na+-K+ ATPase), while Claim 2 reports macroscopic neuroimaging/structural changes in bipolar patients after 8 weeks. They relate by topic but do not duplicate, directly contradict, or present a clear logical premise–conclusion relationship.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium's effects on cellular signaling pathways, but they address different aspects: claim 1 describes general modulatory effects and specific regulatory nodes (GSK3, CREB, Na+-K+ ATPase), while claim 2 reports empirical correlations between lithium-induced structural brain changes and specific neurotrophy-related pathways (GDNF family, NFAT, p53). They are related but not equivalent, contradictory, or a direct premise for one another.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Claim 1 enumerates specific signaling targets and effects of lithium (e.g., GSK3, CREB, Na+-K+ ATPase) that represent mechanistic components of neurotrophic molecular pathways; therefore Claim 1 provides supporting mechanistic premises for the broader conclusion in Claim 2 that lithium acts through several neurotrophic pathways.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Claim 1 describes molecular signaling effects of lithium (e.g., via GSK3 and CREB) that regulate gene expression and neurotrophic pathways. Those signaling-level changes provide a plausible mechanistic basis for the gene-expression alterations and consequent structural brain changes reported in Claim 2; Claim 1 does not itself report the structural findings, so it serves as a premise for Claim 2.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern molecular mechanisms relevant to affective disorders and potential treatments, but they focus on different targets and mechanisms (lithium acting on GSK3/CREB/Na+-K+ ATPase vs GRIN2A/NMDA glutamatergic signaling). They do not contradict or entail one another.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern molecular effects of lithium but address different specific targets and implications. Claim 1 describes general signaling effects and key regulatory nodes (GSK3, CREB, Na+-K+ ATPase), while Claim 2 focuses on lithium's up-regulation of GRIN2A and its potential relevance to bipolar disorder. They are related by topic but neither duplicates, contradicts, nor logically premises the other.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims discuss lithium's molecular effects but focus on different aspects: claim 1 describes specific intracellular signaling nodes and bidirectional modulation of activity, while claim 2 emphasizes the systemic (non–cell-type/region-specific) nature of lithium's effects and downplays myelination as a primary target. They are related but not equivalent or contradictory.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims describe lithium's effects on cellular signaling, but they focus on different scopes: claim 1 describes general signaling nodes and directionality (basal vs stimulated) while claim 2 specifies regulation of immune-specific pathways (BCR, TCR, chemokine) and immunoregulatory outcomes. They are related but not equivalent or directly premise/consequence of one another.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern intracellular signaling mechanisms relevant to neuropsychiatric function: claim 1 describes lithium's effects on signaling nodes (GSK3, CREB, Na+-K+ ATPase) while claim 2 implicates PKC in mood regulation and bipolar disorder. They address related topics (signal transduction in mood disorders) but focus on different molecules and do not duplicate, entail, or contradict each other.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern molecular signaling mechanisms relevant to mood/antimanic effects, but they address different specific targets and findings: claim 1 describes lithium's broad effects and key nodes (GSK3, CREB, Na+-K+ ATPase), while claim 2 reports that PKC inhibition yields antimanic-like behaviors in rats. They are related but not equivalent, contradictory, or a direct premise for one another.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,ae3c78a3-aaea-4b95-88c9-0997465c58c7
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern cellular signaling relevant to mood regulation/bipolar disorder, but they focus on different molecular players: claim 1 describes lithium's effects on GSK3, CREB, and Na+-K+ ATPase, while claim 2 attributes a role to PKC. They do not duplicate or contradict each other, nor is one presented as a direct premise for the other.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern cellular signaling mechanisms relevant to mood/antimanic effects, but they address different specific nodes and findings: claim 1 summarizes lithium's multiple signaling targets (GSK3, CREB, Na+-K+ ATPase) and patterns of basal vs stimulated activity, while claim 2 reports that PKC inhibition yields antimanic-like behavioral effects in rats. Neither claim duplicates or logically entails the other, nor do they contradict, so they are related but different (variant).",ec67c767-39fb-4ccb-be89-27fd2a97ae56,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims describe mechanisms underlying antidepressant actions but for different drugs (lithium vs ketamine). They address related biological processes (cell signaling/synaptogenesis and neurotransmission) without repeating, contradicting, or serving as a logical premise for one another.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims describe lithium's effects on cellular processes but emphasize different, complementary aspects. Claim 1 focuses on lithium's modulation of signaling nodes and differential effects on basal versus stimulated activity (e.g., GSK3, CREB, Na+/K+ ATPase). Claim 2 describes lithium's regulatory roles in brain-specific pathways tied to neuroplasticity and neuroprotection (neurotrophic signaling, ER stress/UPR, autophagy, oxidative stress, mitochondria, inflammation). They are related but not equivalent or contradictory, so they are variants.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims discuss lithium's intracellular actions and both cite GSK3 as a key target, but they emphasize different aspects: Claim 1 lists multiple regulatory nodes (GSK3, CREB, Na+-K+ ATPase) and functional effects on basal vs stimulated activity, while Claim 2 proposes that inhibition of GSK3 and IMPase could underlie lithium's broad responses. They overlap but are not equivalent or contradictory.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both statements concern lithium's molecular actions but emphasize different mechanisms. Claim 1 describes broad effects on signaling nodes (GSK3, CREB, Na+-K+ ATPase) and general basal vs stimulated activity changes, while Claim 2 asserts autophagy promotion as the primary neuroprotective mechanism. They are compatible but different emphases rather than duplicates, contradictions, or a clear premise–conclusion relation.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium affects multiple steps in cellular signaling pathways, typically enhancing basal activities while inhibiting stimulated activities, with key regulatory nodes including GSK3, CREB, and Na+-K+ ATPase.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern lithium's effects on cellular signaling but address different, nonconflicting aspects. Claim 1 is a broad overview of multiple regulatory nodes and a general pattern of effects (GSK3, CREB, Na+-K+ ATPase), while Claim 2 describes a specific, mTOR-independent IP3-mediated mechanism for autophagy enhancement. They are related but neither duplicates, contradicts, nor serves clearly as a direct premise for the other.",ec67c767-39fb-4ccb-be89-27fd2a97ae56,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 proposes mechanisms of lithium's therapeutic action, while claim 2 reports an association between genetic depression liability and poorer lithium response. They are related but neither duplicates, contradicts, nor directly premises the other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,2d5e05cd-d871-42cb-b864-4c444cd9994c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Both claims concern lithium treatment in bipolar disorder but address different non-contradictory aspects: claim 1 proposes a neurobiological mechanism of lithium’s therapeutic action, while claim 2 reports a clinical/genetic predictor of long-term response. Neither claim entails or contradicts the other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,97c81d6e-e353-4dd4-9a45-2c12671217e8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Both claims concern lithium in bipolar disorder but address different aspects: Claim 1 describes neurobiological mechanisms of lithium's therapeutic effects, while Claim 2 reports a clinical association between phenotype (predominant mania) and better lithium response. They do not contradict or directly imply one another, so they are related but not equivalent or premises of each other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,4429ac65-e370-4a8f-8b4f-25845d777d97
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Both claims concern lithium treatment in bipolar disorder but address different, non-conflicting aspects: claim 1 describes mechanisms by which lithium acts, while claim 2 asserts that psychiatric comorbid genetic traits reduce likelihood of optimal response. They are related but not equivalent, contradictory, or a direct logical premise of one another.",daf03de6-256f-437d-ba0a-a16ee56bfc87,4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Both claims concern lithium's mechanisms of action but make different, non-conflicting points. Claim 1 describes a general multi-node dampening/stabilizing mechanism underlying lithium's therapeutic effects in bipolar disorder. Claim 2 asserts that lithium's antidepressant mechanisms are specific and distinct from mechanisms mediating long-term treatment response. They address the same topic without duplicating or contradicting each other, so they are variants.",daf03de6-256f-437d-ba0a-a16ee56bfc87,97bdd2dc-de39-4a2f-a3b2-d374fbd202e0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Both claims address molecular mechanisms/treatment of bipolar disorder, but they describe different mechanisms: claim 1 attributes lithium's therapeutic effects to network-level stabilization, plasticity, stress resilience, and chronobiological regulation, while claim 2 implicates protein kinase C more generally. Claim 1 does not state that lithium acts via PKC, so there is relatedness on the topic but not equivalence, contradiction, or a clear premise relationship.",daf03de6-256f-437d-ba0a-a16ee56bfc87,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Both claims concern lithium in bipolar disorder but address different points: Claim 1 describes lithium's proposed mechanisms of action, while Claim 2 reports a clinical efficacy comparison (tamoxifen + lithium vs lithium alone). Claim 1 does not entail, contradict, or serve as a direct premise for Claim 2, so they are related-topics that differ without contradiction.",daf03de6-256f-437d-ba0a-a16ee56bfc87,2b69a477-3fa3-4a96-9a36-77b58dda0554
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Both claims concern treatments for bipolar/manic symptoms but propose different mechanisms. Claim 1 attributes lithium's benefit to broad dampening and stabilization across multiple regulatory nodes, while Claim 2 asserts that direct PKC inhibition yields rapid anti-manic effects. They are related (same clinical domain) but not equivalent, contradictory, or a direct premise of one another.",daf03de6-256f-437d-ba0a-a16ee56bfc87,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Claim 1 describes lithium's mechanisms and therapeutic effects, providing a biological rationale for its efficacy; this can serve as a premise supporting Claim 2's recommendation that lithium remain first-line, though Claim 1 does not address the adherence and comorbidity concerns mentioned in Claim 2.",daf03de6-256f-437d-ba0a-a16ee56bfc87,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium treatment for bipolar disorder but address different aspects: claim 1 describes proposed biological mechanisms of lithium's therapeutic action, while claim 2 makes a clinical comparative efficacy claim versus valproate for relapse prevention. They discuss the same topic without duplicating, contradicting, or logically entailing one another.",daf03de6-256f-437d-ba0a-a16ee56bfc87,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims concern lithium in bipolar disorder but address different aspects: claim 1 describes a proposed neurobiological mechanism of lithium’s therapeutic action, while claim 2 is a clinical comparative effectiveness statement vs lamotrigine. They do not contradict or logically entail one another, so they are related but variant.",daf03de6-256f-437d-ba0a-a16ee56bfc87,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Claim 1 provides a biological/mechanistic explanation for how lithium could produce therapeutic effects (stabilizing neuronal activity, enhancing plasticity, regulating rhythms). Claim 2 states lithium's clinical effectiveness and evidence base. The mechanistic claim serves as a premise that helps explain and support the clinical effectiveness asserted in Claim 2 (mechanism alone does not prove efficacy but is explanatory/supportive).",daf03de6-256f-437d-ba0a-a16ee56bfc87,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium in bipolar disorder but address different aspects: Claim 1 describes proposed mechanisms of action, while Claim 2 reports comparative clinical efficacy versus anticonvulsants. They do not duplicate or contradict one another, and Claim 1 does not by itself logically entail the comparative superiority asserted in Claim 2.",daf03de6-256f-437d-ba0a-a16ee56bfc87,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Claim 1 describes a biological mechanism (dampening excessive network activity, stabilizing neurons, enhancing plasticity, regulating chronobiology) that plausibly explains how lithium produces therapeutic effects; thus it serves as a premise supporting Claim 2's assertion of clinical benefit. Caveat: Claim 2 makes specific empirical claims about uniqueness and suicide prevention that require clinical outcome evidence beyond mechanistic explanation.",daf03de6-256f-437d-ba0a-a16ee56bfc87,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Claim 1 describes mechanisms (damping excessive activity, enhancing neuronal and synaptic plasticity, stabilizing networks) that plausibly explain structural brain changes. Claim 2 reports empirical increases in cortical thickness and subcortical volumes after lithium treatment; these observations can be a downstream consequence of the mechanistic effects in Claim 1, so Claim 1 serves as a plausible premise for Claim 2.",daf03de6-256f-437d-ba0a-a16ee56bfc87,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 2 reports specific neurotrophy- and signaling-related pathways (GDNF, NFAT, p53) that correlate with lithium-induced structural brain changes; these molecular/pathway-level findings provide mechanistic support for Claim 1's broader assertion that lithium enhances neuronal/synaptic plasticity and stabilizes regulatory networks.",c6b2f073-3921-470e-a771-ed36fdce8709,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims address mechanisms by which lithium improves mood/bipolar symptoms, but at different levels of specificity. Claim 1 describes broad network-level and cellular effects (network dampening, plasticity, chronobiology), while Claim 2 identifies a specific molecular/neuroanatomical pathway (sphingomyelin metabolism and mediodorsal thalamus volume changes) linked to depressive symptom improvement during lithium treatment. They are compatible and related but not equivalent or logically dependent, so 'variant' applies.",daf03de6-256f-437d-ba0a-a16ee56bfc87,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims address mechanisms by which lithium produces therapeutic effects, but at different levels: claim 1 describes network- and systems-level effects (dampening excessive activity, stabilizing neuronal activity, improving plasticity, chronobiology), while claim 2 emphasizes action via neurotrophic molecular pathways inferred from structural and gene-expression data. They are consistent and complementary rather than duplicate, premise, or contradictory.",daf03de6-256f-437d-ba0a-a16ee56bfc87,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 2 provides empirical evidence (lithium-associated structural brain changes correlated with gene expression in neurotrophic and cell-modeling pathways) that supports the mechanism in Claim 1 that lithium improves neuronal and synaptic plasticity. It does not address all mechanisms listed in Claim 1 (e.g., activity damping, stress resilience, chronobiological regulation), so it is partial supporting evidence rather than a full equivalence.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern therapeutic approaches for bipolar disorder but describe different, non-conflicting points: claim 1 attributes lithium's effect to broad, network-level stabilization and plasticity effects, while claim 2 proposes GRIN2A (a glutamatergic receptor subunit) as a specific therapeutic target. They address the same topic without duplication, contradiction, or a clear premise relationship.",daf03de6-256f-437d-ba0a-a16ee56bfc87,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 2 offers a specific molecular mechanism (lithium up-regulates GRIN2A, which is down-regulated in bipolar disorder) that could underlie the general neuroprotective/synaptic-plasticity and regulatory-network effects described in Claim 1. Therefore Claim 2 functions as a premise/evidence supporting Claim 1.",1a142c2f-a016-4716-8019-a883e04a6b5f,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 2 states lithium's molecular effects are systemic rather than cell-type or region-specific, which provides a foundation for Claim 1's description of lithium acting across multiple nodes of regulatory networks to stabilize neuronal activity and modulate plasticity, stress resilience, and chronobiology. The note that myelination is not a central target does not contradict Claim 1.",27a93479-31ed-49b7-950e-3cf4b7671182,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims describe mechanisms of action of lithium but in different biological domains: Claim 1 focuses on neurobiological and chronobiological effects relevant to bipolar disorder, while Claim 2 describes immunoregulatory pathways. They are related (both mechanistic accounts) but not equivalent, not contradictory, and neither serves as a direct premise for the other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Both claims concern modulation of neuronal activity in mood disorders but describe different mechanisms and contexts: Claim 1 states lithium’s therapeutic actions in bipolar disorder (dampening excessive network activity, enhancing plasticity, regulating circadian processes), while Claim 2 describes how mitochondrial dysfunction (reduced ATP) pathologically dampens circuit activity and drives depression via oxidative stress/inflammation. They are related thematically but not equivalent, contradictory, or a direct premise for one another.",daf03de6-256f-437d-ba0a-a16ee56bfc87,e2a99bc5-1b56-47bf-8fe6-dc5063fe7060
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern biological mechanisms influencing bipolar disorder but focus on different agents and mechanisms: claim 1 attributes lithium's therapeutic effects to broad dampening and stabilization of neural networks, plasticity, and chronobiology, while claim 2 identifies PKC as a regulator affecting manic and depressive dimensions. They address the same topic without entailing or contradicting each other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims address molecular mechanisms in bipolar disorder, but they make different, non-conflicting assertions. Claim 1 describes lithium's broad stabilizing effects on regulatory networks and plasticity, while Claim 2 identifies PKC as a key regulator of mood and bipolar states. They are related in topic but neither duplicates, contradicts, nor serves as an explicit premise for the other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern mechanisms producing antimanic effects, but they differ in scope and specifics: claim 1 attributes lithium's therapeutic effects in bipolar disorder to broad dampening of regulatory network activity and related processes, while claim 2 reports a specific preclinical finding that PKC inhibition yields antimanic-like behavior in rats. They are related topical variants rather than duplicates, premises, or contradictions (claim 1 does not explicitly state PKC as the mechanism).",daf03de6-256f-437d-ba0a-a16ee56bfc87,ae3c78a3-aaea-4b95-88c9-0997465c58c7
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern biological mechanisms relevant to mood states in bipolar disorder, but they make different, non-opposing points: Claim 1 describes lithium's broad dampening/stabilizing actions across regulatory networks, while Claim 2 specifically states that PKC activation produces manic-like and antidepressant-like behaviors. They are related topics but neither duplicates, directly contradicts, nor serves as a clear logical premise for the other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,bfdfd15f-1d66-4cb0-bef9-66b87c492ad1
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims address molecular mechanisms relevant to bipolar disorder and are compatible: claim 1 posits lithium dampens excessive activity across multiple regulatory nodes to exert therapeutic effects, while claim 2 identifies PKC as an important mood-regulating node involved in bipolar disorder. Claim 2 could be one example of a node referenced in claim 1 but the statements are not duplicates, direct premises, or contradictions.",daf03de6-256f-437d-ba0a-a16ee56bfc87,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern mechanisms that reduce manic symptoms: claim 1 describes lithium’s broad multi-node dampening/stabilizing actions in bipolar disorder, while claim 2 reports that PKC inhibition produces antimanic-like effects in a rat model. They are related and potentially complementary (PKC could be one node), but they are not equivalent, do not directly contradict, and neither statement is presented as a direct logical premise of the other.",daf03de6-256f-437d-ba0a-a16ee56bfc87,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims address molecular mechanisms relevant to mood regulation/mania but focus on different specifics. Claim 1 describes lithium’s broad dampening/stabilizing effects on regulatory networks (without naming PKC), while Claim 2 reports that PKC activation produces manic-like and antidepressant-like behaviors. They are related (same domain) but not duplicates or direct premises/contradictions because Claim 1 does not explicitly state lithium acts via PKC.",daf03de6-256f-437d-ba0a-a16ee56bfc87,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims address biological regulation in bipolar disorder but focus on different mechanisms. Claim 1 describes broad, multi-node effects of lithium on neuronal stability, plasticity, stress resilience and chronobiology; claim 2 focuses specifically on PKC modulation affecting manic and depressive facets. They are related topic-wise but do not duplicate, contradict, or serve as a direct premise for one another.",daf03de6-256f-437d-ba0a-a16ee56bfc87,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"Both claims concern neuronal plasticity but address different points: Claim 1 attributes lithium's therapeutic effects in bipolar disorder in part to improving neuronal and synaptic plasticity, while Claim 2 states a general role of BDNF in CNS development and plasticity. Claim 2 does not directly assert or logically entail Claim 1, nor do they contradict, so they are related but non-identical.",daf03de6-256f-437d-ba0a-a16ee56bfc87,5d2a635d-4bc1-47e6-8418-e59d0ea7c895
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern neurobiology of bipolar disorder but address different elements: Claim 1 describes lithium's multi-node stabilizing and plasticity-enhancing effects, while Claim 2 asserts BDNF is implicated in bipolar disorder and other conditions. They overlap topically but are neither equivalent, contradictory, nor does one serve clearly as a logical premise for the other (Claim 1 does not mention BDNF and Claim 2 does not describe lithium), so they are variant.",daf03de6-256f-437d-ba0a-a16ee56bfc87,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Related but not equivalent: both claims concern mechanisms of psychiatric treatments and synaptic/neuronal plasticity. Claim 1 attributes lithium's effects to stabilizing activity and enhancing synaptic plasticity; Claim 2 states BDNF mediates antidepressant/antipsychotic mechanisms. There is conceptual overlap (BDNF mediates plasticity and could be involved in lithium's actions) but Claim 2 does not specifically assert anything about lithium, so they differ without contradiction.",daf03de6-256f-437d-ba0a-a16ee56bfc87,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.","Both claims concern synaptic plasticity and neuronal health: Claim 1 says lithium enhances synaptic plasticity as part of its therapeutic action in bipolar disorder, while Claim 2 states BDNF is critical for synaptic plasticity and neuronal health. They are related but not identical, do not contradict, and neither claim is a direct logical premise of the other (Claim 1 does not invoke BDNF and Claim 2 does not mention lithium).",daf03de6-256f-437d-ba0a-a16ee56bfc87,1e7f51f6-eaca-4408-ae8b-756c1531362e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims propose mechanisms for mood-related drugs that involve changes in synaptic function/plasticity, but they describe different drugs (lithium vs ketamine), different primary actions and targets (broad dampening of network hyperactivity, chronobiology and stress resilience for lithium versus rapid synaptogenesis in prefrontal pyramidal neurons and enhanced serotonergic input for ketamine). They are related but not equivalent, contradictory, or premise-linked.",daf03de6-256f-437d-ba0a-a16ee56bfc87,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims address biological mechanisms underlying treatments for mood disorders, but they refer to different specific mechanisms and contexts: Claim 1 describes lithium's broad stabilizing effects in bipolar disorder (network damping, plasticity, chronobiology), while Claim 2 posits Homer1a in medial PFC as a final common pathway for certain rapid-acting antidepressant interventions. They are related at a high topical level but do not restate, contradict, or directly premise one another.",daf03de6-256f-437d-ba0a-a16ee56bfc87,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 2 lists cellular and molecular mechanisms (neurotrophic signaling, ER stress/UPR, autophagy, oxidative stress, mitochondrial function, inflammation) through which lithium exerts neuroprotective and neuroplastic effects. Those mechanisms provide a mechanistic basis that can explain the higher-level outcomes in Claim 1 (dampening excessive network activity, stabilizing neurons, enhancing plasticity and stress resilience), so Claim 2 functions as a premise supporting Claim 1.",0ccc686b-5be5-4aa5-9360-6c97d148920d,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 2 proposes specific molecular mechanisms (inhibition of GSK3 and IMPase) that could underlie lithium's wide intracellular effects. Those molecular actions can serve as a mechanistic foundation explaining the network-level dampening and downstream benefits (stabilized neuronal activity, plasticity, stress resilience, chronobiology) asserted in Claim 1, so Claim 2 is a premise supporting Claim 1.",bc544bb8-5c5d-4d1e-9c34-b51e2f339464,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims concern lithium's mechanisms but in different contexts: claim 1 describes multiple network- and plasticity-related effects in bipolar disorder, while claim 2 highlights autophagy as the primary mechanism for neuroprotection in neurodegenerative diseases. They address related topics without contradicting and could both be true in their respective conditions.",daf03de6-256f-437d-ba0a-a16ee56bfc87,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Lithium produces its therapeutic effect in bipolar disorder by dampening excessive activity at multiple nodes of regulatory networks, thereby stabilizing neuronal activity, enhancing stress resilience, improving neuronal and synaptic plasticity, and regulating chronobiological processes.","Claim 2 specifies a concrete molecular mechanism (mTOR-independent, IP3-related enhancement of autophagy) by which lithium can alter cellular physiology. Increased autophagy can contribute to neuronal health, synaptic plasticity, and stress resilience, so this pathway plausibly represents one of the “multiple nodes” through which lithium stabilizes neuronal activity as described in Claim 1. Thus Claim 2 provides a mechanistic premise that supports Claim 1, though it does not by itself establish all the broad effects claimed in Claim 1.",88027d82-ef95-4b58-ad6b-ef7f74e5cb4d,daf03de6-256f-437d-ba0a-a16ee56bfc87
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Both claims state the same association: higher genetic loading for major depression predicts poorer lithium response in bipolar disorder. Claim 2 restates this relationship with a quantified effect (low vs high loading ≈1.5× better long-term outcomes) but does not change the conclusion.,2d5e05cd-d871-42cb-b864-4c444cd9994c,97c81d6e-e353-4dd4-9a45-2c12671217e8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,"Both claims concern higher genetic predisposition/polygenic scores for major depression in bipolar disorder patients but describe associations with different outcomes: Claim 1 links it to poorer lithium treatment response, Claim 2 to a greater number of lifetime depressive episodes. They are related but not equivalent or logically implied, and they do not contradict.",2d5e05cd-d871-42cb-b864-4c444cd9994c,b1827ba4-9d49-468c-bb64-2c90e09f1a3a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"The first claim links a depressive predisposition to poorer lithium response; the second states better response occurs in manic‑predominant (vs depressive) bipolar phenotypes. Claim 1 provides specific evidence/mechanistic support for the general pattern asserted in Claim 2, so it serves as a premise for Claim 2.",2d5e05cd-d871-42cb-b864-4c444cd9994c,4429ac65-e370-4a8f-8b4f-25845d777d97
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Both claims assert that genetic factors tied to psychiatric comorbidity reduce lithium response in bipolar disorder. Claim 1 specifically names genetic predisposition to major depression, whereas Claim 2 expresses a broader idea (psychiatric comorbid genetic traits generally). They align in direction but differ in scope.",2d5e05cd-d871-42cb-b864-4c444cd9994c,4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Both claims address lithium and treatment response in mood disorders but focus on different aspects: Claim 1 reports an observational genetic association (depression genetic load linked to poorer lithium response in bipolar disorder), while Claim 2 asserts a mechanistic distinction between lithium's antidepressant actions and mechanisms underlying long-term bipolar treatment response. They are related but neither duplicates, contradicts, nor logically entails the other.",2d5e05cd-d871-42cb-b864-4c444cd9994c,97bdd2dc-de39-4a2f-a3b2-d374fbd202e0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Both claims concern bipolar disorder and its treatment but focus on different, non-overlapping aspects: Claim 1 links genetic risk for major depression to lithium response, whereas Claim 2 proposes a role for protein kinase C in bipolar disorder pathophysiology and treatment. They do not duplicate, contradict, or serve as direct premises for one another.",2d5e05cd-d871-42cb-b864-4c444cd9994c,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims concern lithium treatment in bipolar disorder: Claim 1 identifies a genetic subgroup with poorer lithium response, while Claim 2 recommends lithium as first-line for the majority. They address the same topic and Claim 1 adds a caveat/nuance but does not contradict or directly premise Claim 2.",2d5e05cd-d871-42cb-b864-4c444cd9994c,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 reports a genetic predictor of poorer lithium response, while claim 2 compares lithium versus valproate for relapse prevention in type-I bipolar. They do not contradict and one does not logically entail the other, so they are related but different (variant).",2d5e05cd-d871-42cb-b864-4c444cd9994c,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims concern lithium treatment for bipolar disorder but address different aspects: Claim 1 links a genetic predisposition for major depression to poorer lithium response (a pharmacogenetic predictor), while Claim 2 compares overall effectiveness of lithium versus lamotrigine and reports better outcomes with lithium. They are related topical variants rather than duplicates, contradictions, or one being a premise for the other.",2d5e05cd-d871-42cb-b864-4c444cd9994c,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims concern lithium treatment in bipolar disorder but address different non-conflicting aspects: claim 1 links genetic predisposition for major depression to poorer lithium response, while claim 2 compares lithium versus carbamazepine for recurrence and suicide prevention. They are related by topic but not equivalent, contradictory, or a premise of one another.",2d5e05cd-d871-42cb-b864-4c444cd9994c,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium use in bipolar disorder but address different aspects: Claim 2 is a general statement about lithium's overall efficacy in preventing episodes, while Claim 1 describes a specific subgroup (those with genetic predisposition to major depression) who may have poorer lithium response. They are related but not equivalent or contradictory.",2d5e05cd-d871-42cb-b864-4c444cd9994c,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium treatment in bipolar disorder but address different, non-conflicting aspects. Claim 1 concerns genetic predisposition for major depression predicting poorer lithium response, while Claim 2 compares lithium versus anticonvulsant mood stabilizers for prevention of manic (superior) and depressive (no difference) episodes. They are related in topic but do not duplicate, contradict, or provide a direct premise relationship.",2d5e05cd-d871-42cb-b864-4c444cd9994c,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims address lithium treatment in bipolar disorder but focus on different aspects: Claim 1 reports a genetic factor predicting poorer response in a subgroup, while Claim 2 asserts lithium's overall broad efficacy and superiority. They are related but not equivalent or directly contradictory.",2d5e05cd-d871-42cb-b864-4c444cd9994c,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium treatment in bipolar disorder but address different, non-equivalent outcomes: Claim 1 links genetic predisposition to clinical response, while Claim 2 describes structural brain changes after 8 weeks of lithium. They do not duplicate, contradict, or serve as direct premises for one another.",2d5e05cd-d871-42cb-b864-4c444cd9994c,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern biological effects of lithium but address different aspects: Claim 1 links genetic risk for major depression to clinical treatment response in bipolar disorder, while Claim 2 links specific neurotrophy-related pathways to lithium-induced structural brain changes. They are related by topic but not duplicates, premises, or contradictions.",2d5e05cd-d871-42cb-b864-4c444cd9994c,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern biological factors that influence depressive symptom response to lithium treatment, but they describe different, non-identical mechanisms: Claim 1 reports that genetic predisposition to major depression predicts poorer lithium response in bipolar disorder, whereas Claim 2 implicates the sphingomyelin metabolism pathway (mediated by mediodorsal thalamus volume changes) in symptom improvement. They are compatible and not direct duplicates, contradictions, or premises of one another.",2d5e05cd-d871-42cb-b864-4c444cd9994c,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium and genetic/biological effects, but at different levels: Claim 1 is a clinical association (genetic predisposition to major depression linked to poorer lithium response in bipolar disorder), while Claim 2 is a mechanistic finding (lithium-induced structural brain changes correlate with gene expression in neurotrophic/cell‑modeling pathways). They are related topical variants rather than duplicates, premises, or contradictions.",2d5e05cd-d871-42cb-b864-4c444cd9994c,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium treatment in bipolar disorder but address different facets: Claim 1 reports a clinical association (genetic predisposition to major depression predicts poorer lithium response), while Claim 2 proposes a molecular mechanism (lithium up-regulates GRIN2A which may mediate therapeutic effects). They are related but neither duplicates, contradicts, nor directly premises the other.",2d5e05cd-d871-42cb-b864-4c444cd9994c,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims concern lithium but address different aspects: claim 1 is about genetic predictors of clinical response in bipolar disorder, while claim 2 describes lithium's effects on immune signaling pathways. They do not duplicate or contradict one another, and neither claim serves as a direct premise for the other.",2d5e05cd-d871-42cb-b864-4c444cd9994c,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"Both claims concern depression but at different levels and do not assert the same thing: Claim 1 is a clinical association linking genetic risk for major depression to poorer lithium response in bipolar patients, while Claim 2 proposes a cellular mechanism (stress-induced mitochondrial electron transport chain inhibition) contributing to depression. They are related by topic but neither duplicates, contradicts, nor serves as a direct premise for the other.",2d5e05cd-d871-42cb-b864-4c444cd9994c,ffdad4fb-9055-44ab-99f8-e87b94a53af3
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern bipolar disorder and mood regulation but address different non-overlapping aspects: claim 1 links genetic risk for major depression to lithium treatment response, while claim 2 describes PKC's role in mood regulation and bipolar pathophysiology. They do not duplicate, contradict, or serve as direct premises for one another.",2d5e05cd-d871-42cb-b864-4c444cd9994c,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern associations with major depressive disorder but address different aspects: Claim 1 links genetic predisposition for MDD to lithium treatment response in bipolar disorder, while Claim 2 describes miR-135 targeting antidepressant-related genes and its association with MDD. They are topically related but not duplicates, contradictions, or direct premises.",2d5e05cd-d871-42cb-b864-4c444cd9994c,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Genetic predisposition for major depression is associated with poorer response to lithium treatment in patients with bipolar disorder.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern lithium's effects in mood disorders but address different aspects: Claim 1 reports a clinical association between genetic liability to major depression and poorer lithium response in bipolar patients, while Claim 2 describes cellular/molecular mechanisms of lithium action. They are related topic-wise but do not duplicate, premise one another, or contradict.",2d5e05cd-d871-42cb-b864-4c444cd9994c,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,"Both claims concern major depression polygenic scores in bipolar disorder but address different outcomes. Claim 1 links low MD genetic loading to better long-term lithium response; Claim 2 links higher MD polygenic scores to more lifetime depressive episodes. They are consistent and related but not equivalent or directly inferential, so they are variants.",97c81d6e-e353-4dd4-9a45-2c12671217e8,b1827ba4-9d49-468c-bb64-2c90e09f1a3a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Both claims link better lithium response to a lower depressive predisposition, but from different angles: claim 1 is genetic (low major-depression variant loading predicts ~1.5x better outcomes) while claim 2 is clinical (a manic-predominant 'core' bipolar phenotype predicts better response). They are consistent and complementary rather than duplicate or strictly premise/consequence.",97c81d6e-e353-4dd4-9a45-2c12671217e8,4429ac65-e370-4a8f-8b4f-25845d777d97
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Claim 1 provides a specific empirical instance — genetic loading for major depression — showing reduced likelihood of favorable lithium response (high MD genetic loading associated with worse outcomes). Claim 2 is a general statement that psychiatric comorbid genetic traits diminish lithium response. Therefore Claim 1 functions as a premise supporting Claim 2.,97c81d6e-e353-4dd4-9a45-2c12671217e8,4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Both claims concern lithium and treatment response but address different points: Claim 1 reports an association between major-depression genetic loading and long-term lithium outcomes, while Claim 2 asserts a mechanistic distinction between lithium's antidepressant actions and the mechanisms conferring long-term bipolar response. They are related in topic but do not duplicate, directly contradict, or serve as a clear logical premise for one another.",97c81d6e-e353-4dd4-9a45-2c12671217e8,97bdd2dc-de39-4a2f-a3b2-d374fbd202e0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both statements concern lithium treatment for bipolar disorder but address different points: claim 1 reports a specific genetic predictor of better long-term lithium response, while claim 2 is a broader treatment recommendation that lithium remain first-line for most patients. Claim 1 neither duplicates nor directly contradicts claim 2, nor does it strictly serve as a logical premise for that general guideline.",97c81d6e-e353-4dd4-9a45-2c12671217e8,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 is about genetic predictors of favorable long-term response to lithium (low major-depression genetic loading), while claim 2 compares the efficacy of lithium versus valproate for preventing relapses in type-I bipolar disorder. They do not duplicate, contradict, or serve as premises for one another.",97c81d6e-e353-4dd4-9a45-2c12671217e8,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims concern lithium treatment effectiveness in bipolar disorder but address different aspects: claim 1 describes how genetic loading for major depression predicts long-term lithium outcomes, while claim 2 compares lithium versus lamotrigine showing lithium superiority. They are related and compatible but not equivalent, contradictory, or a direct premise.",97c81d6e-e353-4dd4-9a45-2c12671217e8,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium's effectiveness in bipolar disorder but address different aspects. Claim 1 reports a specific genetic moderator of long-term lithium response (low major-depression genetic loading associated with ~1.5x better outcomes), while Claim 2 is a broad statement that lithium is among the most effective drugs for preventing manic and depressive episodes. They are related but not duplicates, premises, or contradictory.",97c81d6e-e353-4dd4-9a45-2c12671217e8,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 describes a genetic predictor of better long-term response to lithium, while claim 2 compares lithium versus anticonvulsants for preventing mania (and reports no difference for depression). They do not duplicate, contradict, or serve as premises for one another.",97c81d6e-e353-4dd4-9a45-2c12671217e8,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium treatment in bipolar disorder but address different points: claim 1 describes a genetic predictor of better long-term lithium outcomes, while claim 2 asserts lithium's unique broad efficacy and value. They are related by topic but do not duplicate, contradict, or serve as direct premises for one another.",97c81d6e-e353-4dd4-9a45-2c12671217e8,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 1 describes how genetic loading for major depression predicts long-term clinical outcomes, while Claim 2 reports short-term neuroanatomical changes after 8 weeks of lithium. They do not duplicate or contradict one another, nor is one a clear logical premise for the other.",97c81d6e-e353-4dd4-9a45-2c12671217e8,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern factors predicting or mediating symptom improvement with lithium treatment, but they address different predictors and mechanisms (genetic loading for major depression variants in Claim 1 versus sphingomyelin metabolism and thalamic volume changes in Claim 2). They do not duplicate, contradict, or provide a direct premise relationship.",97c81d6e-e353-4dd4-9a45-2c12671217e8,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium treatment but address different, non-contradictory aspects: Claim 1 is about genetic predictors of long-term clinical response in bipolar disorder, while Claim 2 describes lithium-induced structural and gene-expression changes in brain pathways. They are related by topic but neither duplicates, contradicts, nor directly serves as a logical premise for the other.",97c81d6e-e353-4dd4-9a45-2c12671217e8,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 1 is a clinical association (polygenic major-depression loading predicts better lithium outcome), while Claim 2 proposes a molecular mechanism (lithium up-regulates GRIN2A). They do not duplicate, contradict, or directly premise one another.",97c81d6e-e353-4dd4-9a45-2c12671217e8,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Both claims concern depression-related biology but address different, non-conflicting aspects: Claim 1 is about genetic loading for major depression variants predicting lithium treatment outcomes in bipolar patients, while Claim 2 proposes mitochondrial dysfunction as a pathophysiological mechanism for depression. They are related topicaly but neither duplicates, contradicts, nor directly provides a logical premise for the other.",97c81d6e-e353-4dd4-9a45-2c12671217e8,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern biological factors related to major depressive disorder and treatment response, but they address different levels/mechanisms (polygenic loading affecting lithium response in bipolar disorder vs a specific microRNA implicated in antidepressant actions). They do not duplicate, contradict, or serve as direct premises for one another.",97c81d6e-e353-4dd4-9a45-2c12671217e8,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern lithium treatment but at different levels of analysis: claim 1 reports a clinical/genetic association (polygenic depression load predicting lithium response), while claim 2 describes cellular mechanisms of lithium action. They address related topics without entailing or contradicting each other.",97c81d6e-e353-4dd4-9a45-2c12671217e8,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Bipolar disorder patients with low genetic loading for major depression variants are approximately 1.5 times more likely to have favorable long-term outcomes following lithium treatment compared to those with high major depression genetic loading.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but at different levels: Claim 1 reports a clinical/genetic predictor of lithium response in bipolar disorder, while Claim 2 describes molecular mechanisms (GSK3 and IMPase inhibition). They address related topics without duplicating, implying, or contradicting each other.",97c81d6e-e353-4dd4-9a45-2c12671217e8,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Both claims concern the balance of depressive vs. manic features in bipolar disorder but describe different associations: claim_1 links higher polygenic risk for major depression to more lifetime depressive episodes, while claim_2 links better lithium response to a manic‑predominant (less depressive) 'core' bipolar phenotype. They are related by topic but do not duplicate, contradict, or directly serve as premises for one another.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,4429ac65-e370-4a8f-8b4f-25845d777d97
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Both claims concern genetic influences/comorbidity in bipolar disorder but address different outcomes. Claim 1 links major depression polygenic scores to more lifetime depressive episodes; Claim 2 links psychiatric comorbid genetic traits to poorer lithium response. They are related topic-wise but neither duplicate, contradict, nor serve as a direct premise for the other.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Both claims concern bipolar disorder but address different, non-overlapping aspects: claim 1 links polygenic risk for major depression to episode burden in bipolar patients, while claim 2 implicates protein kinase C in the pathophysiology and treatment of bipolar disorder. They are related by topic but are neither duplicates, contradictions, nor logical premises of one another.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern genetic/biological aspects of bipolar disorder but make different, non-conflicting points: claim 1 reports an association between polygenic depression risk and episode count, while claim 2 proposes GRIN2A as a therapeutic target. They are related in topic but not duplicate, contradictory, or a direct premise for one another.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Both claims concern depression but address different, non-overlapping aspects: Claim 1 links polygenic risk for major depression to episode frequency in bipolar patients, while Claim 2 proposes mitochondrial dysfunction as a pathophysiological mechanism for depression. They do not duplicate, contradict, or serve as a direct premise for one another.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Both claims concern factors involved in depression, but at different levels and addressing different questions: claim 1 reports an association between polygenic risk for major depression and episode count in bipolar patients, while claim 2 describes a mitochondrial-mechanistic pathway contributing to depression pathogenesis. They do not duplicate, contradict, or serve as direct premises for one another.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,e2a99bc5-1b56-47bf-8fe6-dc5063fe7060
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern bipolar disorder but address different mechanisms and findings: Claim 1 links polygenic depression risk to number of depressive episodes, while Claim 2 concerns PKC signaling affecting manic and depressive dimensions. They are related by topic but not equivalent, contradictory, or a premise for one another.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological contributors to depressive features of bipolar disorder (polygenic risk vs a molecular PKC mechanism). They address the same topic but describe different, noncontradictory mechanisms and neither claim serves as a direct premise for the other.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Higher polygenic scores for major depression are associated with a higher number of lifetime depressive episodes in bipolar disorder patients.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern biological associations with major depression but involve different markers and contexts: Claim 1 links polygenic risk scores to number of depressive episodes in bipolar patients, while Claim 2 implicates miR-135 and its target genes in major depressive disorder and antidepressant actions. They address related topics without entailing or contradicting one another.",b1827ba4-9d49-468c-bb64-2c90e09f1a3a,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Both claims concern predictors of lithium response in bipolar disorder but refer to different, non-identical factors. Claim 1 links better response to a manic‑predominant ‘core’ phenotype; Claim 2 links poorer response to the presence of psychiatric comorbid genetic traits. They address the same topic without duplicating, implying, or contradicting each other.",4429ac65-e370-4a8f-8b4f-25845d777d97,4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Both claims concern lithium response in bipolar disorder but address different aspects: claim 1 links a clinical phenotype (predominant manic features) to better lithium responsiveness, while claim 2 distinguishes lithium's antidepressant mechanisms from mechanisms conferring long-term treatment response. They are related topic-wise but not equivalent, contradictory, or a direct premise/consequence.",4429ac65-e370-4a8f-8b4f-25845d777d97,97bdd2dc-de39-4a2f-a3b2-d374fbd202e0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Both claims concern bipolar disorder but address different aspects: claim 1 relates clinical phenotype and lithium responsiveness, while claim 2 addresses a molecular mechanism (protein kinase C) implicated in pathophysiology and treatment. They do not duplicate, contradict, or serve as direct premises for one another.",4429ac65-e370-4a8f-8b4f-25845d777d97,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Both statements concern treatment of bipolar disorder with lithium, but they address different, non-conflicting points: Claim 1 links lithium responsiveness to a manic-predominant phenotype (a predictor), while Claim 2 asserts that adding tamoxifen to lithium improves rapid reduction of manic symptoms (a treatment comparison). There is no direct equivalence, premise relation, or contradiction.",4429ac65-e370-4a8f-8b4f-25845d777d97,2b69a477-3fa3-4a96-9a36-77b58dda0554
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Both claims concern treatment/clinical features of manic behavior in bipolar disorder, but they address different points: claim 1 links a manic-predominant phenotype to better lithium response, while claim 2 asserts that direct PKC inhibition produces rapid antimanic effects. They do not contradict or premise one another, but are related by topic.",4429ac65-e370-4a8f-8b4f-25845d777d97,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims concern lithium use in bipolar disorder but address different points: Claim 1 describes a predictor of better lithium response (a predominantly manic 'core' phenotype), while Claim 2 is a general recommendation that lithium remain first-line for most patients despite adherence/comorbidity concerns. Claim 1 could inform treatment decisions but does not itself assert the broad guideline, so they are related but not duplicate, premise, or contradictory.",4429ac65-e370-4a8f-8b4f-25845d777d97,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium efficacy in bipolar disorder but address different aspects: Claim 1 links better lithium response to a predominantly manic (‘core’) phenotype, while Claim 2 compares lithium versus valproate for relapse prevention in type I bipolar. They are related topics but neither duplicates, contradicts, nor directly serves as a logical premise for the other.",4429ac65-e370-4a8f-8b4f-25845d777d97,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 1 describes a clinical predictor (a mania-predominant 'core' phenotype) associated with better lithium response, while Claim 2 reports a comparative effectiveness result that lithium is more effective than lamotrigine with fewer medication switches and hospitalizations. They do not duplicate, contradict, or logically serve as a direct premise for one another.",4429ac65-e370-4a8f-8b4f-25845d777d97,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 describes a clinical phenotype (predominant manic features) associated with better lithium responsiveness, while claim 2 asserts lithium's superiority over carbamazepine for preventing recurrences in bipolar I and preventing suicide. They are related by topic but not duplicates, contradictions, or premises of one another.",4429ac65-e370-4a8f-8b4f-25845d777d97,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium treatment in bipolar disorder but make different, non-conflicting points: Claim 1 asserts a phenotype (manic-predominant) predicts better lithium response, while Claim 2 makes a general statement about lithium's overall effectiveness and evidence base. Neither entails nor contradicts the other.",4429ac65-e370-4a8f-8b4f-25845d777d97,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium's greater efficacy for manic versus depressive aspects of bipolar disorder but make different points: Claim 1 links better lithium response to a predominantly manic 'core' phenotype (a patient-level predictor), while Claim 2 compares lithium to anticonvulsants for prevention of manic versus depressive episodes (a drug-class comparison). They are compatible and related but not equivalent or premises of one another.",4429ac65-e370-4a8f-8b4f-25845d777d97,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium treatment in bipolar disorder but make different, non-equivalent points: Claim 1 is about which bipolar phenotype shows better lithium response (predominant mania), while Claim 2 asserts broad, unique efficacy of lithium across acute mania, bipolar depression, relapse prevention and suicide prevention. They do not duplicate, contradict, or serve as direct premises for one another.",4429ac65-e370-4a8f-8b4f-25845d777d97,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium response in bipolar disorder but address different aspects: Claim 1 is a clinical/phenotypic association (better overall lithium response in manic‑predominant patients), while Claim 2 identifies a molecular/neuroanatomical pathway (sphingomyelin metabolism and mediodorsal thalamus volume) linked specifically to depressive symptom improvement during lithium. They are related but not equivalent or contradictory; one does not logically entail the other.",4429ac65-e370-4a8f-8b4f-25845d777d97,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium in the context of bipolar disorder but address different aspects: Claim 1 links clinical phenotype (manic-predominant) to treatment response, while Claim 2 describes lithium-induced brain structural and gene-expression changes. They are topically related but neither entails, contradicts, nor serves as a clear premise for the other.",4429ac65-e370-4a8f-8b4f-25845d777d97,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium in bipolar disorder but address different aspects: claim 1 describes a clinical phenotype (predominant manic features) linked to better lithium response, while claim 2 proposes a molecular mechanism (lithium up-regulates GRIN2A). They do not duplicate, contradict, or serve as direct premises for one another.",4429ac65-e370-4a8f-8b4f-25845d777d97,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims address bipolar disorder and the manic vs depressive dimensions, but they concern different aspects: Claim 1 links clinical lithium responsiveness to a manic-predominant ‘core’ phenotype, while Claim 2 states that PKC modulation affects both manic and depressive facets. They do not contradict or logically entail one another, so they are related but different (variant).",4429ac65-e370-4a8f-8b4f-25845d777d97,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern bipolar disorder but address different, noncontradictory aspects: Claim 1 is a clinical observation about lithium response linked to a manic-predominant phenotype, while Claim 2 is a molecular/neurobiological assertion about PKC involvement in mood regulation across manic and depressive states. They are related by topic but neither duplicates, contradicts, nor directly premises the other.",4429ac65-e370-4a8f-8b4f-25845d777d97,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern manic-like phenotypes (one a clinical association between predominant manic features and lithium response, the other an experimental finding that PKC activation produces manic- and antidepressant-like behaviors). They address the same general topic (mania-related biology/behavior) but at different levels (clinical phenotype vs. molecular/animal model) and neither duplicates, directly contradicts, nor serves as a clear logical premise for the other.",4429ac65-e370-4a8f-8b4f-25845d777d97,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Better lithium responsiveness in bipolar disorder is associated with a 'core' bipolar phenotype characterized by predominant manic features rather than depressive features.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern manic vs depressive dimensions of bipolar disorder but address different aspects and do not entail or contradict each other: Claim 1 is a clinical association (lithium responsiveness linked to a manic‑predominant 'core' phenotype), while Claim 2 is a mechanistic statement (PKC modulation affects both manic and depressive facets). No direct premise or contradiction exists.",4429ac65-e370-4a8f-8b4f-25845d777d97,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Both claims concern lithium treatment response in bipolar disorder but address different aspects. Claim 1 asserts that psychiatric comorbid genetic traits reduce the likelihood of an optimal lithium response; Claim 2 states that lithium's antidepressant mechanisms differ from mechanisms underlying long-term treatment response. They are related and complementary but neither duplicates, contradicts, nor directly entails the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,97bdd2dc-de39-4a2f-a3b2-d374fbd202e0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Both claims concern treatment outcomes with lithium in bipolar disorder, but they address different aspects: Claim 1 concerns genetic/psychiatric comorbid predictors of poorer lithium response, while Claim 2 reports that adding tamoxifen to lithium improves rapid reduction of manic symptoms. They do not duplicate, contradict, or serve as premises for one another, so they are related but different (variant).",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,2b69a477-3fa3-4a96-9a36-77b58dda0554
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.","Both statements concern lithium treatment in bipolar disorder but address different, non-conflicting aspects: claim 1 concerns genetic comorbidity affecting likelihood of optimal lithium response, while claim 2 concerns the tolerability of combining tamoxifen with lithium in acute mania. They are related by topic but not duplicates, premises, or contradictions.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,e94c05b3-ab35-4b9f-86a5-009428370c62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims address lithium use in bipolar disorder and the impact of comorbidities: claim 1 reports that certain psychiatric comorbid genetic traits reduce the likelihood of optimal lithium response, while claim 2 recommends lithium remain first-line for the majority despite adherence and comorbidity concerns. They concern the same issue and could inform each other (claim 1 may indicate subgroups where lithium is less effective) but do not directly contradict or serve as a clear premise-to-conclusion for the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium treatment in bipolar disorder but address different aspects. Claim 1 concerns genetic/psychiatric comorbidity predictors of individual response to lithium (reduced likelihood of optimal response), while Claim 2 asserts a population-level comparative efficacy (lithium superior to valproate for preventing relapses in type I bipolar). They are related by topic but are neither duplicates, direct premises, nor contradictory.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims concern treatment of bipolar disorder and lithium, but they address different, non-conflicting points: Claim 1 is about genetic comorbidity reducing optimal response to lithium in some patients, while Claim 2 is a comparative effectiveness statement that lithium overall outperforms lamotrigine. They can both be true and neither entails the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims concern lithium treatment in bipolar disorder but address different issues: claim 1 concerns genetic/comorbid predictors of lithium response, while claim 2 asserts lithium's superiority over carbamazepine for recurrence prevention in BD-I and for suicide prevention overall. They discuss the same general topic without duplicating information or contradicting each other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 2 asserts lithium's overall strong efficacy for preventing episodes, while Claim 1 identifies a subgroup (patients with psychiatric comorbid genetic traits) who are less likely to achieve optimal lithium response. These statements are compatible and represent a difference in scope/detail rather than a contradiction.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium treatment in bipolar disorder but focus on different, non-conflicting aspects: claim 1 addresses how psychiatric comorbid genetic traits reduce likelihood of optimal lithium response (a predictor/modifier of response), while claim 2 compares lithium versus anticonvulsants for prevention of manic (and depressive) episodes. They are related but not duplicates, premises, or contradictions.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium's efficacy in bipolar disorder but address different aspects. Claim 1 notes a subgroup-level modifier (psychiatric comorbid genetic traits) that can reduce optimal lithium response; Claim 2 makes a broad claim that lithium is the most valuable and uniquely proven mood stabilizer across several outcomes. These statements are compatible but differ in scope and nuance, so they are variants rather than duplicates or contradictions.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 1 claims that psychiatric comorbid genetic traits reduce the likelihood of an optimal clinical response to lithium, while Claim 2 reports neuroanatomical changes after 8 weeks of lithium. They do not repeat the same assertion, do not contradict each other, and neither is a direct logical premise for the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium treatment in the context of brain/psychiatric biology, but they address different non-conflicting aspects: claim 1 concerns how psychiatric comorbidity genetics affects clinical response to lithium, while claim 2 describes molecular/neurotrophic pathways associated with lithium-induced structural brain changes. They are related by topic but neither duplicates, contradicts, nor serves as a direct logical premise for the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern predictors/biological correlates of response to lithium treatment but address different factors and levels: Claim 1 describes a genetic comorbidity effect reducing likelihood of optimal lithium response, while Claim 2 identifies a specific metabolic pathway and brain-structure-mediated mechanism linked to depressive symptom improvement on lithium. They are related but neither duplicates, directly contradicts, nor serves as a logical premise for the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims concern lithium but address different aspects: Claim 1 is a clinical/predictive claim about genetic comorbidity reducing likelihood of optimal lithium response in bipolar disorder, while Claim 2 is a mechanistic claim that lithium acts via neurotrophic molecular pathways based on brain and peripheral gene expression. They are related topics but do not duplicate, directly contradict, or serve as a clear logical premise for one another.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium and genetics/neurobiology but address different aspects: Claim 1 is about how psychiatric comorbid genetic traits predict poorer lithium treatment response in bipolar disorder, while Claim 2 describes lithium-induced structural brain changes correlated with gene expression in neurotrophic and cell-modeling pathways. They are related topics but neither duplicates, contradicts, nor serves as a direct logical premise for the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 says psychiatric comorbid genetic traits reduce likelihood of optimal lithium response, while claim 2 proposes a specific molecular mechanism (GRIN2A up-regulation) for lithium’s therapeutic effect. They do not duplicate, contradict, or serve as direct premises for one another.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims concern lithium but address different aspects: claim 1 concerns clinical/genetic predictors of treatment response in bipolar disorder, while claim 2 concerns lithium's molecular mechanism being systemic and not specifically targeting myelination. They do not duplicate or contradict each other, nor does one serve as a clear logical premise for the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims concern lithium but address different aspects: Claim 1 relates genetic/clinical predictors of treatment response in bipolar disorder, while Claim 2 describes lithium's immunoregulatory mechanisms. They do not duplicate, contradict, or serve as direct premises for one another.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both statements concern bipolar disorder but address different aspects: Claim 1 concerns genetic comorbidities affecting lithium treatment response, while Claim 2 concerns the role of PKC in mood regulation across bipolar states. They are related by topic but neither duplicates, contradicts, nor serves as a direct premise for the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The presence of psychiatric comorbid genetic traits in bipolar disorder diminishes the likelihood of optimal treatment response to lithium.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern lithium in the context of bipolar disorder but address different, non-conflicting aspects: Claim 1 is a clinical/genetic predictor of lithium treatment response, while Claim 2 describes molecular/cellular mechanisms of lithium action. Neither duplicates, contradicts, nor logically entails the other.",4e4f2a56-f04b-41ff-8c1f-e9ffb4811ef6,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Both claims concern mechanisms of action for treatments of mood disorders, but they address different agents and outcomes: claim 1 contrasts lithium's antidepressant mechanisms with mechanisms for long-term bipolar response, while claim 2 states that direct PKC inhibition yields rapid anti-manic effects. They are related topic-wise but neither duplicates, contradicts, nor serves as a premise for the other.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims concern lithium but address different aspects: Claim 1 describes mechanistic distinctions (antidepressant vs long-term response mechanisms), while Claim 2 is a clinical recommendation to keep lithium as first-line treatment. They do not duplicate, contradict, or serve as direct premises for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims concern lithium in bipolar disorder but address different aspects: claim 1 is about lithium's pharmacological mechanisms (antidepressant vs long-term response mechanisms), while claim 2 is about comparative clinical effectiveness versus lamotrigine (higher switching/hospitalization with lamotrigine). They do not contradict or serve as premises for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims concern lithium and bipolar disorder but address different aspects: claim 1 is about distinct mechanistic actions (antidepressant vs long-term response mechanisms), while claim 2 is a clinical effectiveness comparison (lithium vs carbamazepine for recurrence prevention and suicide). They do not duplicate, contradict, or serve as premises for one another, so they are related but non-equivalent.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium in bipolar disorder but address different aspects: Claim 1 asserts a distinction between antidepressant mechanisms and mechanisms of long-term treatment response, while Claim 2 states lithium's strong clinical efficacy for preventing mood episodes. They are related (same topic) but not equivalent, contradictory, or a direct premise for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium in bipolar disorder but address different aspects: Claim 1 is about distinct biological mechanisms (antidepressant vs long-term response), while Claim 2 is a clinical efficacy comparison (better at preventing mania vs no advantage for preventing depression). They are related but neither duplicates, contradicts, nor directly premises the other.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium and bipolar disorder but address different aspects: claim 1 discusses mechanistic distinctions between lithium's antidepressant actions and mechanisms underlying long-term treatment response, while claim 2 asserts lithium's broad clinical efficacy and comparative value. They do not duplicate, contradict, or serve as direct premises for one another, so they are related variants.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium effects in bipolar disorder but address different aspects: claim 1 asserts a conceptual distinction between antidepressant mechanisms and long-term treatment mechanisms, while claim 2 reports specific neuroanatomical changes after 8 weeks of lithium treatment. Claim 2 does not state whether those changes correspond to antidepressant versus long-term mechanisms, so the claims are related by topic but not duplicative, contradictory, or a clear premise for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium's biological effects but address different aspects: Claim 2 identifies specific neurotrophy-related pathways linked to lithium-induced structural brain changes, while Claim 1 asserts that antidepressant mechanisms are distinct from mechanisms conferring long-term bipolar treatment response. Claim 2 does not state or imply the distinction in Claim 1 nor contradict it, so they are related on topic but not duplicates, premises, or contradictions.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Claim 2 describes a specific antidepressant mechanism during lithium treatment (sphingomyelin metabolism → mediodorsal thalamus volume changes → depressive symptom improvement). This provides evidence supporting Claim 1's general assertion that lithium has specific antidepressant mechanisms (distinct from long-term bipolar response mechanisms), even though Claim 2 does not address long-term treatment mechanisms directly.",12694b8a-03de-462a-a0da-b8412687c380,97bdd2dc-de39-4a2f-a3b2-d374fbd202e0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims address lithium's mechanisms of action but focus on different aspects. Claim 1 asserts a distinction between antidepressant mechanisms and those underlying long-term bipolar treatment response; Claim 2 identifies neurotrophic molecular pathways as mechanisms (from brain structure and peripheral gene expression data) but does not specify which clinical effects these pathways underlie. They are related on the same topic without duplicating, entailing, or contradicting each other.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium's biological effects, but they address different aspects: Claim 1 asserts a distinction between antidepressant mechanisms and long-term bipolar treatment mechanisms, while Claim 2 reports lithium-induced structural and gene-expression changes (neurotrophic/cell modeling) without linking them to either antidepressant effects or long-term bipolar response. They are related but neither duplicates nor directly supports/contradicts the other.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern therapeutic mechanisms for affective/bipolar disorder but address different specific mechanisms/targets (lithium's distinct antidepressant vs long-term mechanisms vs GRIN2A as a glutamatergic therapeutic target). They do not duplicate, contradict, or serve as direct premises for one another, but discuss related aspects of treatment.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium's mechanisms in mood disorders but address different points. Claim 1 makes a general distinction between antidepressant mechanisms and mechanisms for long-term bipolar treatment; Claim 2 proposes GRIN2A up-regulation as a specific mechanism for lithium's therapeutic effect in bipolar disorder. Claim 2 neither duplicates nor contradicts Claim 1, nor is it a direct premise, so they are related but different (variant).",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims concern lithium's mechanisms of action but address different aspects. Claim 1 asserts distinct antidepressant mechanisms versus mechanisms for long-term bipolar response; Claim 2 characterizes lithium effects as systemic (not cell-type/region-specific) and downplays myelination as a central target. These statements are related but not equivalent, do not logically entail one another, and do not directly contradict, so they are variants.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Both claims concern biological mechanisms related to depression but make different, non‑contradictory points: Claim 1 is about lithium’s specific antidepressant mechanisms versus mechanisms for long‑term bipolar treatment response; Claim 2 asserts a role for mitochondrial dysfunction in depression. They are related by topic but not duplicates, contradictions, or direct premises of one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Both claims concern mechanisms relevant to treating depression (claim 1 about lithium having distinct antidepressant mechanisms; claim 2 about targeting early mitochondrial dysfunction), but they address different specific mechanisms and do not duplicate, contradict, or serve as direct premises for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern mechanisms of action of psychiatric treatments (Claim 1: lithium's antidepressant mechanisms vs long-term bipolar response; Claim 2: BDNF involvement in antidepressant/antipsychotic mechanisms). They are topically related but do not restate the same claim, contradict, or serve as direct premises for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims describe mechanisms underlying antidepressant effects, but they refer to different drugs and distinct mechanisms (lithium's relationship between acute antidepressant action and long-term bipolar response vs ketamine-driven synaptogenesis and serotonergic enhancement). They do not duplicate, contradict, or serve as premises for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern antidepressant-related mechanisms, but they address different entities and contexts: claim 1 concerns lithium’s specific antidepressant mechanisms versus its long-term bipolar treatment mechanisms, while claim 2 concerns miR-135 targeting genes linked to antidepressant actions and its association with major depressive disorder. They are related by topic but neither duplicates, contradicts, nor serves as a direct premise for the other.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern mechanisms underlying antidepressant effects but address different specifics. Claim 1 asserts lithium has specific mechanisms distinct from those mediating long-term bipolar treatment response; Claim 2 proposes Homer1a expression in medial PFC as a common pathway for several antidepressant interventions (sleep deprivation, imipramine, ketamine). They overlap in topic (antidepressant mechanisms) but do not restate, contradict, or logically entail one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern antidepressant mechanisms but address different drugs and points: Claim 1 discusses lithium having distinct antidepressant mechanisms versus those responsible for long-term bipolar response, while Claim 2 highlights ketamine as a paradigm for rapid, non-monoaminergic antidepressants. They are related by topic but make different, noncontradictory claims.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims discuss lithium's mechanisms of action, but they address different points: Claim 1 asserts a distinction between antidepressant mechanisms and those underlying long-term bipolar response, while Claim 2 lists specific cellular pathways lithium regulates (neuroplasticity/neuroprotection) without asserting whether these are the same or different mechanisms for antidepressant versus long-term bipolar effects. Thus they are related but not equivalent or contradictory.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium's mechanisms of action but focus on different aspects: Claim 1 asserts that antidepressant mechanisms differ from those mediating long-term bipolar response, while Claim 2 proposes specific molecular targets (GSK3 and IMPase) underlying many intracellular effects. They discuss the same topic without duplicating, contradicting, or serving as direct premises for one another.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims concern lithium's mechanisms of action but address different effects and contexts: Claim 1 concerns antidepressant vs long-term bipolar mechanisms, while Claim 2 claims autophagy underlies neuroprotective effects in neurodegeneration. They do not contradict or serve as premises for one another, but discuss related topics with different specifics.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium possesses specific antidepressant mechanisms of action that are different from the mechanisms conferring long-term treatment response in bipolar disorder.,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern lithium's mechanisms of action, but they are not the same claim nor contradictory. Claim 1 asserts a high-level distinction between antidepressant mechanisms and long-term bipolar-response mechanisms; Claim 2 provides a specific autophagy-related, mTOR-independent IP3 signaling mechanism. Claim 2 does not explicitly state which clinical effect it explains, so it does not directly support or contradict Claim 1.",97bdd2dc-de39-4a2f-a3b2-d374fbd202e0,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Claim 1 asserts that PKC is involved in bipolar disorder pathophysiology and treatment. Tamoxifen is a PKC inhibitor, and Claim 2 reports that tamoxifen combined with lithium is superior to lithium alone for rapid reduction of mania, which relies on the premise that targeting PKC can be therapeutic. Therefore Claim 1 is a logical premise for Claim 2.",76a66954-b970-4954-87d8-b1658e951b14,2b69a477-3fa3-4a96-9a36-77b58dda0554
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Claim 2 provides a specific therapeutic observation — direct PKC inhibition produces rapid anti-manic effects — that supports the broader Claim 1 that protein kinase C is involved in the pathophysiology and treatment of bipolar disorder. Thus Claim 2 serves as a premise/evidence for Claim 1.,068c21c4-d223-4419-a3a6-e74d3c4d6bf0,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims concern bipolar disorder and its treatment but address different aspects: claim 1 states a molecular/pathophysiological role for protein kinase C (and potential therapeutic targeting), while claim 2 is a clinical recommendation that lithium remain first-line. They do not contradict or directly premise one another, so they are related but different (variant).",76a66954-b970-4954-87d8-b1658e951b14,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims concern bipolar disorder and its treatment but address different aspects: claim 1 is a mechanistic statement about protein kinase C's role, while claim 2 is a clinical comparison of lithium versus carbamazepine for recurrence prevention and suicide. They do not assert the same fact, contradict each other, or serve as direct premises for one another.",76a66954-b970-4954-87d8-b1658e951b14,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern bipolar disorder and its treatment, but they address different aspects: claim 1 asserts a role for protein kinase C in pathophysiology and treatment mechanisms, while claim 2 states lithium's strong efficacy for preventing mood episodes. They are related topical variants rather than duplicates, contradictions, or premises.",76a66954-b970-4954-87d8-b1658e951b14,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern bipolar disorder and its treatment but address different aspects: Claim 1 asserts a role for protein kinase C in pathophysiology and treatment, while Claim 2 reports lithium-associated increases in brain volumes/thickness after 8 weeks. They do not duplicate, contradict, or serve as direct premises for one another.",76a66954-b970-4954-87d8-b1658e951b14,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern biological mechanisms related to bipolar disorder and its treatment, but they refer to different molecular pathways: Claim 1 implicates protein kinase C broadly in pathophysiology and treatment, while Claim 2 describes lithium-associated neurotrophy-related pathways (GDNF family, NFAT, p53) linked to structural brain changes. They are related topic-wise but not equivalent, premises, or contradictory.",76a66954-b970-4954-87d8-b1658e951b14,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims concern molecular mechanisms relevant to bipolar disorder treatment—claim 1 implicates protein kinase C, while claim 2 describes lithium acting via neurotrophic pathways. They address related topics but make different, noncontradictory claims and neither serves as a direct premise for the other.",76a66954-b970-4954-87d8-b1658e951b14,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern biological mechanisms relevant to bipolar disorder treatment but address different processes: Claim 1 implicates protein kinase C in pathophysiology and treatment broadly, while Claim 2 describes lithium-induced structural brain changes linked to neurotrophic and cell‑modeling gene expression. There is no direct entailment or contradiction between them.",76a66954-b970-4954-87d8-b1658e951b14,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims propose molecular targets for bipolar disorder treatment but refer to different proteins/mechanisms: Claim 1 implicates protein kinase C, Claim 2 implicates GRIN2A (a glutamatergic NMDA receptor subunit). They address the same topic without contradicting or logically entailing each other.",76a66954-b970-4954-87d8-b1658e951b14,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern molecular mechanisms relevant to bipolar disorder treatment but refer to different targets (protein kinase C vs GRIN2A). They do not restate the same claim, contradict one another, or provide a direct logical premise for the other.",76a66954-b970-4954-87d8-b1658e951b14,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims concern biological mechanisms relevant to bipolar disorder and its treatment: claim 1 implicates protein kinase C in bipolar pathophysiology and treatment, while claim 2 describes lithium's effects on immune signaling pathways. They address different mechanisms and do not duplicate, imply, or contradict each other.",76a66954-b970-4954-87d8-b1658e951b14,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims discuss the role of protein kinase C (PKC) in bipolar disorder. Claim 2 provides a more specific description (PKC regulates opposing facets—manic and depressive—and modulation affects both) but does not restate claim 1 nor contradict it, so they are related variations rather than duplicates or premises.",76a66954-b970-4954-87d8-b1658e951b14,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims assert PKC involvement in bipolar disorder and mood regulation, but Claim 2 specifies roles in manic and depressive states while Claim 1 emphasizes pathophysiology and treatment. They overlap but differ in scope/detail, so they are variants.",76a66954-b970-4954-87d8-b1658e951b14,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Claim 2 provides experimental evidence that inhibiting PKC produces antimanic-like effects in an animal model (reduced amphetamine-induced hyperlocomotion and risk-taking). This supports Claim 1 by showing PKC activity influences mania-related behaviors and that PKC inhibition has therapeutic potential for bipolar disorder (animal evidence is supportive but not definitive for human clinical efficacy).,ae3c78a3-aaea-4b95-88c9-0997465c58c7,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Claim 2 reports experimental evidence that manipulating PKC (chronic inhibition) alters mood-related behavior and hippocampal neurogenesis in rats. These findings provide mechanistic support that PKC activity influences mood-related neurobiology and therefore serve as a premise supporting Claim 1 that PKC is involved in the pathophysiology and a potential treatment target for bipolar disorder (with the caveat that animal-model depressive-like effects and species differences do not by themselves prove human bipolar causation).,9ccfdc45-aa16-4546-abcf-7333a5b07623,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Claim 2 reports that PKC activation produces manic-like and antidepressant-like behavioral effects (enhanced risk-taking; reduced immobility in forced swim test), which are experimental findings that support the broader assertion in Claim 1 that PKC is involved in the pathophysiology (mania-relevant effects) and treatment (antidepressant-like effects) of bipolar disorder.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",Both claims assert that protein kinase C is implicated in bipolar disorder; Claim 2 elaborates on mood regulation and specific phases (manic and depressive) but does not change or contradict the core claim that PKC is involved in the pathophysiology/treatment of bipolar disorder.,76a66954-b970-4954-87d8-b1658e951b14,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Claim 2 provides experimental (rat) evidence that PKC inhibition produces antimanic-like effects (reduced amphetamine-induced hyperlocomotion and decreased risk-taking), which supports Claim 1's assertion that PKC is involved in the pathophysiology and is a treatment target for bipolar disorder.",c989f22f-aa0e-401c-81e7-044a608fa580,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Claim 2 provides experimental evidence that manipulating PKC (chronic inhibition) alters mood-related behavior and hippocampal neurogenesis in rats. This supports the broader Claim 1 that PKC is involved in the pathophysiology and treatment of mood disorders such as bipolar disorder (indirect animal-model evidence relevant to the claim).,982b4346-2957-418d-8cf9-da662ceb1b52,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Claim 2 provides experimental evidence that PKC activation produces manic-like (enhanced risk-taking) and antidepressant-like (reduced immobility in forced swim) effects in models; these findings support the broader claim that PKC is involved in bipolar disorder pathophysiology and could be a treatment target, so Claim 2 is a premise for Claim 1.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,76a66954-b970-4954-87d8-b1658e951b14
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern PKC but in different contexts: claim 1 links PKC to bipolar disorder (clinical/pathophysiological role), while claim 2 describes PKC's role in adult hippocampal cell proliferation (a cellular/neurobiological effect). Claim 2 does not directly support, duplicate, or contradict claim 1, so they are related but distinct (variant).",76a66954-b970-4954-87d8-b1658e951b14,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims address PKC's role in bipolar disorder and are compatible, but they differ in specificity: Claim 1 states a general involvement in pathophysiology and treatment, while Claim 2 specifies that PKC modulation affects both manic and depressive (opposite) facets. Claim 2 adds detail rather than duplicating or contradicting Claim 1.",76a66954-b970-4954-87d8-b1658e951b14,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern mechanisms involved in bipolar disorder, but they refer to different biological factors (protein kinase C vs BDNF). They address the same topic without duplicating, contradicting, or serving as direct premises for one another.",76a66954-b970-4954-87d8-b1658e951b14,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims assert involvement of molecular factors in psychiatric disease mechanisms and treatment, but they refer to different molecules (protein kinase C vs BDNF) and different treatment contexts (bipolar disorder vs antidepressants/antipsychotics for psychiatric disorders). They are related in topic but not equivalent, contradictory, or a direct premise of one another.",76a66954-b970-4954-87d8-b1658e951b14,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims address intracellular signaling mechanisms relevant to psychiatric disorders and treatment, but they refer to different molecular targets: Claim 1 implicates PKC in bipolar disorder, while Claim 2 attributes lithium’s effects to inhibition of GSK3 and IMPase. They are related topical variants rather than duplicates, contradictions, or premises of one another.",76a66954-b970-4954-87d8-b1658e951b14,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Protein kinase C is involved in the pathophysiology and treatment of bipolar disorder.,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern molecular mechanisms relevant to bipolar disorder treatment, but they describe different, non-conflicting pathways. Claim 1 implicates protein kinase C in bipolar disorder pathophysiology/treatment; Claim 2 describes lithium enhancing autophagy via an mTOR-independent IP3 pathway. They are related by topic but not duplicates, contradictions, or premises of one another.",76a66954-b970-4954-87d8-b1658e951b14,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.","Both claims concern tamoxifen combined with lithium in acutely manic patients but address different aspects: Claim 1 states superior efficacy for rapid reduction of manic symptoms, while Claim 2 describes tolerability/safety (few side effects). They do not duplicate or contradict each other, nor is one a direct logical premise of the other.",2b69a477-3fa3-4a96-9a36-77b58dda0554,e94c05b3-ab35-4b9f-86a5-009428370c62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Claim 2 states that tamoxifen has a rapid antimanic effect (by day 7). That provides a plausible causal basis for Claim 1, which asserts that adding tamoxifen to lithium yields a superior rapid reduction in manic symptoms compared with lithium alone. Claim 2 supports (is a premise for) Claim 1 rather than duplicating or contradicting it.",fd1d30e8-f335-4a58-a073-46c46d8eab1f,2b69a477-3fa3-4a96-9a36-77b58dda0554
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Tamoxifen is a known protein kinase C (PKC) inhibitor; Claim 1 reports that adding tamoxifen to lithium produces rapid reductions in manic symptoms. Thus Claim 1 provides empirical support (a clinical example) for the more general mechanistic claim that direct PKC inhibition produces rapid therapeutic effects in mania. (Not a duplicate or contradiction; mechanism inference is reasonable though tamoxifen has other actions.),2b69a477-3fa3-4a96-9a36-77b58dda0554,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims concern lithium use in bipolar disorder but make different, non-opposing points: Claim 1 reports that tamoxifen+lithium is superior to lithium alone for rapid reduction of acute manic symptoms, while Claim 2 asserts lithium should remain first-line for most patients despite adherence/comorbidity concerns. They address related clinical decisions but are neither duplicates, direct premises, nor contradictions.",2b69a477-3fa3-4a96-9a36-77b58dda0554,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium in bipolar disorder but address different questions and contexts: Claim 1 is about adding tamoxifen to lithium for rapid reduction of acute manic symptoms (acute treatment), while Claim 2 is about lithium versus valproate monotherapy for preventing manic and depressive relapses in type I bipolar disorder (maintenance/relapse prevention). They are related but not equivalent, not contradictory, and neither serves as a direct logical premise for the other.",2b69a477-3fa3-4a96-9a36-77b58dda0554,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims concern treatment efficacy in bipolar disorder but compare different interventions and outcomes (tamoxifen+ lithium vs lithium alone in acute mania vs lithium vs lamotrigine more broadly). They are topically related but not equivalent, contradictory, or a direct premise of one another.",2b69a477-3fa3-4a96-9a36-77b58dda0554,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium in bipolar disorder but address different contexts and outcomes. Claim 1 asserts that adding tamoxifen to lithium gives more rapid reduction of acute manic symptoms (short-term adjunctive effect). Claim 2 describes lithium's strong evidence as a maintenance/preventive treatment for manic and depressive episodes (long-term prophylaxis). These are related but distinct and not contradictory, so they are variants.",2b69a477-3fa3-4a96-9a36-77b58dda0554,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium treatment in bipolar disorder but address different questions and comparisons: Claim 1 concerns adding tamoxifen to lithium for rapid reduction of acute manic symptoms, while Claim 2 compares lithium versus mood-stabilizing anticonvulsants for prevention of manic episodes (prophylaxis) and notes outcomes for depressive episodes. They relate to the same clinical domain but differ in intervention, timing (acute vs prevention), and outcome, so they are not duplicates, premises, or contradictions.",2b69a477-3fa3-4a96-9a36-77b58dda0554,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern treatment of bipolar mania but address different points: Claim 1 reports that adding tamoxifen to lithium yields faster reduction of manic symptoms versus lithium alone, while Claim 2 makes a broader claim that lithium is the only mood stabilizer with proven efficacy across multiple outcomes. They are not duplicates or direct contradictions — the first could be compatible with the second — so they are related but different (variant).",2b69a477-3fa3-4a96-9a36-77b58dda0554,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium treatment but address different aspects: Claim 1 is a clinical efficacy comparison (tamoxifen + lithium vs lithium alone for acute mania), while Claim 2 describes mechanistic correlations between lithium-induced brain structural changes and specific pathways. They do not duplicate, contradict, or serve as direct premises for one another.",2b69a477-3fa3-4a96-9a36-77b58dda0554,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium treatment but address different aspects: Claim 1 compares tamoxifen+ lithium vs lithium for rapid reduction of manic symptoms, while Claim 2 links sphingomyelin metabolism and mediodorsal thalamus volume changes to depressive symptom improvement during lithium treatment. They are related by topic (lithium) but differ in outcome, mechanism, and intervention, without duplicating or contradicting each other.",2b69a477-3fa3-4a96-9a36-77b58dda0554,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 is a clinical efficacy statement about tamoxifen combined with lithium for rapid mania reduction, while claim 2 is a molecular/mechanistic claim that lithium up‑regulates GRIN2A which may contribute to its therapeutic effect. They do not duplicate or contradict each other, nor does one directly serve as a premise for the other.",2b69a477-3fa3-4a96-9a36-77b58dda0554,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Tamoxifen is a protein kinase C (PKC) inhibitor; clinical evidence that tamoxifen plus lithium rapidly reduces manic symptoms supports the idea that PKC modulation affects the manic dimension of bipolar disorder. However, Claim 1 does not address depressive symptoms, so it only partially supports Claim 2's broader claim that PKC regulates both manic and depressive facets.",2b69a477-3fa3-4a96-9a36-77b58dda0554,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Claim 2 asserts that PKC modulation influences manic and depressive dimensions of bipolar disorder. Tamoxifen is a PKC inhibitor, so Claim 2 provides a mechanistic rationale supporting why tamoxifen (added to lithium) could rapidly reduce manic symptoms. Claim 2 does not itself claim clinical efficacy, so it functions as a premise rather than a duplicate or contradiction.",1b1b68ed-d73c-418f-abed-03484f767103,2b69a477-3fa3-4a96-9a36-77b58dda0554
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen combined with lithium is superior to lithium alone for the rapid reduction of manic symptoms in patients with acute bipolar mania.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern lithium but at different levels: Claim 1 is a clinical efficacy comparison (tamoxifen + lithium versus lithium alone for rapid mania reduction), while Claim 2 describes lithium's cellular mechanisms (neuroplasticity, ER stress/UPR, autophagy, oxidative stress, mitochondrial function, inflammation). They address related topics without contradicting and one is not a direct logical premise of the other.",2b69a477-3fa3-4a96-9a36-77b58dda0554,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.",Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.,"Both claims concern tamoxifen in acute mania but address different aspects: claim 1 reports tolerability of tamoxifen combined with lithium, while claim 2 reports rapid antimanic efficacy of tamoxifen. They are related but neither duplicates, contradicts, nor serves as a direct premise for the other.",e94c05b3-ab35-4b9f-86a5-009428370c62,fd1d30e8-f335-4a58-a073-46c46d8eab1f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Both claims concern treatments for mania and are related (tamoxifen acts as a protein kinase C inhibitor), but they make different points: claim 1 reports tolerability of tamoxifen combined with lithium, while claim 2 asserts that direct PKC inhibition produces rapid therapeutic effects. They address different aspects (safety vs mechanism/efficacy) and do not duplicate or contradict each other.",e94c05b3-ab35-4b9f-86a5-009428370c62,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Both claims concern lithium use in bipolar disorder but address different aspects: Claim 1 reports tolerability of combining tamoxifen with lithium in acutely manic patients, while Claim 2 recommends lithium as first-line treatment for most bipolar patients despite adherence and comorbidity concerns. They are related on the same topic but do not duplicate, contradict, or serve as a direct premise for one another.",e94c05b3-ab35-4b9f-86a5-009428370c62,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.",Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Both claims concern lithium in bipolar disorder but address different interventions and outcomes: Claim 1 reports tolerability of tamoxifen combined with lithium in acute mania, while Claim 2 states lithium monotherapy is superior to valproate for relapse prevention in type-I bipolar disorder. They are related but not duplicates, premises, or contradictory.",e94c05b3-ab35-4b9f-86a5-009428370c62,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.",Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims concern lithium use in bipolar disorder but address different, non-conflicting aspects: Claim 1 is about tolerability of tamoxifen combined with lithium in acute mania; Claim 2 is about lithium’s superiority over carbamazepine for preventing recurrences and suicide. They discuss related topics without duplicating, implying, or contradicting each other.",e94c05b3-ab35-4b9f-86a5-009428370c62,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.","Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern lithium but address different, non-conflicting points. Claim 1 reports tolerability of combining tamoxifen with lithium in acutely manic patients (safety/tolerability in an acute setting), while Claim 2 asserts lithium's strong efficacy for preventing manic and depressive episodes in bipolar disorder (long-term prophylactic effectiveness). They are related but not duplicates, premises, or contradictions.",e94c05b3-ab35-4b9f-86a5-009428370c62,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.","Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern lithium use in bipolar/manic disorder but address different aspects: claim 1 reports tolerability of tamoxifen+ lithium in acutely manic patients (safety), while claim 2 reports lithium's comparative efficacy versus anticonvulsants for preventing manic episodes (prophylactic efficacy). They are related by topic but do not duplicate, contradict, or serve as premises for one another.",e94c05b3-ab35-4b9f-86a5-009428370c62,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium in the treatment of mania/bipolar disorder but address different aspects: claim 1 reports tolerability of combining tamoxifen with lithium in acutely manic patients, while claim 2 asserts lithium's unique efficacy and overall value as a mood stabilizer. They neither duplicate nor contradict each other, nor does one directly serve as a logical premise for the other.",e94c05b3-ab35-4b9f-86a5-009428370c62,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium in bipolar/mania contexts but address different non-conflicting aspects: claim 1 reports clinical tolerability of combining lithium with tamoxifen in acutely manic patients, while claim 2 reports neuroanatomical volume/thickness changes after lithium treatment. They are related by topic but not duplicates, premises, or contradictions.",e94c05b3-ab35-4b9f-86a5-009428370c62,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The combination of tamoxifen with lithium is well tolerated in acutely manic patients, with no clinically important side effects except fatigue.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium but address different, non-conflicting aspects: claim 1 reports clinical tolerability of tamoxifen plus lithium in acutely manic patients, while claim 2 describes lithium-associated structural brain and gene expression changes. They are related by topic but are not duplicates, premises, or contradictions.",e94c05b3-ab35-4b9f-86a5-009428370c62,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.,"Claim 2 asserts that direct protein kinase C (PKC) inhibition yields rapid antimanic effects. Tamoxifen is known to inhibit PKC, so the general mechanistic claim (2) provides a plausible foundation explaining why tamoxifen (claim 1) would produce a rapid antimanic effect. This depends on the assumption that tamoxifen’s clinical effect is mediated via PKC inhibition.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,fd1d30e8-f335-4a58-a073-46c46d8eab1f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern treatments for bipolar/manic symptoms but make different, non-conflicting points. Claim 1 asserts a rapid antimanic effect of tamoxifen (acute treatment), while Claim 2 states lithium is highly effective for preventing manic and depressive episodes with the strongest evidence—different drugs and different treatment roles, so they are related but not duplicates or contradictions.",fd1d30e8-f335-4a58-a073-46c46d8eab1f,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern treatment of mania/bipolar disorder but refer to different interventions and endpoints: Claim 1 describes a rapid antimanic effect of tamoxifen (acute effect by day 7), while Claim 2 compares lithium versus anticonvulsant mood stabilizers for prevention of manic episodes. They are related in topic but not equivalent, contradictory, or a direct premise.",fd1d30e8-f335-4a58-a073-46c46d8eab1f,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.,"Claim 2 describes that PKC inhibition produces antimanic-like effects in rats; tamoxifen is a known PKC inhibitor, so the preclinical finding provides mechanistic support for tamoxifen producing antimanic effects (Claim 1). Note the evidence in Claim 2 is preclinical (rats) while Claim 1 is a clinical observation, so the support is indirect.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,fd1d30e8-f335-4a58-a073-46c46d8eab1f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Tamoxifen induces a rapid antimanic effect as early as day 7 of treatment.,"Claim 2 reports that PKC inhibition yields antimanic-like effects in rats (reduced amphetamine-induced hyperlocomotion and risk-taking). Tamoxifen is known to inhibit PKC, so Claim 2 provides a mechanistic basis supporting Claim 1's observation that tamoxifen produces rapid antimanic effects. This is an inferential (premise) relationship rather than a duplicate or direct proof, and species/model differences and clinical extrapolation should be noted.",c989f22f-aa0e-401c-81e7-044a608fa580,fd1d30e8-f335-4a58-a073-46c46d8eab1f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims concern treatments for manic/bipolar disorder but make different, nonconflicting assertions: Claim 1 proposes that direct PKC inhibition yields rapid therapeutic effects for mania, while Claim 2 states lithium is highly effective for preventing manic and depressive episodes. They address related topics but are neither equivalent nor contradictory.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims concern treatment of mania/bipolar disorder but address different interventions and contexts. Claim 1 asserts a mechanistic/acute therapeutic effect of direct PKC inhibition, while Claim 2 reports lithium's superiority over anticonvulsants for preventing manic episodes (prophylaxis); they neither duplicate nor contradict each other nor serve as direct premises.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern treatments for mania/bipolar disorder but make different, non-equivalent points: Claim 1 reports that protein kinase C inhibition yields rapid therapeutic effects for manic behavior (an alternative mechanism/treatment), while Claim 2 asserts lithium is the only mood stabilizer with broad proven efficacy. They address the same topic without duplicating, directly contradicting, or serving as logical premises for one another.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern treatments for bipolar/manic illness but describe different interventions and distinct outcomes: Claim 1 asserts rapid symptomatic effects from direct PKC inhibition, while Claim 2 reports structural brain changes after 8 weeks of lithium. They are related by topic but are neither equivalent nor contradictory, nor does one serve as a direct premise for the other.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",Both claims propose therapeutic approaches for affective disorders/bipolar mania but involve different molecular targets and mechanisms (protein kinase C inhibition vs the GRIN2A/NMDA glutamatergic target). They address the same clinical domain without contradicting or logically entailing one another.,068c21c4-d223-4419-a3a6-e74d3c4d6bf0,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern mechanisms underlying treatments for mania/bipolar disorder but describe different, non-overlapping molecular mechanisms (PKC inhibition vs GRIN2A modulation by lithium). They do not contradict or entail one another, so they are related but variant.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Claim 2 states that PKC modulation influences both manic and depressive aspects of bipolar disorder, which provides a mechanistic foundation supporting Claim 1's specific therapeutic claim that direct PKC inhibition can rapidly treat manic behavior. They are not duplicates because Claim 2 is a general regulatory statement while Claim 1 asserts a specific treatment effect.",38c47f6f-9f2f-4c59-95e5-89c32b7e6241,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Claim 2 asserts that PKC is critically involved in mood regulation and in both manic and depressive states, which provides a mechanistic rationale for targeting PKC to alter mood symptoms. That makes Claim 2 a supporting premise for Claim 1, which makes the specific therapeutic claim that direct PKC inhibition produces rapid improvement in manic behavior (Claim 1 goes beyond Claim 2 by asserting a treatment effect and rapidity).",679feb8f-e96a-4b0e-a6bc-f3447c3b774b,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Claim 2 provides preclinical evidence (antimanic-like effects in rats: reduced amphetamine-induced hyperlocomotion and decreased risk-taking) that supports the broader therapeutic claim in Claim 1. Thus Claim 2 can serve as a premise for Claim 1, though animal data do not by themselves prove rapid clinical therapeutic effects in humans.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern effects of PKC inhibition but in different contexts: Claim 1 describes rapid/acute therapeutic effects on manic behavior, while Claim 2 reports deleterious effects (depressive-like behavior and reduced hippocampal cell proliferation) after chronic PKC inhibition in rats. These can coexist (different time courses, doses, endpoints, and possibly species), so they are related but not duplicates or direct contradictions.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Claim 2 states that PKC activation induces manic-like behaviors; Claim 1 says PKC inhibition produces therapeutic effects for mania. If activation promotes manic symptoms, then inhibition would be expected to counteract them, so Claim 2 provides a mechanistic premise supporting Claim 1 (though Claim 2's note about antidepressant-like effects indicates additional complexity).",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern PKC inhibition but describe different, non-conflicting outcomes and timescales: Claim 1 asserts rapid therapeutic effects on manic behavior, while Claim 2 reports that chronic PKC inhibition reduces adult hippocampal cell proliferation. They are related by topic but are neither duplicates, contradictions, nor logical premises of one another.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,f46b86ed-7e0f-49ea-a715-326d1b9e3bf5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Claim 2 states that PKC is critically involved in mood regulation and in both manic and depressive aspects of bipolar disorder, which provides a mechanistic rationale for targeting PKC. That makes Claim 2 a logical premise supporting Claim 1 (which asserts that direct PKC inhibition yields rapid therapeutic effects in mania), though Claim 2 does not itself prove clinical efficacy.",44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Claim 2 reports experimental antimanic-like effects of PKC inhibition in a rat model (reduced amphetamine-induced hyperlocomotion and risk-taking), which provides empirical support for the broader therapeutic claim in Claim 1. They are not duplicates (one is animal evidence, the other a general treatment claim), so Claim 2 functions as a premise for Claim 1.",c989f22f-aa0e-401c-81e7-044a608fa580,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern PKC inhibition but describe different contexts and outcomes: claim 1 asserts rapid therapeutic (antimanic) effects from direct/acute PKC inhibition, whereas claim 2 reports chronic PKC inhibition in rats produces depressive-like behavior and reduced hippocampal cell proliferation. The difference in timescale (acute vs chronic), outcomes, and likely models/species means they address related but non-identical effects rather than duplicating or directly contradicting each other.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Claim 2 reports that PKC activation induces manic-like behaviors (and related behavioral changes); this implies that reducing PKC activity would counter those effects. Thus Claim 2 provides a mechanistic premise supporting Claim 1 that direct PKC inhibition produces therapeutic effects in mania.,8558ce87-1df5-4a7f-88b6-63efb39b40e9,068c21c4-d223-4419-a3a6-e74d3c4d6bf0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern PKC inhibition but describe different outcomes and timescales: Claim 1 asserts rapid therapeutic effects on manic behavior, while Claim 2 reports that chronic PKC inhibition reduces adult hippocampal cell proliferation. They are related by topic but are neither duplicates nor direct premises for one another, nor do they directly contradict each other.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 1 reports that direct PKC inhibition produces rapid therapeutic effects on manic behavior, providing specific evidence that modulation of PKC affects the manic facet of bipolar disorder. Claim 2 is a broader statement that PKC modulation affects both manic and depressive dimensions; thus Claim 1 serves as a supporting premise for the manic aspect of Claim 2 (it does not address the depressive facet).",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern molecular mechanisms underlying psychiatric treatments, but they refer to different pathways and treatment contexts: Claim 1 asserts that direct PKC inhibition rapidly treats manic behavior, while Claim 2 states that BDNF is involved in the actions of antidepressants and antipsychotics. They address related high-level topic (mechanisms of psychiatric drugs) without duplicating, contradicting, or serving as premises for one another.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern rapid-acting neuropsychiatric treatments using non-traditional (non-monoaminergic) mechanisms, but they address different disorders and mechanisms: Claim 1 concerns PKC inhibition for mania, while Claim 2 concerns ketamine as a rapid-acting antidepressant. They are related but not identical, not premises of one another, and do not contradict.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern mechanisms of psychiatric treatments in the brain but describe different, non-conflicting mechanisms. Claim 1 asserts that direct inhibition of protein kinase C yields rapid anti-manic effects, while Claim 2 summarizes lithium's broad regulatory effects on neuroplasticity and neuroprotective pathways. They are related topically but neither duplicates, contradicts, nor logically follows from the other, so they are a variant relationship.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Direct protein kinase C inhibition produces rapid therapeutic effects in the treatment of manic behavior.,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern molecular mechanisms relevant to treatments for mood/mania, but they describe different, noncontradictory mechanisms: claim 1 attributes rapid antimanic effects to direct PKC inhibition, while claim 2 describes lithium enhancing autophagy via an mTOR-independent, IP3-related pathway. Neither entails nor contradicts the other.",068c21c4-d223-4419-a3a6-e74d3c4d6bf0,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 2 provides mechanistic evidence (PCP/ketamine, as NMDA antagonists, increase glutamate efflux and produce dopaminergic, motoric, and cognitive effects). This supports the NMDA antagonist model invoked in Claim 1 and thus serves as a premise underpinning the suggestion that the model may guide drug design for schizophrenia symptoms.",3610ee8a-4b5d-40c5-a800-21bdec74117f,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 2 provides experimental evidence that monoamine-targeting drugs (haloperidol, clozapine, M100907) do not block PCP (an NMDA antagonist)-induced glutamate efflux in prefrontal cortex. This supports Claim 1's assertion that the NMDA antagonist model highlights mechanisms not addressed by monoamine-based antipsychotics and therefore could guide development of novel drugs for cognitive/other symptoms resistant to monoamine therapies.",591b4592-fa77-435a-ac20-f3cbb5263f56,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims concern the NMDA antagonist/PCP model and pharmacological effects relevant to schizophrenia, but they address different points. Claim 1 is a general proposition that the NMDA antagonist model could guide development of drugs for cognitive and other symptoms not responsive to monoamine antipsychotics. Claim 2 reports a specific experimental finding that M100907 (a 5‑HT2A antagonist) fails to block PCP-induced dopaminergic and motor effects. They do not duplicate or directly contradict one another, though Claim 2 is a specific result that could inform the drug-design considerations in Claim 1.",bc25b976-8b05-4146-9fb5-13f238c08ee9,49b4d9c8-db47-4ae4-9471-c57e91439ecc
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 2 reports that PCP (an NMDA antagonist) triggers glutamate efflux in prefrontal cortex independent of dopaminergic and 5-HT2A (monoaminergic) mechanisms. This supports Claim 1 by showing NMDA-antagonist effects act via non-monoaminergic pathways, providing a mechanistic basis for using the NMDA antagonist model to develop drugs for symptoms not addressed by monoamine-based antipsychotics.",f08ed696-e6ae-4062-9a3e-2a086d625f62,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Both claims concern NMDA/PCP glutamate models versus conventional monoamine antipsychotics. Claim 2 states the PCP glutamate activation model does not predict the effects of conventional monoamine-based drugs, which supports Claim 1's suggestion that NMDA antagonist models could be useful for designing novel drugs to target symptoms not addressed by monoamine-based antipsychotics.",a6a0b022-06db-4138-bd34-61d976fd59a6,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 2 gives a mechanistic account (PCP/ketamine NMDA antagonism increases glutamate efflux in PFC leading to dopaminergic, motoric, and cognitive effects) that supports the NMDA‑antagonist model invoked in Claim 1; thus Claim 2 serves as a premise backing Claim 1's suggestion that the NMDA antagonist model can guide novel drug design for cognitive symptoms of schizophrenia.",66319bf8-0459-4763-8cea-9412aba98c25,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 2 provides experimental evidence that common monoamine-targeting antipsychotics (haloperidol, clozapine, M100907) do not block PCP (an NMDA antagonist)-induced glutamate efflux, supporting the idea in Claim 1 that an NMDA antagonist model highlights mechanisms not addressed by monoamine drugs and could guide novel drug design for those symptoms.",fdcdf1bb-91e2-474a-817a-8c79abdf372e,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 2 shows that a monoamine-targeting drug (M100907) does not block the dopaminergic/motor effects of phencyclidine, an NMDA antagonist. This provides evidence that monoamine-based drugs may fail to address effects produced by NMDA antagonism, supporting Claim 1's point that the NMDA antagonist model is useful for designing drugs targeting symptoms not responsive to monoamine antipsychotics.",7248d5f5-3c2b-4aae-9daf-66dfecd35127,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 2 provides mechanistic evidence: PCP (an NMDA antagonist) produces glutamate efflux in prefrontal cortex independent of dopaminergic and 5-HT2A mechanisms, indicating NMDA-antagonist effects act via non-monoamine (glutamatergic) pathways. This supports Claim 1's proposal that the NMDA antagonist model can guide design of drugs targeting symptoms not responsive to monoamine-based antipsychotics.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,bc25b976-8b05-4146-9fb5-13f238c08ee9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Both claims concern glutamate/NMDA models and their relation to conventional monoamine-based antipsychotics, but they make different non-contradictory points: Claim 1 proposes the NMDA antagonist model could guide development of drugs for symptoms not addressed by monoamine antipsychotics, while Claim 2 states the PCP glutamate activation model does not predict the effects of conventional monoamine-based antipsychotics. They address the same domain but differ in focus and implication, so they are variants.",bc25b976-8b05-4146-9fb5-13f238c08ee9,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,The two claims are verbatim identical—same wording and meaning—so they state the same claim.,bc25b976-8b05-4146-9fb5-13f238c08ee9,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims propose targeting the glutamatergic/NMDA system for psychiatric treatment, but they differ in specifics: claim 1 argues for an NMDA-antagonist-based approach for cognitive and other schizophrenia symptoms, while claim 2 nominates GRIN2A (an NMDA receptor subunit) as a target for affective disorders including bipolar disorder. They are related but not the same and do not contradict.",bc25b976-8b05-4146-9fb5-13f238c08ee9,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern NMDA receptor-related mechanisms and therapeutic implications in psychiatric disorders, but they address different disorders (schizophrenia vs bipolar) and different mechanisms/targets (NMDA antagonist model vs GRIN2A expression modulation). They are related but not equivalent, contradictory, or a direct premise of one another.",bc25b976-8b05-4146-9fb5-13f238c08ee9,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern psychiatric disorders and explicitly mention schizophrenia, but they address different mechanisms and implications: Claim 1 discusses the NMDA antagonist model for designing drugs targeting schizophrenia symptoms, while Claim 2 asserts a broad role for BDNF in many psychiatric/neurodevelopmental disorders. There is no direct duplication, entailment, or contradiction between them.",bc25b976-8b05-4146-9fb5-13f238c08ee9,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern NMDA-antagonist–related pharmacology but address different contexts and points: claim 1 proposes using the NMDA antagonist model to guide schizophrenia drug design, while claim 2 states ketamine's antidepressant effects depend on HNK/AMPA/mTOR pathways rather than NMDA antagonism alone. They overlap in topic but make different, noncontradictory claims.",bc25b976-8b05-4146-9fb5-13f238c08ee9,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern NMDA receptor antagonism and psychiatric drug effects, but they address different outcomes and mechanisms: claim 1 suggests the NMDA antagonist model could guide drug design for schizophrenia symptoms not helped by monoamine antipsychotics, while claim 2 describes ketamine's antidepressant mechanism (synaptogenesis and enhanced serotonergic output). They relate topically but do not duplicate, contradict, or serve as direct premises for one another.",bc25b976-8b05-4146-9fb5-13f238c08ee9,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims promote non-monoaminergic (NMDA antagonist) approaches to develop novel psychotropic drugs, but they address different disorders and specific claims: Claim 1 suggests NMDA-antagonist models may guide drugs for schizophrenia symptoms resistant to monoamine antipsychotics, while Claim 2 highlights ketamine's impact on rapid-acting antidepressant development for depression. They are related but not equivalent, contradictory, or a direct premise/consequence.",bc25b976-8b05-4146-9fb5-13f238c08ee9,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.","Both claims concern PCP-induced increases in prefrontal cortical glutamate efflux, but they make different non-conflicting points: claim 1 asserts that that increase contributes to dopaminergic, motoric and cognitive effects, while claim 2 reports that specific antipsychotics and a 5-HT2A antagonist do not block the PCP-induced glutamate efflux. They are related on the same phenomenon but are not duplicates, premises for one another, or contradictory.",3610ee8a-4b5d-40c5-a800-21bdec74117f,591b4592-fa77-435a-ac20-f3cbb5263f56
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims address PCP-induced dopaminergic and motoric effects but focus on different aspects: claim 1 proposes a glutamate-efflux mechanism contributing to those effects, while claim 2 reports that the 5-HT2A antagonist M100907 does not inhibit them. They are related but neither duplicates, premises, nor contradicts the other.",3610ee8a-4b5d-40c5-a800-21bdec74117f,49b4d9c8-db47-4ae4-9471-c57e91439ecc
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Both claims address PCP-activated glutamate efflux in the prefrontal cortex but focus on different aspects: Claim 1 emphasizes that the efflux contributes to dopaminergic, motoric, and cognitive effects, while Claim 2 states that the efflux is independent of dopaminergic and 5-HT2A-mediated mechanisms. The statements are compatible and discuss different causal directions rather than repeating or contradicting each other.",3610ee8a-4b5d-40c5-a800-21bdec74117f,f08ed696-e6ae-4062-9a3e-2a086d625f62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Both claims concern the PCP/ketamine glutamate activation model but address different aspects: claim 1 asserts a mechanistic role for increased prefrontal glutamate efflux in producing dopaminergic, motoric, and cognitive effects, while claim 2 states a limitation of the model (lack of predictive validity for conventional monoamine antipsychotics). They discuss the same topic without entailing, contradicting, or serving as direct premises for one another.",3610ee8a-4b5d-40c5-a800-21bdec74117f,a6a0b022-06db-4138-bd34-61d976fd59a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The two claims are textually identical and assert the same proposition about glutamate efflux in PFC mediating PCP/ketamine effects; they are the same claim repeated.,3610ee8a-4b5d-40c5-a800-21bdec74117f,66319bf8-0459-4763-8cea-9412aba98c25
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.","Both claims concern PCP-induced increase in glutamate efflux in the prefrontal cortex but make different, non-conflicting points: Claim 1 proposes that the efflux contributes to dopaminergic, motoric, and cognitive effects, while Claim 2 reports that certain antipsychotics (haloperidol, clozapine) and the 5-HT2A antagonist M100907 do not block that efflux. They address the same phenomenon from different angles without entailing or contradicting each other.",3610ee8a-4b5d-40c5-a800-21bdec74117f,fdcdf1bb-91e2-474a-817a-8c79abdf372e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims concern PCP's dopaminergic and motoric effects but state different, noncontradictory points: Claim 1 attributes those effects in part to PCP/ketamine-induced glutamate efflux in PFC, while Claim 2 reports that M100907 (a 5-HT2A antagonist) does not inhibit those effects. They address the same topic with different findings rather than repeating, contradicting, or serving as a direct premise for one another.",3610ee8a-4b5d-40c5-a800-21bdec74117f,7248d5f5-3c2b-4aae-9daf-66dfecd35127
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Claim 2 states that PCP-triggered glutamate efflux in PFC is independent of dopaminergic (and 5-HT2A) mechanisms, which implies the glutamate release is not driven by dopamine signaling and therefore can act upstream to produce dopaminergic, motoric, and cognitive effects as asserted in Claim 1. The statements are consistent and Claim 2 provides a mechanistic premise supporting Claim 1.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,3610ee8a-4b5d-40c5-a800-21bdec74117f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Both claims concern the PCP/glutamate activation model: claim 1 asserts a mechanistic role for increased prefrontal glutamate efflux in PCP/ketamine effects, while claim 2 critiques the model's predictive validity for conventional monoamine antipsychotics. They address different aspects (mechanism versus predictive utility) and neither duplicates, contradicts, nor serves as a direct premise for the other.",3610ee8a-4b5d-40c5-a800-21bdec74117f,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 provides mechanistic evidence that NMDA antagonists (PCP/ketamine) produce glutamate efflux and schizophrenia-like dopaminergic, motoric, and cognitive effects in the prefrontal cortex; this supports Claim 2's suggestion that the NMDA antagonist model could be useful for designing novel treatments for cognitive and other schizophrenia symptoms not addressed by monoamine-based drugs.",3610ee8a-4b5d-40c5-a800-21bdec74117f,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern ketamine-related glutamatergic effects but address different outcomes and mechanisms: Claim 1 links PCP/ketamine-induced glutamate efflux in prefrontal cortex to psychotomimetic (dopaminergic, motoric, cognitive) effects, while Claim 2 attributes ketamine's antidepressant action to HNK-driven AMPA receptor activation and mTOR signaling rather than NMDA antagonism. They are related but not the same, do not contradict, and one is not a clear logical premise for the other.",3610ee8a-4b5d-40c5-a800-21bdec74117f,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern ketamine-related actions in the prefrontal cortex but describe different, non-conflicting outcomes and mechanisms: Claim 1 links glutamate efflux to psychotomimetic (dopaminergic/motoric/cognitive) effects, while Claim 2 attributes antidepressant effects to synaptogenesis in PFC pyramidal neurons and enhanced descending serotonergic input. They discuss the same topic without duplication or contradiction.",3610ee8a-4b5d-40c5-a800-21bdec74117f,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern ketamine-related mechanisms in the prefrontal cortex but describe different pathways and outcomes: Claim 1 links increased glutamate efflux to psychotomimetic (dopaminergic, motoric, cognitive) effects of PCP/ketamine, while Claim 2 implicates Homer1a expression as a mediator of antidepressant effects of ketamine and other treatments. They are related but not equivalent, not premises of one another, and do not contradict.",3610ee8a-4b5d-40c5-a800-21bdec74117f,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims involve ketamine and non-monoaminergic/glutamatergic actions, but they address different phenomena: claim 1 attributes glutamate efflux to psychotomimetic (dopaminergic, motoric, cognitive) effects of PCP/ketamine, while claim 2 discusses ketamine's role as a rapid-acting antidepressant and a paradigm shift in drug development. They do not duplicate, contradict, or directly premise one another.",3610ee8a-4b5d-40c5-a800-21bdec74117f,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims report that M100907 is ineffective against effects of phencyclidine, but they refer to different outcomes—claim 1 addresses glutamate efflux in the prefrontal cortex while claim 2 addresses dopaminergic and motoric effects—so they are related but not equivalent or mutually entailing.",591b4592-fa77-435a-ac20-f3cbb5263f56,49b4d9c8-db47-4ae4-9471-c57e91439ecc
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Claim 1 reports that dopaminergic (haloperidol), mixed dopamine/5-HT2A (clozapine), and a selective 5-HT2A antagonist (M100907) do not block PCP-induced glutamate efflux in PFC. Those negative pharmacological results support Claim 2's conclusion that PCP-activated glutamate efflux is independent of dopaminergic and 5-HT2A-mediated mechanisms.",591b4592-fa77-435a-ac20-f3cbb5263f56,f08ed696-e6ae-4062-9a3e-2a086d625f62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 reports experimental evidence that haloperidol, clozapine, and a 5-HT2A antagonist do not block PCP-induced glutamate efflux in prefrontal cortex. This directly supports the general conclusion in Claim 2 that the PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotics, so Claim 1 functions as a premise for Claim 2.",591b4592-fa77-435a-ac20-f3cbb5263f56,a6a0b022-06db-4138-bd34-61d976fd59a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.","The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Both claims concern PCP-induced increases in prefrontal glutamate efflux but make different, non-conflicting points: claim 1 reports that haloperidol, clozapine, and M100907 do not block that glutamate increase; claim 2 asserts that the glutamate increase contributes to the drugs' dopaminergic, motoric, and cognitive effects. They address the same phenomenon without duplicating, contradicting, or directly serving as a premise for one another.",591b4592-fa77-435a-ac20-f3cbb5263f56,66319bf8-0459-4763-8cea-9412aba98c25
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.","Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.","The two claims are textually identical and assert the same proposition: that haloperidol, clozapine, and M100907 do not block PCP-induced increase in prefrontal glutamate efflux.",591b4592-fa77-435a-ac20-f3cbb5263f56,fdcdf1bb-91e2-474a-817a-8c79abdf372e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims report that M100907 is ineffective against effects of phencyclidine, but they refer to different outcome measures: claim 1 concerns PCP-induced glutamate efflux in prefrontal cortex (and also mentions haloperidol and clozapine), while claim 2 concerns dopaminergic and motoric effects. They are related but not duplicate or contradictory.",591b4592-fa77-435a-ac20-f3cbb5263f56,7248d5f5-3c2b-4aae-9daf-66dfecd35127
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,Claim 1 reports that blockade of dopaminergic (haloperidol) and 5-HT2A (M100907) receptors does not prevent PCP-induced glutamate efflux in PFC. That experimental negative result supports the conclusion in Claim 2 that PCP-activated glutamate efflux is independent of dopaminergic and 5-HT2A-mediated mechanisms.,591b4592-fa77-435a-ac20-f3cbb5263f56,c1cc9e43-ed77-466f-98ee-a4ba62cb7888
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 reports experimental evidence that haloperidol (a conventional monoamine antipsychotic), clozapine, and a 5-HT2A antagonist do not block PCP-induced glutamate efflux in prefrontal cortex. Because the PCP glutamate activation model is used to predict antipsychotic efficacy, the failure of these monoamine-targeting drugs to affect the PCP-induced glutamate response undermines the model's ability to predict conventional monoamine-based antipsychotics. Thus Claim 1 serves as a premise supporting Claim 2.",591b4592-fa77-435a-ac20-f3cbb5263f56,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 provides experimental evidence that monoamine-based antipsychotics (haloperidol, clozapine) and a 5-HT2A antagonist do not block PCP (an NMDA antagonist)-induced glutamate efflux in prefrontal cortex. This supports Claim 2's assertion that the NMDA antagonist model reveals pathophysiology not addressed by monoamine drugs, making it useful for designing novel treatments for symptoms unresponsive to monoamine-based antipsychotics.",591b4592-fa77-435a-ac20-f3cbb5263f56,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Both claims address mechanisms of PCP action and indicate a lack of involvement of dopaminergic and 5-HT2A pathways, but they refer to different outcomes: Claim 1 concerns M100907's inability to block PCP's dopaminergic and motoric effects, while Claim 2 concerns PCP-induced glutamate efflux in the prefrontal cortex. They are consistent but not equivalent or directly premise/consequence of one another.",49b4d9c8-db47-4ae4-9471-c57e91439ecc,f08ed696-e6ae-4062-9a3e-2a086d625f62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 reports that M100907 (a monoamine receptor-targeting agent) fails to block PCP-induced dopaminergic and motor effects. This is direct evidence that the PCP glutamate activation model does not predict efficacy of a monoamine-based drug in this assay, so Claim 1 supports Claim 2 (premise_1_to_2).",49b4d9c8-db47-4ae4-9471-c57e91439ecc,a6a0b022-06db-4138-bd34-61d976fd59a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Both claims concern the dopaminergic and motoric effects of PCP but make different, non-conflicting points: Claim 1 reports that the 5-HT2A antagonist M100907 does not inhibit these effects, while Claim 2 proposes that increased prefrontal glutamate efflux contributes to those effects. The second does not logically follow from the first nor contradict it, so they are related but not duplicate or premise-linked.",49b4d9c8-db47-4ae4-9471-c57e91439ecc,66319bf8-0459-4763-8cea-9412aba98c25
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.","Both claims report lack of efficacy of M100907 against PCP-induced effects, but they refer to different endpoints: claim 1 concerns dopaminergic and motoric effects, while claim 2 concerns PCP-induced glutamate efflux in prefrontal cortex (and also mentions haloperidol and clozapine). The claims are consistent but not duplicates.",49b4d9c8-db47-4ae4-9471-c57e91439ecc,fdcdf1bb-91e2-474a-817a-8c79abdf372e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The two claims are identical in wording and meaning: both state that M100907 is ineffective at inhibiting the dopaminergic and motoric effects of phencyclidine.,49b4d9c8-db47-4ae4-9471-c57e91439ecc,7248d5f5-3c2b-4aae-9daf-66dfecd35127
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Both claims concern PCP and report that dopaminergic and 5-HT2A mechanisms are not involved, but they address different outcomes: claim 1 concerns M100907's (a 5-HT2A antagonist) inability to block PCP-induced dopaminergic and motoric effects, while claim 2 concerns PCP-evoked glutamate efflux in prefrontal cortex being independent of dopaminergic and 5-HT2A mechanisms. They are related but not equivalent or a direct premise/consequence.",49b4d9c8-db47-4ae4-9471-c57e91439ecc,c1cc9e43-ed77-466f-98ee-a4ba62cb7888
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 reports an empirical negative result: M100907 (a monoamine-targeting agent) fails to block PCP-induced dopaminergic and motor effects. That finding is direct evidence that the PCP glutamate activation model does not predict the actions of at least this monoamine-based drug, supporting the broader assertion in Claim 2 that the PCP model lacks predictive validity for conventional monoamine-based antipsychotics.",49b4d9c8-db47-4ae4-9471-c57e91439ecc,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Both claims concern the NMDA antagonist/PCP model and drug effects, but they address different points: claim 1 reports a specific negative finding about M100907's inability to block PCP-induced dopaminergic and motor effects, while claim 2 is a general proposition that the NMDA antagonist model can guide development of drugs for cognitive symptoms not helped by monoamine antipsychotics. They are related but not equivalent, contradictory, or a direct premise.",49b4d9c8-db47-4ae4-9471-c57e91439ecc,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 states PCP-induced glutamate efflux in PFC is independent of dopaminergic and 5-HT2A mechanisms. Conventional antipsychotics act via monoamine (dopamine/5-HT2A) pathways, so that mechanistic independence supports the conclusion in Claim 2 that the PCP glutamate activation model lacks predictive validity for monoamine-based antipsychotics.",f08ed696-e6ae-4062-9a3e-2a086d625f62,a6a0b022-06db-4138-bd34-61d976fd59a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Both claims address PCP-induced glutamate efflux in the prefrontal cortex but focus on different, non-conflicting aspects: claim 1 states the efflux is independent of dopaminergic and 5-HT2A mediation, while claim 2 asserts the efflux contributes to dopaminergic, motoric, and cognitive effects. They are related but not duplicates, direct premises, or contradictions.",f08ed696-e6ae-4062-9a3e-2a086d625f62,66319bf8-0459-4763-8cea-9412aba98c25
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Claim 2 reports that dopaminergic antagonists (haloperidol, clozapine) and a selective 5-HT2A antagonist (M100907) do not block PCP-induced glutamate efflux in the prefrontal cortex. Those negative pharmacological results provide direct evidence supporting Claim 1's conclusion that the efflux is independent of dopaminergic and 5-HT2A-mediated mechanisms.",fdcdf1bb-91e2-474a-817a-8c79abdf372e,f08ed696-e6ae-4062-9a3e-2a086d625f62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims concern PCP mechanisms and the role of 5-HT2A/dopaminergic systems. Claim 1 states PCP-evoked glutamate efflux in PFC is independent of dopamine and 5-HT2A; Claim 2 reports the 5-HT2A antagonist M100907 fails to block PCP's dopaminergic and motor effects. They overlap in implying limited 5-HT2A involvement but address different specific outcomes (glutamate release vs dopaminergic/motor effects), so they are related but not duplicates, premises, or contradictory.",f08ed696-e6ae-4062-9a3e-2a086d625f62,7248d5f5-3c2b-4aae-9daf-66dfecd35127
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The two claims are textually identical and assert the same proposition: PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,f08ed696-e6ae-4062-9a3e-2a086d625f62,c1cc9e43-ed77-466f-98ee-a4ba62cb7888
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 states that PCP-induced glutamate efflux in prefrontal cortex occurs independently of dopaminergic and 5-HT2A mechanisms. That mechanistic independence explains why a PCP glutamate-activation model would not reliably predict the efficacy of conventional monoamine-based antipsychotics (which act via dopamine/5-HT2A pathways), so Claim 1 serves as a premise supporting Claim 2.",f08ed696-e6ae-4062-9a3e-2a086d625f62,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 reports that PCP (an NMDA antagonist) drives glutamate efflux via mechanisms independent of dopaminergic and 5-HT2A systems, providing mechanistic evidence for non-monoaminergic pathways. This supports Claim 2's conclusion that the NMDA-antagonist model can inform development of drugs targeting schizophrenia symptoms not addressed by monoamine-based antipsychotics.",f08ed696-e6ae-4062-9a3e-2a086d625f62,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern the glutamatergic system but address different points: Claim 1 is a specific mechanistic finding about PCP-induced glutamate efflux in the prefrontal cortex (independence from dopaminergic and 5-HT2A mechanisms), while Claim 2 is a broader therapeutic assertion that GRIN2A is a promising target for affective disorders. They are related by topic but not duplicates, premises, or contradictions.",f08ed696-e6ae-4062-9a3e-2a086d625f62,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern mechanisms of dissociative/NMDA-targeting drugs and glutamate-related signaling, but they address different drugs, outcomes and mechanisms: Claim 1 concerns PCP-triggered glutamate efflux in PFC being independent of dopaminergic and 5-HT2A pathways, while Claim 2 attributes ketamine's antidepressant effects to HNK-mediated AMPA activation and mTOR signaling rather than NMDA antagonism. They are related by topic but do not duplicate, contradict, or serve as premises for one another.",f08ed696-e6ae-4062-9a3e-2a086d625f62,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern molecular/neurochemical mechanisms in the prefrontal cortex related to psychotropic agents, but they address different specific mechanisms and purposes. Claim 1 concerns PCP-triggered glutamate efflux being independent of dopaminergic and 5-HT2A pathways, while Claim 2 proposes Homer1a expression in mPFC as a common downstream mediator of antidepressant effects (including ketamine). They do not contradict or logically imply one another, but are related topic-wise.",f08ed696-e6ae-4062-9a3e-2a086d625f62,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Both claims address PCP/ketamine-induced glutamate activity, but they make different points: Claim 2 asserts a mechanistic role for increased prefrontal glutamate efflux in producing psychotomimetic effects, while Claim 1 argues that the PCP glutamate activation model does not have predictive validity for conventional monoamine antipsychotics. They are related topical variants (mechanism vs. predictive validity) without duplication or direct contradiction.",a6a0b022-06db-4138-bd34-61d976fd59a6,66319bf8-0459-4763-8cea-9412aba98c25
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 2 provides empirical evidence that haloperidol, clozapine and a 5-HT2A antagonist do not block PCP-induced glutamate efflux in PFC. That observation explains why a PCP glutamate-activation model would fail to predict the effects of conventional monoamine-based antipsychotics, so Claim 2 is a premise supporting Claim 1.",fdcdf1bb-91e2-474a-817a-8c79abdf372e,a6a0b022-06db-4138-bd34-61d976fd59a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,Claim 2 reports that M100907 (a monoamine/5-HT2A-targeting drug) fails to block PCP-induced dopaminergic and motor effects. This specific negative finding supports the broader Claim 1 that the PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,7248d5f5-3c2b-4aae-9daf-66dfecd35127,a6a0b022-06db-4138-bd34-61d976fd59a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 2 states a mechanistic independence: PCP-driven glutamate efflux in PFC does not involve dopaminergic or 5-HT2A pathways. That explains why conventional monoamine-based antipsychotics (which target dopamine/5-HT2A) would not modulate the PCP glutamate activation, supporting Claim 1 that the PCP glutamate activation model lacks predictive validity for those drugs.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,a6a0b022-06db-4138-bd34-61d976fd59a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,The two claims are textually identical and convey the same assertion that the PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,a6a0b022-06db-4138-bd34-61d976fd59a6,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 states that the PCP/NMDA glutamate activation model does not predict responses to conventional monoamine antipsychotics; this limitation supports Claim 2's suggestion that the NMDA antagonist model could instead be useful for designing novel, non-monoamine treatments targeting cognitive and other symptoms unresponsive to monoamine drugs.",a6a0b022-06db-4138-bd34-61d976fd59a6,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern the glutamatergic system but address different points: Claim 1 critiques the predictive validity of a PCP glutamate activation model for conventional monoamine antipsychotics, while Claim 2 proposes GRIN2A as a therapeutic target for affective disorders (including bipolar). They are topically related but do not duplicate, contradict, or serve as a direct premise for one another.",a6a0b022-06db-4138-bd34-61d976fd59a6,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern glutamate/non-monoaminergic versus monoamine-based psychiatric drugs, but they address different contexts and conclusions: claim 1 critiques a PCP-glutamate model's predictive validity for monoamine antipsychotics, while claim 2 highlights ketamine's impact on antidepressant development. They are related thematically but neither duplicates, contradicts, nor serves as a direct premise for the other.",a6a0b022-06db-4138-bd34-61d976fd59a6,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.","Both claims address PCP-induced glutamate efflux in the prefrontal cortex but focus on different aspects: claim 1 asserts that this efflux contributes to dopaminergic, motoric, and cognitive effects, while claim 2 reports that haloperidol, clozapine, and M100907 do not block the PCP-induced efflux. They are related but neither duplicates, contradicts, nor directly serves as a premise for the other.",66319bf8-0459-4763-8cea-9412aba98c25,fdcdf1bb-91e2-474a-817a-8c79abdf372e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims address the mechanisms of PCP-induced dopaminergic and motoric effects but from different angles: claim 1 implicates increased prefrontal glutamate efflux as contributing to these effects, while claim 2 reports that the 5-HT2A antagonist M100907 does not inhibit those effects. The statements are consistent and neither entails nor contradicts the other.",66319bf8-0459-4763-8cea-9412aba98c25,7248d5f5-3c2b-4aae-9daf-66dfecd35127
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Claim 2 states that PCP-triggered glutamate efflux in PFC occurs independently of dopaminergic and 5-HT2A mechanisms, implying the glutamate release is upstream rather than downstream of those systems. That independence supports the idea in Claim 1 that the increased glutamate efflux can contribute to dopaminergic, motoric, and cognitive effects (i.e., Claim 2 provides a premise for Claim 1). The statements are compatible, not contradictory.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,66319bf8-0459-4763-8cea-9412aba98c25
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Both claims address the PCP/glutamate activation model in the prefrontal cortex but make different, noncontradictory points: Claim 1 asserts a mechanistic role for PCP-/ketamine-induced glutamate efflux in producing dopaminergic, motoric, and cognitive effects, while Claim 2 critiques the model's predictive validity for conventional monoamine-based antipsychotics. They relate to the same topic but do not duplicate, premise, or contradict one another.",66319bf8-0459-4763-8cea-9412aba98c25,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 provides mechanistic evidence that NMDA antagonists (PCP, ketamine) produce glutamate-mediated dopaminergic, motoric and cognitive effects resembling aspects of schizophrenia. This supports Claim 2's proposal that the NMDA antagonist model could be useful for designing drugs to target cognitive and other schizophrenia symptoms not addressed by monoamine-based antipsychotics.",66319bf8-0459-4763-8cea-9412aba98c25,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern ketamine’s neuropharmacology but address different effects and mechanisms. Claim 1 attributes increased prefrontal glutamate efflux to the psychotomimetic (dopaminergic, motoric, cognitive) effects of PCP/ketamine. Claim 2 addresses ketamine’s antidepressant action and attributes it to HNK-driven AMPA receptor activation and mTOR signaling rather than NMDA antagonism. The claims are related by topic but neither restates, contradicts, nor logically entails the other.",66319bf8-0459-4763-8cea-9412aba98c25,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern ketamine effects in the prefrontal cortex but describe different mechanisms and outcomes. Claim 1 links ketamine/PCP-induced glutamate efflux to dopaminergic, motoric, and cognitive (psychotomimetic) effects; claim 2 attributes ketamine's antidepressant action to increased synaptogenesis in PFC pyramidal neurons and enhanced serotonergic drive to the raphe. The claims are compatible and related but not equivalent, contradictory, or a direct premise of one another.",66319bf8-0459-4763-8cea-9412aba98c25,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The increase in glutamate efflux in the prefrontal cortex produced by phencyclidine (PCP) and ketamine contributes to the dopaminergic, motoric, and cognitive effects of these psychotomimetic drugs.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern ketamine actions in the prefrontal cortex but describe different effects and mechanisms: Claim 1 links ketamine/PCP-induced glutamate efflux to dopaminergic, motoric, and cognitive (psychotomimetic) effects, whereas Claim 2 implicates Homer1a expression in mPFC as a pathway mediating antidepressant effects of treatments including ketamine. They address related topics but are neither equivalent, contradictory, nor a direct premise of one another.",66319bf8-0459-4763-8cea-9412aba98c25,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,"Both claims report lack of efficacy of M100907 against phencyclidine effects, but they refer to different outcome measures: claim 1 concerns PCP-induced glutamate efflux in prefrontal cortex (and also mentions haloperidol and clozapine), while claim 2 concerns dopaminergic and motoric effects. They are related but not the same claim or a premise of one another.",fdcdf1bb-91e2-474a-817a-8c79abdf372e,7248d5f5-3c2b-4aae-9daf-66dfecd35127
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Both claims state the same conclusion: PCP-induced glutamate efflux in the prefrontal cortex is not mediated by dopaminergic or 5-HT2A mechanisms. Claim 1 provides specific drug evidence (haloperidol, clozapine, M100907) that fail to block the effect; Claim 2 expresses this as a general independence from those mechanisms.",fdcdf1bb-91e2-474a-817a-8c79abdf372e,c1cc9e43-ed77-466f-98ee-a4ba62cb7888
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 reports that haloperidol (a conventional monoamine antipsychotic), clozapine, and a 5-HT2A antagonist fail to block PCP-induced glutamate efflux in prefrontal cortex. This experimental finding supports Claim 2's conclusion that the PCP glutamate-activation model does not predict the actions of conventional monoamine-based antipsychotic drugs.",fdcdf1bb-91e2-474a-817a-8c79abdf372e,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Haloperidol, clozapine, and the 5-HT2A antagonist M100907 do not block phencyclidine-induced increase in glutamate efflux in the prefrontal cortex.",The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 provides experimental evidence that monoamine-based antipsychotics (haloperidol, clozapine, a 5-HT2A antagonist) fail to block PCP (an NMDA antagonist)-induced glutamate efflux in prefrontal cortex. This supports Claim 2's conclusion that the NMDA antagonist model reveals pathology not addressed by monoamine drugs and so may be useful for designing novel treatments for cognitive/other schizophrenia symptoms unresponsive to monoamine-based antipsychotics.",fdcdf1bb-91e2-474a-817a-8c79abdf372e,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Both claims address PCP mechanisms and implicate that dopaminergic and 5-HT2A pathways do not mediate certain PCP effects, but they refer to different endpoints: claim 1 reports M100907 (a 5-HT2A antagonist) fails to block PCP-induced dopaminergic and motor effects, while claim 2 states PCP-induced glutamate efflux in PFC is independent of dopaminergic and 5-HT2A mechanisms. They are related but not equivalent or directly premise/consequence, so they are variants.",7248d5f5-3c2b-4aae-9daf-66dfecd35127,c1cc9e43-ed77-466f-98ee-a4ba62cb7888
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,Claim 1 reports a specific negative result: M100907 (a monoamine-targeting 5-HT2A antagonist) fails to inhibit PCP-induced dopaminergic and motor effects. That single-case failure of a monoamine-targeting compound in the PCP model supports the general Claim 2 that the PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,7248d5f5-3c2b-4aae-9daf-66dfecd35127,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,M100907 is ineffective in inhibiting the dopaminergic and motoric effects of phencyclidine.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Both statements concern the NMDA-antagonist (phencyclidine/PCP) model, but they address different points: claim 1 reports a specific negative finding about M100907 failing to block PCP-induced dopaminergic and motor effects, while claim 2 makes a general methodological point that the NMDA antagonist model may help design drugs for cognitive/other schizophrenia symptoms. They are related in topic but not equivalent, do not contradict, and one is not a logical premise of the other.",7248d5f5-3c2b-4aae-9daf-66dfecd35127,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Claim 1 asserts that PCP-induced glutamate efflux in the PFC is independent of dopaminergic and 5-HT2A mechanisms. Conventional antipsychotics act via monoamine (dopamine/5-HT2A) pathways, so a model whose key effect is independent of those pathways would not be expected to predict the efficacy of monoamine-based drugs. Therefore Claim 1 functions as a premise supporting Claim 2.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,fc094750-8733-464d-b345-437a216b0769
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 reports that PCP (an NMDA antagonist) induces glutamate efflux in prefrontal cortex via mechanisms independent of dopaminergic and 5-HT2A systems, indicating NMDA-antagonist effects operate through non-monoaminergic pathways. This mechanistic finding supports Claim 2's claim that the NMDA antagonist model can inform design of drugs targeting symptoms not responsive to monoamine-based antipsychotics.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern the glutamatergic system but address different aspects: claim 1 is a specific neuropharmacological finding about PCP-evoked glutamate efflux being independent of dopaminergic and 5-HT2A mechanisms; claim 2 is a therapeutic assertion that GRIN2A (an NMDA/glutamate receptor subunit) is a target for affective disorders. They are related thematically but neither duplicates, contradicts, nor directly premises the other.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern glutamatergic effects of NMDA‑receptor antagonists (PCP and ketamine) but make different, nonconflicting points. Claim 1 reports that PCP‑induced glutamate efflux in prefrontal cortex does not depend on dopaminergic or 5‑HT2A mechanisms. Claim 2 argues that ketamine’s antidepressant effect involves HNK‑driven AMPA activation and mTOR signaling rather than NMDA antagonism alone. They address related neurochemical themes but are neither duplicates, direct contradictions, nor logical premises of one another.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,PCP-activated glutamate efflux in the prefrontal cortex is independent of dopaminergic and 5-HT2A-mediated mechanisms.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern NMDA-antagonist effects in the prefrontal cortex and involve glutamate/serotonergic systems, but they make different, noncontradictory assertions: claim 1 states PCP-induced glutamate efflux is independent of dopaminergic and 5-HT2A mechanisms, while claim 2 attributes ketamine’s antidepressant effects to synaptogenesis in PFC pyramidal neurons and enhanced serotonergic output to the raphe. They are related topical variants rather than duplicates, contradictions, or direct premises.",c1cc9e43-ed77-466f-98ee-a4ba62cb7888,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Claim 1 states the PCP/NMDA glutamate activation model does not predict effects of conventional monoamine antipsychotics, which implies the model reflects different mechanisms and outcomes. That provides a logical basis for Claim 2's proposal that the NMDA antagonist model could be useful for designing novel drugs targeting cognitive or other schizophrenia symptoms not addressed by monoamine-based drugs.",fc094750-8733-464d-b345-437a216b0769,25286171-950a-4c3c-abf6-dbab297a47a8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The PCP glutamate activation model lacks predictive validity for conventional monoamine-based antipsychotic drugs.,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern glutamatergic mechanisms of psychoactive drugs (NMDA/AMPA-related models), but they address different questions: Claim 1 critiques the predictive validity of a PCP-based glutamate activation model for conventional monoamine antipsychotics, while Claim 2 proposes a specific mechanism (HNK→AMPA activation and mTOR) underlying ketamine's antidepressant effects. They are about the same topical domain without repeating, supporting, or contradicting each other.",fc094750-8733-464d-b345-437a216b0769,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern the glutamatergic/NMDA system as a source of therapeutic targets for psychiatric disorders, but they focus on different specific targets and conditions: Claim 1 discusses the NMDA antagonist model and drug design for schizophrenia symptoms, while Claim 2 highlights GRIN2A (an NMDA receptor subunit) as a target for affective disorders including bipolar disorder. They are related topically but not equivalent or contradictory.",25286171-950a-4c3c-abf6-dbab297a47a8,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims relate to schizophrenia and biological mechanisms relevant to treatment/pathophysiology, but they focus on different mechanisms (NMDA antagonist model vs BDNF involvement). They do not duplicate, contradict, or serve as direct premises for one another.",25286171-950a-4c3c-abf6-dbab297a47a8,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern mechanisms relevant to psychiatric drug action but refer to different biological mechanisms and contexts: claim 1 focuses on NMDA antagonist models and drug design for schizophrenia cognitive symptoms, while claim 2 concerns BDNF's role in antidepressant/antipsychotic mechanisms. They are related but not equivalent, contradictory, or a direct premise of one another.",25286171-950a-4c3c-abf6-dbab297a47a8,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern mechanisms of psychotropic drugs involving NMDA-related pathways but address different conditions and conclusions: Claim 1 suggests NMDA-antagonist models could guide schizophrenia drug design, while Claim 2 argues ketamine’s antidepressant action is mediated by HNK-driven AMPA activation and mTOR rather than NMDA antagonism alone. They are related topics but do not directly duplicate or contradict one another.",25286171-950a-4c3c-abf6-dbab297a47a8,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern NMDA receptor antagonists but address different applications and mechanisms: claim 1 suggests using the NMDA antagonist model to design drugs for schizophrenia symptoms, while claim 2 describes ketamine's antidepressant mechanisms (synaptogenesis and enhanced serotonergic transmission). They are topically related but not equivalent, contradictory, or a direct premise for one another.",25286171-950a-4c3c-abf6-dbab297a47a8,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,The NMDA antagonist model may be useful for designing novel drugs that target cognitive and other symptoms of schizophrenia that are not responsive to monoamine-based antipsychotic drugs.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims endorse non-monoaminergic (NMDA antagonist) approaches as offering therapeutic advantages over monoamine-based drugs, but they concern different clinical contexts and claims: Claim 1 discusses using the NMDA antagonist model to design drugs for schizophrenia symptoms, while Claim 2 highlights ketamine as an example in antidepressant development. They are related but not equivalent or premise-linked.",25286171-950a-4c3c-abf6-dbab297a47a8,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,Claim 2 provides direct clinical evidence (lithium superior to valproate for preventing manic and depressive relapses in type-I bipolar disorder) that supports Claim 1's recommendation that lithium remain first-line for most patients. The claims are compatible; Claim 2 strengthens Claim 1 though it does not address adherence or comorbidity caveats.,bd479224-5c5a-404d-9c45-468f2e68bcef,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,Claim 2 provides evidence that lithium is more effective than an alternative (lamotrigine) and that lamotrigine is associated with more switching and hospitalizations; this supports the recommendation in Claim 1 that lithium remain first-line for most patients.,10899945-abc8-4bbb-b952-ac3c573494ab,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Claim 2 provides specific comparative efficacy evidence (lithium superior to carbamazepine for preventing recurrences in BD I and for preventing suicide across the bipolar population), which supports the recommendation in Claim 1 that lithium remain first-line for most patients. Claim 2 does not address adherence or comorbidities, but its efficacy and suicide-prevention data function as a premise in favor of Claim 1.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,Claim 2 asserts that lithium is highly effective with the strongest evidence for preventing manic and depressive episodes; that efficacy/evidence base serves as a justification for Claim 1's recommendation that lithium remain first-line for most patients despite adherence and comorbidity concerns.,d4e77fc9-7d46-473c-86f9-13b018308d00,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Claim 2 provides comparative efficacy evidence (lithium is superior to mood-stabilizing anticonvulsants for preventing manic episodes) that supports Claim 1's recommendation to keep lithium as first-line treatment. Claim 2 does not address adherence or comorbidities, but its efficacy finding functions as a premise for the treatment recommendation in Claim 1.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Claim 2 states that lithium uniquely has proven efficacy across acute mania, bipolar depression, relapse prevention (both poles), and suicide prevention. Those efficacy claims provide the evidentiary foundation that supports Claim 1's recommendation that lithium remain first-line for most patients despite concerns about adherence and comorbidities; therefore Claim 2 is a premise for Claim 1.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Claim 2 presents biological/neuroanatomical effects of lithium in bipolar patients (increased cortical thickness and subcortical volumes) that can serve as supporting evidence for lithium's therapeutic value, thus providing a premise for recommending lithium as first-line treatment in Claim 1. It does not, however, directly address adherence, comorbidity, or clinical outcome effectiveness, so it is supportive but not conclusive.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium treatment but at different levels: claim 1 is a clinical recommendation about using lithium as first-line therapy, while claim 2 reports a specific biological mechanism (sphingomyelin metabolism and mediodorsal thalamus volume changes) associated with response. They are related but distinct, not duplicates or contradictions, and claim 2 does not directly serve as a premise for claim 1.",0878e73e-5f4f-4dcb-812c-48b086d33682,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims concern lithium but address different aspects: Claim 1 is a clinical treatment recommendation, while Claim 2 describes molecular mechanisms. They relate to the same topic without duplicating, contradicting, or serving as a direct logical premise for one another.",0878e73e-5f4f-4dcb-812c-48b086d33682,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern treatment approaches for bipolar disorder but propose different, non-conflicting strategies: Claim 1 endorses lithium as first-line treatment, while Claim 2 identifies GRIN2A as a potential therapeutic target. They are related in topic but neither duplicates, contradicts, nor serves as a premise for the other.",0878e73e-5f4f-4dcb-812c-48b086d33682,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Claim 2 offers a putative biological mechanism (lithium up-regulates GRIN2A, which is down-regulated in bipolar disorder) that would support lithium's therapeutic efficacy and thus bolsters the recommendation in Claim 1. It is supportive evidence rather than definitive proof, so it functions as a premise for Claim 1.",1a142c2f-a016-4716-8019-a883e04a6b5f,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Claim 2 describes biological mechanisms (neuroplasticity and neuroprotection via multiple cellular pathways) that plausibly underlie lithium's clinical benefits. Those mechanistic effects provide a scientific premise supporting Claim 1's recommendation that lithium remain first-line for most patients, although clinical factors like adherence and comorbidities are distinct considerations.",0ccc686b-5be5-4aa5-9360-6c97d148920d,0878e73e-5f4f-4dcb-812c-48b086d33682
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but at different levels: claim 1 is a clinical treatment recommendation for bipolar disorder, while claim 2 describes molecular mechanisms (GSK3 and IMPase inhibition). They address related subject matter without repeating, contradicting, or directly serving as a premise for one another.",0878e73e-5f4f-4dcb-812c-48b086d33682,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium should remain the first-line treatment for bipolar disorder in the majority of patients despite concerns about adherence and comorbidities.,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern lithium but at different levels: Claim 1 is a clinical recommendation about lithium as first-line treatment for bipolar disorder, while Claim 2 describes a molecular mechanism (lithium enhances autophagy via an mTOR-independent, IP3-related pathway). They do not restate or contradict each other, nor does the mechanistic claim directly serve as a premise for the clinical treatment recommendation, so they are related but distinct (variant).",0878e73e-5f4f-4dcb-812c-48b086d33682,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Both claims assert lithium is more effective in bipolar disorder but compare it to different drugs and outcomes. Claim 1 compares lithium vs valproate for preventing manic and depressive relapses in type-I bipolar disorder; Claim 2 compares lithium vs lamotrigine regarding treatment, medication switching, and hospitalization. They address the same topic but differ in comparator and specific endpoints, so they are variants.",bd479224-5c5a-404d-9c45-468f2e68bcef,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims assert lithium's superiority for preventing relapses/recurrences in bipolar I, but they compare lithium to different drugs (valproate vs carbamazepine) and claim 2 also adds a broader claim about suicide prevention in the entire bipolar population. They address the same topic with different specifics, so they are variants rather than duplicates or contradictions.",bd479224-5c5a-404d-9c45-468f2e68bcef,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.",Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Claim 2 states a general conclusion that lithium is among the most effective drugs with the strongest evidence for preventing manic and depressive episodes, which supports the specific comparative claim in Claim 1 that lithium is superior to valproate. They are not duplicates because Claim 1 is a narrower, specific comparison (lithium vs. valproate, monotherapy, type‑I bipolar) that Claim 2 does not explicitly assert.",d4e77fc9-7d46-473c-86f9-13b018308d00,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,contradiction,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","The claims disagree about lithium's effect on depressive relapses: Claim 1 states lithium is superior to valproate for both manic and depressive relapses, while Claim 2 says lithium is superior for manic episodes but shows no significant difference for depressive episodes versus mood-stabilizing anticonvulsants (a class that includes valproate). These statements cannot both be true regarding depressive episode prevention.",bd479224-5c5a-404d-9c45-468f2e68bcef,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium's efficacy in bipolar disorder, but they differ in scope and strength. Claim 1 is a specific comparative finding (lithium superior to valproate for preventing manic and depressive relapses in type I bipolar), whereas Claim 2 is a broader, stronger assertion (lithium is the only mood stabilizer proven for multiple outcomes including suicide prevention and is the most valuable option). Claim 1 does not logically entail the exclusivity or the additional outcomes claimed in Claim 2, so they are related but not duplicates or premises/contradictions.",bd479224-5c5a-404d-9c45-468f2e68bcef,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern effects of lithium treatment but on different levels: Claim 1 is a clinical efficacy comparison (lithium vs valproate for relapse prevention in bipolar I), while Claim 2 describes neurotrophic signaling pathways correlated with lithium-induced structural brain changes. They do not duplicate, contradict, or serve as a direct logical premise for one another, but are related as different aspects of lithium's effects.",bd479224-5c5a-404d-9c45-468f2e68bcef,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims concern lithium but address different aspects: Claim 1 is a clinical comparison of relapse prevention versus valproate, while Claim 2 describes molecular/neurotrophic mechanisms of lithium. They do not duplicate, contradict, or serve as direct premises for one another.",bd479224-5c5a-404d-9c45-468f2e68bcef,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium but address different aspects: Claim 1 is a clinical efficacy comparison (lithium vs valproate for relapse prevention in bipolar I), while Claim 2 describes mechanistic/biological effects of lithium on brain structure and gene expression. They do not duplicate or contradict each other, nor does one serve as a clear logical premise for the other, so they are related by topic but differ in content.",bd479224-5c5a-404d-9c45-468f2e68bcef,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern therapeutic approaches for bipolar disorder but address different interventions/mechanisms: claim 1 compares clinical efficacy of lithium versus valproate for relapse prevention, while claim 2 proposes GRIN2A as a molecular therapeutic target. They do not contradict or serve as premises for one another, but they are related on the same broad topic.",bd479224-5c5a-404d-9c45-468f2e68bcef,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium in bipolar disorder but address different aspects: Claim 1 is a clinical efficacy comparison (lithium vs valproate), while Claim 2 proposes a molecular mechanism (GRIN2A up-regulation). They do not duplicate, contradict, or serve as direct premises for one another.",bd479224-5c5a-404d-9c45-468f2e68bcef,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern bipolar disorder and effects on manic and depressive dimensions, but they address different levels: Claim 1 is a clinical comparison of lithium vs valproate relapse prevention, while Claim 2 is a mechanistic statement about PKC regulation. They do not duplicate, contradict, or directly premise one another.",bd479224-5c5a-404d-9c45-468f2e68bcef,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Claim 2 describes lithium’s molecular mechanisms (effects on neuroplasticity, autophagy, mitochondrial function, inflammation, etc.) that plausibly underlie clinical benefits in mood stabilization. Those mechanisms can serve as a mechanistic premise supporting Claim 1’s observation that lithium is effective at preventing relapses. (Claim 2 does not itself provide a direct comparison with valproate, so it supports but does not prove the superiority.)",0ccc686b-5be5-4aa5-9360-6c97d148920d,bd479224-5c5a-404d-9c45-468f2e68bcef
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium monotherapy is superior to valproate monotherapy in preventing both manic and depressive relapses in patients with type-I bipolar disorder.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but at different levels: Claim 1 is a clinical efficacy comparison (lithium vs valproate for relapse prevention in type‑I bipolar disorder), while Claim 2 describes molecular mechanisms (GSK3 and IMPase inhibition). The mechanism claim does not directly prove or contradict the clinical efficacy claim, so they are related by topic but not logically the same or in contradiction.",bd479224-5c5a-404d-9c45-468f2e68bcef,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.",Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Both claims assert lithium is superior in treating bipolar disorder, but they compare lithium to different drugs (lamotrigine vs carbamazepine) and refer to different outcomes (medication switching and hospitalization vs recurrence prevention and suicide prevention). They do not duplicate or contradict each other and neither serves as a direct premise for the other.",10899945-abc8-4bbb-b952-ac3c573494ab,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Claim 2 makes a general, well-supported claim that lithium is among the most effective drugs for preventing manic and depressive episodes with the strongest evidence base; this general assertion provides a foundation for Claim 1's specific comparative claim that lithium is more effective than lamotrigine. They are not duplicates because Claim 1 adds specific comparative outcomes (increased switching and hospitalization with lamotrigine).",d4e77fc9-7d46-473c-86f9-13b018308d00,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims compare lithium to anticonvulsant mood stabilizers and are consistent (lamotrigine is an anticonvulsant), but they focus on different outcomes. Claim 1 asserts lithium is more effective than the specific drug lamotrigine and cites higher switching/hospitalization with lamotrigine; Claim 2 asserts lithium is superior to anticonvulsants for preventing manic episodes and reports no difference for depressive episodes. The claims overlap in topic but are not equivalent, do not directly contradict, and one does not logically entail the other.",10899945-abc8-4bbb-b952-ac3c573494ab,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Claim 1 asserts lithium is more effective than lamotrigine and cites worse outcomes (medication switching, hospitalization) with lamotrigine; this provides direct comparative support for Claim 2's broader assertion that lithium is the more valuable treatment. However Claim 1 does not by itself establish the stronger, unique claims in Claim 2 (efficacy across mania, bipolar depression, prevention of both episode types and suicide), so it functions as a supporting premise rather than a duplicate.",10899945-abc8-4bbb-b952-ac3c573494ab,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 1 is a clinical comparison (effectiveness versus lamotrigine, switching/hospitalization outcomes), while Claim 2 reports neuroimaging/structural brain changes after lithium. They do not duplicate, contradict, or serve as direct premises for one another.",10899945-abc8-4bbb-b952-ac3c573494ab,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium but address different aspects: Claim 1 is a clinical effectiveness comparison (lithium vs lamotrigine), while Claim 2 describes molecular/neurotrophic pathways linked to lithium-induced structural brain changes. They do not contradict or duplicate each other, nor does Claim 2 serve as a direct premise for Claim 1.",10899945-abc8-4bbb-b952-ac3c573494ab,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium treatment outcomes but address different aspects: Claim 1 is a clinical comparison of efficacy versus lamotrigine, while Claim 2 describes a molecular/neuroanatomical mechanism associated with improvement during lithium. They relate to the same general topic without duplicating, contradicting, or directly serving as a premise for one another.",10899945-abc8-4bbb-b952-ac3c573494ab,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims concern lithium but address different aspects: claim 1 is a clinical comparison of effectiveness versus lamotrigine, while claim 2 describes lithium's molecular/neurotrophic mechanisms. They are related but neither duplicates, contradicts, nor directly serves as a strict logical premise for the other.",10899945-abc8-4bbb-b952-ac3c573494ab,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern effects of lithium but on different levels: claim 1 is a clinical comparative effectiveness statement (lithium vs lamotrigine), while claim 2 describes neurobiological/structural and gene-expression changes induced by lithium. Claim 2 does not directly support or contradict the clinical comparison, so they are related but non-contradictory and not duplicates.",10899945-abc8-4bbb-b952-ac3c573494ab,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern treatments for bipolar disorder but address different aspects: claim 1 compares effectiveness of two existing medications (lithium vs lamotrigine), while claim 2 proposes GRIN2A as a potential molecular therapeutic target. They are related topical variants rather than duplicates, premises, or contradictions.",10899945-abc8-4bbb-b952-ac3c573494ab,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Claim 2 offers a biological mechanism (lithium up-regulates GRIN2A, which is down-regulated in bipolar disorder) that could explain lithium's therapeutic efficacy. This mechanistic explanation supports Claim 1's clinical assertion that lithium is more effective than lamotrigine, even though Claim 2 does not directly compare lamotrigine.",1a142c2f-a016-4716-8019-a883e04a6b5f,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both statements concern lithium but address different aspects: Claim 1 is about clinical effectiveness of lithium versus lamotrigine in bipolar disorder, while Claim 2 describes lithium's immunoregulatory actions on B-cell, T-cell, and chemokine pathways. Claim 2 does not directly support, contradict, or serve as a clear premise for Claim 1, so they are related topics but distinct claims.",10899945-abc8-4bbb-b952-ac3c573494ab,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.",Claim 2 describes lithium's neuroprotective and neuroplastic mechanisms that plausibly underlie superior clinical outcomes; therefore Claim 2 provides a mechanistic premise supporting the clinical effectiveness comparison made in Claim 1.,0ccc686b-5be5-4aa5-9360-6c97d148920d,10899945-abc8-4bbb-b952-ac3c573494ab
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is more effective than lamotrigine in treating bipolar disorder, with lamotrigine-treated patients showing increased rates of medication switching and hospitalization.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but address different aspects: Claim 1 is a clinical comparison (efficacy vs lamotrigine and outcomes), while Claim 2 describes proposed molecular mechanisms (GSK3 and IMPase inhibition). They do not duplicate, contradict, or serve as direct premises for one another.",10899945-abc8-4bbb-b952-ac3c573494ab,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Both claims assert lithium's effectiveness for preventing recurrences/episodes in bipolar disorder, but they differ in scope and specifics: Claim 1 makes a specific superiority claim vs carbamazepine and about suicide prevention across the bipolar population, while Claim 2 is a broader statement that lithium is among the most effective drugs with the strongest evidence. They overlap without contradicting.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims compare lithium to anticonvulsant mood stabilizers, but they address different comparators and outcomes. Claim 1 specifically compares lithium to carbamazepine and claims superiority for preventing recurrences in bipolar I and for reducing suicide risk across bipolar disorder. Claim 2 makes a broader comparison to the class of mood-stabilizing anticonvulsants, claiming superiority for preventing manic episodes and no difference for depressive episodes. These are related but not equivalent, not contradictory, and neither is a clear logical premise of the other.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims assert lithium’s superiority in preventing suicide and episode recurrence, but they differ in scope and strength: Claim 1 specifically compares lithium to carbamazepine and limits the recurrence claim to bipolar I, while Claim 2 makes broader, exclusive claims (lithium as the only proven mood stabilizer for mania, bipolar depression, prevention of both types of episodes, and suicide). These statements overlap without directly contradicting each other.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium treatment in bipolar disorder but address different aspects: claim 1 makes a clinical comparative efficacy/suicide-prevention claim versus carbamazepine, while claim 2 reports neuroimaging structural changes after 8 weeks of lithium. They do not duplicate or contradict one another, nor does one directly entail the other.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both statements concern effects of lithium but at different levels: Claim 1 is a clinical comparison (efficacy/suicide prevention vs carbamazepine), while Claim 2 reports molecular/neurotrophic pathways correlated with lithium-induced brain structural changes. The claims do not duplicate, contradict, or logically entail one another, but they address related aspects of lithium’s effects.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium treatment but address different aspects: Claim 1 is a clinical effectiveness comparison (preventing recurrences and suicide), while Claim 2 describes a molecular/neuroanatomical mechanism linked to depressive symptom improvement during lithium treatment. They do not duplicate, contradict, or directly serve as a premise for one another.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both claims concern lithium but focus on different aspects: claim 1 makes clinical efficacy/suicide-prevention assertions versus carbamazepine, while claim 2 describes mechanistic neurotrophic pathways. The mechanistic claim does not directly support, refute, or serve as a formal premise for the clinical superiority claim, so they are related but non-equivalent.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both statements concern lithium treatment but at different levels: claim 1 asserts clinical superiority (efficacy/suicide prevention) while claim 2 describes brain structural and gene-expression correlations (a biological mechanism). They do not contradict and claim 2 is not presented as direct evidence that explains the clinical superiority, so they are related variants rather than duplicates or premises.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern therapeutic approaches for bipolar disorder but address different, non-conflicting topics: Claim 1 reports a clinical comparison (lithium vs carbamazepine for recurrence and suicide prevention), while Claim 2 proposes GRIN2A as a molecular therapeutic target. They are related by topic but neither duplicates, contradicts, nor serves as a direct premise for the other.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium in bipolar disorder but address different aspects: claim 1 is a clinical/comparative efficacy statement (superiority vs carbamazepine and suicide prevention), while claim 2 is a mechanistic hypothesis (GRIN2A modulation). The mechanistic claim does not directly imply or contradict the comparative clinical claim.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims concern lithium but address different levels: claim 1 is about clinical effectiveness (prevention of recurrences and suicide vs carbamazepine), while claim 2 is about lithium's molecular/mechanistic effects (systemic action, myelination not central). They do not contradict or serve as premises for one another, so they are related by topic but differ in focus.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both statements concern lithium but address different aspects: claim 1 is about clinical superiority (recurrence and suicide prevention) versus carbamazepine, while claim 2 describes immunoregulatory mechanisms. The mechanistic claim does not directly establish the comparative clinical benefits, nor contradict them, so they are related but not premises or duplicates.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,Claim 2 describes biological mechanisms by which lithium may promote neuroprotection and neuroplasticity; these mechanisms plausibly provide a mechanistic basis supporting the clinical benefits asserted in Claim 1 (reduced recurrence and suicide). Claim 2 is supportive evidence but does not by itself establish the comparative clinical superiority versus carbamazepine.,0ccc686b-5be5-4aa5-9360-6c97d148920d,75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Lithium is superior to carbamazepine in preventing recurrences in bipolar disorder type I and preventing suicide in the entire bipolar disorder population.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but at different levels: claim 1 is a clinical efficacy statement (superiority to carbamazepine for preventing recurrences and suicide), while claim 2 is a mechanistic hypothesis about intracellular targets (GSK3 and IMPase). They address related topics but do not restate, directly support, or contradict each other.",75bbf7a9-66b3-4d0c-98ef-699cd4e79c6e,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Both claims address lithium's efficacy in preventing manic and depressive episodes in bipolar disorder but differ in scope. Claim 2 is a narrower comparative statement (lithium > anticonvulsants for mania; no difference for depression). Claim 1 is a broader claim about lithium being one of the most effective treatments for both pole episodes and having the strongest evidence versus any drug. Claim 2 does not contradict Claim 1 but does not fully support its broader assertions, so they are related but variant.",d4e77fc9-7d46-473c-86f9-13b018308d00,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims state lithium is highly effective for preventing manic and depressive episodes, but Claim 2 makes stronger, exclusive assertions (claims lithium is the only mood stabilizer proven for mania, bipolar depression, prevention of episodes, and suicide prevention) that go beyond Claim 1's more measured claim (one of the most effective with the most robust evidence). They differ in scope and strength rather than directly contradicting.",d4e77fc9-7d46-473c-86f9-13b018308d00,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 1 states clinical efficacy for episode prevention, while Claim 2 reports neuroanatomical changes after 8 weeks. They do not duplicate or contradict each other, nor does one logically entail the other.",d4e77fc9-7d46-473c-86f9-13b018308d00,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium treatment but address different aspects: Claim 1 states clinical efficacy in preventing bipolar episodes, while Claim 2 reports neurobiological pathways correlated with lithium-induced structural brain changes. They are related and complementary but not duplicates, contradictions, or logical premises of one another.",d4e77fc9-7d46-473c-86f9-13b018308d00,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium's effects in bipolar disorder but at different levels: claim 1 states a broad clinical-efficacy conclusion, while claim 2 reports a specific biological mechanism (sphingomyelin pathway and mediodorsal thalamus volume changes) associated with depressive symptom improvement during lithium treatment. The second does not duplicate, directly support as a full premise for, or contradict the first.",d4e77fc9-7d46-473c-86f9-13b018308d00,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Both statements concern lithium but address different aspects: claim 1 is about clinical efficacy in preventing bipolar episodes, while claim 2 describes mechanistic neurotrophic pathways. They do not contradict or entail one another — they are related but different types of claims.",d4e77fc9-7d46-473c-86f9-13b018308d00,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium but at different levels: claim 1 asserts clinical efficacy for preventing bipolar episodes, while claim 2 describes lithium-associated structural and gene-expression changes. They address related topics (drug and biological effects) without duplicating, contradicting, or providing a direct logical premise for one another.",d4e77fc9-7d46-473c-86f9-13b018308d00,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern treatments for bipolar disorder but make different, non-conflicting points: Claim 1 states lithium is the most evidence-backed preventive treatment, while Claim 2 proposes GRIN2A as a promising therapeutic target. They address the same topic without duplicating, contradicting, or logically entailing one another.",d4e77fc9-7d46-473c-86f9-13b018308d00,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Claim 2 offers a possible biological mechanism (lithium up‑regulates GRIN2A, which is down‑regulated in bipolar disorder) that could underlie lithium’s clinical effectiveness described in Claim 1, so Claim 2 functions as a premise supporting Claim 1.",1a142c2f-a016-4716-8019-a883e04a6b5f,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims concern lithium but address different aspects: Claim 1 states clinical effectiveness in bipolar disorder, while Claim 2 states a mechanistic view about lithium's molecular effects not targeting myelination. They do not contradict or restate one another, nor does one serve as a direct logical premise for the other.",d4e77fc9-7d46-473c-86f9-13b018308d00,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both statements concern lithium but address different aspects: Claim 1 is about clinical efficacy in bipolar disorder, while Claim 2 is about molecular/immunoregulatory mechanisms. They do not duplicate or contradict each other, nor is one a direct logical premise of the other.",d4e77fc9-7d46-473c-86f9-13b018308d00,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.",Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Both claims concern therapeutic approaches for mood disorders but make different, non-conflicting points: claim 1 asserts lithium's established efficacy for preventing bipolar episodes, while claim 2 proposes targeting mitochondrial dysfunction as a potential novel treatment for depression. They address different conditions/mechanisms rather than duplicating, contradicting, or providing a direct premise relationship.",d4e77fc9-7d46-473c-86f9-13b018308d00,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims address bipolar disorder and claim effects on both manic and depressive dimensions, but they refer to different things: Claim 1 asserts lithium's superior clinical efficacy in preventing episodes, while Claim 2 describes PKC as a molecular regulator affecting mania and depression. They do not contradict or entail one another, so they are related but different (variant).",d4e77fc9-7d46-473c-86f9-13b018308d00,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern bipolar disorder and involvement in manic and depressive states, but they address different aspects (clinical efficacy of lithium vs molecular role of PKC). They do not duplicate, contradict, or serve as a direct premise for one another.",d4e77fc9-7d46-473c-86f9-13b018308d00,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern influences on both manic and depressive dimensions of bipolar disorder, but they refer to different entities and levels of explanation: Claim 1 asserts lithium's clinical efficacy, while Claim 2 asserts a regulatory role for PKC. Neither claim duplicates or contradicts the other, nor does one clearly serve as a logical premise for the other.",d4e77fc9-7d46-473c-86f9-13b018308d00,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern bipolar disorder but address different aspects: Claim 1 concerns lithium’s clinical efficacy in preventing mood episodes, while Claim 2 concerns BDNF’s role in the pathophysiology of multiple psychiatric disorders (including bipolar). They are related but neither duplicates, contradicts, nor logically entails the other.",d4e77fc9-7d46-473c-86f9-13b018308d00,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Claim 2 provides mechanistic explanations (neuroplasticity, neuroprotection, mitochondrial function, etc.) that can plausibly underlie and support Claim 1's statement about lithium's clinical efficacy in preventing manic and depressive episodes. The statements are complementary rather than duplicate or contradictory.",0ccc686b-5be5-4aa5-9360-6c97d148920d,d4e77fc9-7d46-473c-86f9-13b018308d00
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is one of the most effective treatments for preventing both manic and depressive episodes in bipolar disorder, with the most robust evidence base compared to any other drug.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but address different aspects: Claim 1 states its clinical efficacy in bipolar disorder, while Claim 2 proposes cellular mechanisms (GSK3 and IMPase inhibition) underlying lithium's intracellular effects. They do not contradict or directly serve as premises for one another, so they are related but different.",d4e77fc9-7d46-473c-86f9-13b018308d00,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,contradiction,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims address lithium vs other mood stabilizers, but they conflict on prevention of depressive episodes: Claim 1 says there are no significant differences between lithium and mood-stabilizing anticonvulsants for preventing depressive episodes, whereas Claim 2 asserts lithium is the only mood stabilizer proven to prevent depressive (and manic) episodes. These statements cannot both be true.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium treatment in bipolar disorder but address different aspects: Claim 1 reports comparative clinical efficacy (preventing mania vs anticonvulsant mood stabilizers), while Claim 2 reports neuroimaging/structural brain changes after lithium. They do not contradict or directly duplicate each other, nor does one clearly serve as a logical premise for the other.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium treatment but at different levels: Claim 1 is a clinical efficacy comparison (prevention of manic vs depressive episodes), while Claim 2 describes neurobiological pathways correlating with lithium-induced structural brain changes. They address related topics but neither entails, contradicts, nor serves as a direct premise for the other.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium and its effects on depressive outcomes but address different aspects: Claim 1 is a clinical comparative effectiveness statement (lithium vs mood-stabilizing anticonvulsants for preventing mania and depression), while Claim 2 is a mechanistic/biomarker finding linking sphingomyelin metabolism and mediodorsal thalamus volume to depressive symptom improvement during lithium treatment. They do not duplicate, contradict, or serve as direct premises for one another.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium but at different levels: claim 1 is about comparative clinical efficacy (prevention of mania vs depression), while claim 2 describes neurobiological/structural and gene-expression effects of lithium. They do not duplicate, contradict, or provide a direct logical premise for one another, but are related topics without direct entailment.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern treatments for bipolar disorder but address different aspects: claim 1 compares the clinical efficacy of existing drugs (lithium vs mood-stabilizing anticonvulsants) for preventing manic and depressive episodes, while claim 2 proposes GRIN2A as a molecular therapeutic target for affective disorders including bipolar disorder. They are thematically related but do not duplicate, contradict, or serve as a direct premise for one another.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both statements concern lithium in bipolar disorder but address different aspects: claim 1 is a clinical comparative efficacy claim (lithium vs mood-stabilizing anticonvulsants for mania), while claim 2 proposes a molecular mechanism (lithium up-regulates GRIN2A) that could contribute to therapeutic effects. They do not duplicate or contradict one another, and claim 2 is not presented as a direct premise that proves claim 1.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern bipolar disorder and the control of manic and depressive dimensions, but they address different aspects: Claim 1 is a clinical comparison of lithium versus anticonvulsant mood stabilizers for preventing mania vs depression, while Claim 2 is a mechanistic statement about PKC regulation of both facets. They are related in topic but do not duplicate, contradict, or directly premise one another.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern bipolar disorder but address different aspects: Claim 1 is a clinical comparison of lithium versus anticonvulsant mood stabilizers for preventing mania/depression, while Claim 2 is a mechanistic statement about PKC’s role in mood regulation. They do not duplicate, contradict, or serve as direct premises for one another, so they are related but different (variant).",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern antimanic effects but at different levels and with different focus: Claim 1 is a clinical comparison (lithium vs anticonvulsant mood stabilizers) in bipolar patients, while Claim 2 is preclinical evidence that PKC inhibition produces antimanic-like effects in rats. They are related topic-wise but do not duplicate, contradict, or directly serve as a logical premise for one another.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,ae3c78a3-aaea-4b95-88c9-0997465c58c7
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern antimanic effects but at different levels and do not directly support or contradict each other: Claim 1 is a clinical comparison of lithium versus anticonvulsants for preventing mania in bipolar disorder, while Claim 2 is preclinical evidence that PKC inhibition has antimanic-like effects in rats. The animal/mechanistic result could be relevant to mechanisms of clinical drugs but does not by itself establish lithium's superiority over anticonvulsants.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern bipolar disorder and its manic/depressive dimensions, but they address different aspects: Claim 1 is a clinical comparison of lithium versus anticonvulsants for preventing mania (and notes no difference for depression), while Claim 2 is a mechanistic claim about PKC modulation affecting both manic and depressive facets. They are related in topic but do not duplicate, contradict, or serve as direct premises for one another.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Claim 2 gives mechanistic biological rationale (neuroplasticity, neuroprotection, effects on ER stress, autophagy, mitochondria, inflammation, etc.) that could explain lithium's clinical efficacy for mood stabilization. Thus it can serve as a premise supporting why lithium might be superior at preventing mania, but it is mechanistic/supportive and does not by itself provide direct comparative clinical evidence versus anticonvulsants.",0ccc686b-5be5-4aa5-9360-6c97d148920d,fee98cc5-6e1b-4570-ac74-0c3966fa8c32
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but address different, non-contradictory aspects: claim 1 is a clinical efficacy comparison (prevention of mania vs depression), while claim 2 describes molecular mechanisms (GSK3 and IMPase inhibition) and their broader neuropathological relevance. Neither duplicates, contradicts, nor directly premises the other.",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is superior to mood-stabilizing anticonvulsants in preventing manic episodes in bipolar disorder, without significant differences in preventing depressive episodes.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern lithium but address different levels: Claim 1 is about clinical comparative efficacy in bipolar disorder, while Claim 2 is a molecular mechanism (autophagy via mTOR‑independent/IP3). They do not duplicate, contradict, or provide a direct premise for one another, so they are related but different (variant).",fee98cc5-6e1b-4570-ac74-0c3966fa8c32,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Both claims concern lithium use in bipolar disorder but address different kinds of evidence: Claim 1 asserts broad clinical efficacy and superiority for mood symptoms and suicide prevention, while Claim 2 reports neuroanatomical imaging changes after 8 weeks. Claim 2 does not directly establish the clinical outcomes in Claim 1, nor contradict them, so they are related but not logically equivalent or premise-linked.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Both claims concern lithium treatment but address different aspects: Claim 1 makes clinical-efficacy and comparative assertions about lithium for bipolar disorder, while Claim 2 reports molecular/neurotrophic pathways correlated with lithium-induced structural brain changes. Claim 2 does not directly support or contradict Claim 1, nor is either claim a direct premise of the other.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims concern lithium treatment but address different aspects: claim 1 makes a broad clinical-efficacy/value claim about lithium for bipolar disorder, while claim 2 reports a specific biological mechanism (sphingomyelin pathway and thalamic volume change) associated with depressive improvement during lithium therapy. Claim 2 does not duplicate or contradict claim 1 and is not a direct logical premise that would by itself establish claim 1, so they are related but different (variant).",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Claim 2 provides a mechanistic explanation (lithium acting via neurotrophic molecular pathways) that can support why lithium produces the clinical effects described in Claim 1. Thus Claim 2 functions as a supporting premise for Claim 1, though mechanistic evidence alone does not by itself prove the clinical superiority asserted.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Both claims concern lithium. Claim 2 provides mechanistic/biological evidence (lithium-induced structural brain and gene-expression changes in neurotrophic/cell-modeling pathways) that could plausibly underlie and therefore support the clinical benefits asserted in Claim 1. It does not by itself prove the full set of clinical outcomes in Claim 1, but it functions as a supporting premise for why lithium might be efficacious.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern therapeutic approaches for bipolar disorder but make different, non-conflicting assertions: Claim 1 asserts lithium's established, broad efficacy and clinical value, while Claim 2 proposes GRIN2A as a promising molecular target. They address the same topic without duplicating or contradicting each other.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Claim 2 offers a biological mechanism (lithium up‑regulates GRIN2A, which is down‑regulated in bipolar disorder) that could help explain lithium's therapeutic effects described in Claim 1. Thus Claim 2 functions as supporting evidence/premise for lithium's efficacy, although mechanistic up‑regulation alone does not fully establish the stronger claim that lithium is the single most valuable or only proven mood stabilizer.",1a142c2f-a016-4716-8019-a883e04a6b5f,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both statements concern lithium but address different aspects: Claim 1 asserts clinical superiority in bipolar treatment and suicide prevention, while Claim 2 describes molecular immunoregulatory effects. They are related by topic but neither duplicates, contradicts, nor directly premises the other.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern bipolar disorder but address different aspects: Claim 1 asserts lithium's unique, broad clinical efficacy and suicide prevention; Claim 2 states that PKC modulation affects both manic and depressive dimensions (a mechanistic point). They do not duplicate or contradict each other and neither is a direct premise for the other.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern bipolar disorder but address distinct aspects: Claim 1 makes a clinical-efficacy statement about lithium as a treatment, while Claim 2 asserts a molecular role for PKC in mood regulation. They do not duplicate or contradict each other, nor is one clearly a logical premise for the other.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Claim 2 describes biological mechanisms (neuroplasticity, neuroprotection, etc.) by which lithium could exert therapeutic effects. Those mechanisms provide a mechanistic foundation that can support Claim 1's assertions about lithium's clinical efficacy and value, but Claim 2 alone does not by itself prove the clinical superiority asserted in Claim 1.",0ccc686b-5be5-4aa5-9360-6c97d148920d,d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern lithium but address different aspects: Claim 1 asserts clinical efficacy and superiority for bipolar disorder, while Claim 2 proposes molecular mechanisms (GSK3 and IMPase inhibition) that might underlie lithium's cellular effects. They relate to the same topic without duplicating, directly contradicting, or serving as a strict logical premise for one another.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium is the only mood stabilizer with proven efficacy in treating mania, bipolar depression, preventing both manic and depressive episodes, and preventing suicide, making it the most valuable treatment option for bipolar disorder.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both statements concern lithium but at different levels: claim 1 is a clinical efficacy/therapeutic claim about bipolar disorder, while claim 2 is a mechanistic molecular claim about lithium's action on autophagy via an mTOR-independent IP3 pathway. They do not contradict or directly support one another, so they are related topics but distinct claims.",d8fa1dd9-4fbe-4c3c-8558-bbd7ef11fa64,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Claim 2 links molecular pathways to structural brain changes induced by lithium. Claim 1 documents specific lithium-induced structural changes in bipolar patients (increases in cortical thickness and regional volumes), so Claim 1 provides empirical observations that form a premise/evidence base for the correlations asserted in Claim 2.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,c6b2f073-3921-470e-a771-ed36fdce8709
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Claim 1 reports that lithium increases volumes of thalamic nuclei and thalamic substructures (and cortical/hippocampal measures) in bipolar patients, which supports the plausibility that mediodorsal thalamus volume can change during lithium treatment. Claim 2 claims the sphingomyelin pathway’s association with depressive improvement is mediated via mediodorsal thalamus volume changes. Thus Claim 1 provides a structural-change premise relevant to Claim 2’s mediation claim, though it does not address sphingomyelin or the mediation analysis itself.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Claim 1 reports lithium-induced brain structural changes (increased cortical thickness and regional volumes) that would serve as part of the empirical evidence integrated with peripheral gene expression in Claim 2 to infer neurotrophic molecular pathways. Claim 1 alone does not prove the molecular mechanism but is a logical premise for the integrative conclusion.,33a04b51-6903-488b-91e5-7fd6dbb7c78f,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,Claim 1 reports lithium-induced structural brain changes (increases in cortical thickness and volumes). Claim 2 links such structural changes to gene-expression changes in neurotrophic/cell-modeling pathways. Thus Claim 1 provides an empirical premise that supports the correlation asserted in Claim 2.,33a04b51-6903-488b-91e5-7fd6dbb7c78f,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern treatments for bipolar disorder but address different mechanisms and findings: Claim 1 reports structural brain changes after lithium treatment, while Claim 2 proposes GRIN2A as a therapeutic target in the glutamatergic system. They are related by topic but do not duplicate, imply, or contradict each other.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium's effects in bipolar disorder but at different levels: Claim 1 reports structural brain changes after treatment, while Claim 2 proposes a molecular mechanism (GRIN2A up-regulation). They address related topics without duplicating, supporting, or contradicting each other.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims address lithium's effects on the brain but at different levels: Claim 1 reports region-specific structural changes after treatment, while Claim 2 describes the molecular actions as systemic and not cell-type/area-specific (and downplays myelination). These statements are about different levels of explanation and can coexist (systemic molecular effects could lead indirectly to regional volumetric changes), so they do not duplicate or directly contradict one another.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern hippocampal-related brain changes but describe different interventions, species, and outcomes: Claim 1 reports increased hippocampal volume in human bipolar patients after lithium treatment; Claim 2 reports reduced hippocampal cell proliferation and depressive-like behavior in rats after chronic PKC inhibition. They are related by the general topic (hippocampal plasticity) but are not duplicates, contradictions, or premises for one another.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern bipolar disorder but address different mechanisms and levels: claim 1 reports lithium-induced structural brain changes after 8 weeks, while claim 2 describes PKC's role in modulating manic vs depressive symptoms. They do not contradict or entail each other and are related only by topic.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Claim 2 describes cellular mechanisms (enhanced neuroplasticity/neuroprotection via neurotrophic signaling, autophagy, mitochondrial function, reduced inflammation, etc.) that can plausibly produce the structural brain changes (increased gray matter, cortical thickness, and regional volumes) reported in Claim 1, so Claim 2 provides a mechanistic premise supporting Claim 1.",0ccc686b-5be5-4aa5-9360-6c97d148920d,33a04b51-6903-488b-91e5-7fd6dbb7c78f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern effects of lithium but at different levels: Claim 1 reports clinical/neuroimaging changes in brain structure after lithium treatment, while Claim 2 proposes molecular mechanisms (GSK3 and IMPase inhibition) that may underlie lithium's cellular actions. Claim 2 does not directly state or prove the specific structural changes in Claim 1, nor contradict them, so they are related but not premise/consequence or duplicate.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium treatment increases gray matter fraction, global cortical thickness, frontal and parietal cortical thickness, as well as volumes of putamen, hippocampus, thalamic nuclei, and thalamic substructures in bipolar disorder patients after 8 weeks.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims concern lithium's effects on the brain but at different levels and contexts: Claim 1 reports short-term structural MRI changes in bipolar disorder patients, while Claim 2 asserts a molecular mechanism (autophagy) as the primary explanation for lithium's neuroprotective effects in neurodegenerative diseases. They address related topics but differ in outcome, scale (clinical imaging vs molecular mechanism), and patient populations, so they are related variants rather than duplicates, premises, or contradictions.",33a04b51-6903-488b-91e5-7fd6dbb7c78f,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Both claims link molecular pathways to lithium-associated brain structural changes, but they refer to different specific pathways (neurotrophy-related GDNF/NFAT/p53 vs sphingomyelin metabolism), different regional focus (multiple regions vs mediodorsal thalamus), and different outcomes (correlation with structural changes vs mediation of symptom improvement). They are related on topic but not equivalent, contradictory, or a direct premise of one another.",c6b2f073-3921-470e-a771-ed36fdce8709,12694b8a-03de-462a-a0da-b8412687c380
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Claim 1 provides specific evidence that three neurotrophy-related pathways correlate with lithium-induced structural brain changes; Claim 2 is a broader conclusion that integrating brain structure and gene expression shows lithium acts through several neurotrophic pathways. Thus Claim 1 serves as a supporting premise for Claim 2.,c6b2f073-3921-470e-a771-ed36fdce8709,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Claim 1 gives specific neurotrophy-related pathways (GDNF family, NFAT immune-response, p53-signaling) that correlate with lithium-induced structural brain changes; Claim 2 is a broader statement that such structural changes correlate with gene expression in neurotrophic and cell-modeling pathways. Thus Claim 1 provides specific supporting evidence for Claim 2.",c6b2f073-3921-470e-a771-ed36fdce8709,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern neurobiological mechanisms relevant to mood/affective disorders (including bipolar disorder) and potential treatment-related biology, but they refer to different specific pathways/targets (neurotrophy-related pathways linked to lithium-induced structural changes vs the glutamatergic receptor GRIN2A) and do not contradict or imply one another.",c6b2f073-3921-470e-a771-ed36fdce8709,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern molecular/biological effects of lithium in the brain, but they describe different specific mechanisms: Claim 1 links lithium-induced structural changes to three neurotrophy-related pathways, while Claim 2 implicates regulation of the GRIN2A gene as part of lithium's therapeutic effect in bipolar disorder. They address related topics without repeating, contradicting, or serving as direct premises for one another.",c6b2f073-3921-470e-a771-ed36fdce8709,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Claim 1 reports that specific neurotrophy-related pathways correlate with lithium-induced structural changes across multiple brain regions, which supports the idea in Claim 2 that lithium’s molecular effects are systemic rather than narrowly localized. However, Claim 1 does not address cell-type specificity or the role of myelination, so it only partially supports Claim 2.",c6b2f073-3921-470e-a771-ed36fdce8709,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims describe lithium's effects on molecular pathways, but they focus on different sets of pathways and different outcomes: claim 1 links specific neurotrophy- and immune-related pathways (GDNF, NFAT, p53) to structural brain changes, while claim 2 highlights regulation of adaptive immune signaling (B-cell, T-cell, chemokine) and immunoregulation. They are related but not the same claim, do not contradict, and neither is a direct premise for the other.",c6b2f073-3921-470e-a771-ed36fdce8709,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",Neurotrophins activate multiple signaling pathways by binding to two distinct receptor types: Trk receptor tyrosine kinases and the p75 NTR receptor.,"Both claims concern neurotrophy-related signaling pathways, but they address different points: Claim 1 reports specific pathways (GDNF, NFAT, p53) correlating with lithium-induced structural brain changes, while Claim 2 describes a general mechanism by which neurotrophins signal (via Trk and p75 receptors). They are related topical variants but do not duplicate, contradict, or serve as a direct premise for one another.",c6b2f073-3921-470e-a771-ed36fdce8709,32039099-7adb-448e-9ab9-b51dbee4866b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","While Trk receptor signaling pathways are well-characterized, p75 NTR signaling is more complex and its in vivo significance remains incompletely determined.","Both statements concern neurotrophic signaling pathways but address different specific pathways and questions: claim 1 links GDNF, NFAT, and p53 pathways to lithium-related brain structural changes, while claim 2 discusses characterization and uncertain in vivo significance of Trk vs p75NTR signaling. They are related topic-wise but not duplicative, contradictory, or a direct premise of one another.",c6b2f073-3921-470e-a771-ed36fdce8709,e39212d2-772a-428b-a2fa-5e5f17b75391
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"Both claims concern neurotrophic factors: claim 1 reports a specific empirical finding linking certain neurotrophy-related pathways to lithium-induced brain structural changes, while claim 2 makes a general statement that neurotrophins are incompletely understood and promising for future discoveries. They are thematically related but not equivalent, contradictory, or a clear logical premise for one another.",c6b2f073-3921-470e-a771-ed36fdce8709,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"Both claims concern neurotrophic signaling and effects on brain structure/plasticity, but they address different factors and assertions. Claim 1 links specific pathways (GDNF family, NFAT, p53) to lithium-induced structural changes, while Claim 2 states a general role for BDNF in CNS development and plasticity. They are related topicaly but are neither the same claim, a premise of one another, nor contradictory.",c6b2f073-3921-470e-a771-ed36fdce8709,5d2a635d-4bc1-47e6-8418-e59d0ea7c895
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern neurotrophic/neurobiology mechanisms and brain/psychiatric effects, but they address different factors and findings: claim 1 links GDNF-family, NFAT, and p53 pathways to lithium-related structural brain changes, while claim 2 asserts a central role for BDNF in psychiatric/neurodevelopmental disorders. They are related in topic but not equivalent, nor do they premise or contradict each other.",c6b2f073-3921-470e-a771-ed36fdce8709,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern neurotrophic mechanisms related to psychiatric treatments, but they address different molecules and interventions. Claim 1 links GDNF-family, NFAT immune-response, and p53 pathways to lithium-induced structural brain changes, while Claim 2 states BDNF is involved in mechanisms of antidepressants and antipsychotics. They are related thematically but not equivalent, not contradictory, and neither provides a direct premise for the other.",c6b2f073-3921-470e-a771-ed36fdce8709,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.","Both claims concern neurotrophic mechanisms and brain health, but they address different specific factors and findings: claim 1 links GDNF-family, NFAT immune-response, and p53-signaling to lithium-induced structural changes, while claim 2 states the general importance of BDNF for development and plasticity. They are related topically without duplicating, contradicting, or serving as a direct premise for one another.",c6b2f073-3921-470e-a771-ed36fdce8709,1e7f51f6-eaca-4408-ae8b-756c1531362e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern neurotrophic signaling and brain structure/function, but they address different molecules, regions, and contexts. Claim 1 links GDNF-family, NFAT, and p53 pathways to lithium-induced structural changes across multiple regions; Claim 2 describes region-specific BDNF reduction in the dentate gyrus lowering neurogenesis and producing depressive-like behavior. They are topically related but not equivalent, contradictory, or a direct premise of one another.",c6b2f073-3921-470e-a771-ed36fdce8709,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Claim 1 gives specific evidence that lithium correlates with modulation of neurotrophy-related pathways (GDNF family), NFAT immune-response, and p53 signaling across brain regions. These specific pathway effects substantiate Claim 2's broader assertion that lithium regulates neurotrophic, immune/inflammation-related, and cell-stress pathways important for neuroplasticity and neuroprotection.",c6b2f073-3921-470e-a771-ed36fdce8709,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims address lithium's biological effects but at different levels and with different specifics: Claim 1 links lithium-induced structural brain changes to particular neurotrophy-related pathways, while Claim 2 attributes lithium's broad intracellular responses to inhibition of GSK3 and IMPase. They are related but neither duplicates, directly contradicts, nor serves as a clear logical premise for the other.",c6b2f073-3921-470e-a771-ed36fdce8709,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims address molecular mechanisms of lithium but focus on different pathways and outcomes. Claim 1 identifies neurotrophy-related pathways correlated with lithium-induced structural brain changes; Claim 2 asserts autophagy promotion as the primary mechanism for lithium's neuroprotective effects. They overlap in topic (lithium mechanisms) but do not entail, premise, or directly contradict each other.",c6b2f073-3921-470e-a771-ed36fdce8709,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Three neurotrophy-related pathways (GDNF family of ligands, NFAT immune-response, and p53-signaling pathway) correlate with structural brain changes induced by lithium treatment in multiple regions.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern molecular mechanisms of lithium but describe different, noncontradictory aspects: claim 1 links lithium-induced structural brain changes to neurotrophy-related pathways (GDNF, NFAT, p53), while claim 2 describes lithium enhancing autophagy via an mTOR-independent IP3 pathway. They are related topic-wise but not duplicates or premises of one another.",c6b2f073-3921-470e-a771-ed36fdce8709,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Claim 1 gives a specific example (sphingomyelin metabolism linked to clinical improvement mediated by mediodorsal thalamus volume) that supports the broader claim in Claim 2 that lithium acts via multiple neurotrophic molecular pathways integrating brain structure and peripheral gene expression.,12694b8a-03de-462a-a0da-b8412687c380,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Both claims concern lithium-associated structural brain changes and molecular pathways, but they focus on different pathways and endpoints. Claim 1 links sphingomyelin metabolism to depressive symptom improvement mediated by mediodorsal thalamus volume changes, while Claim 2 reports correlations between lithium-induced structural changes and gene expression in neurotrophic and cell‑modeling pathways. They are related but not equivalent or contradictory.",12694b8a-03de-462a-a0da-b8412687c380,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Both claims concern molecular/neurobiological aspects of affective disorders, but they address different mechanisms: claim 1 implicates sphingomyelin metabolism and thalamic volume changes in lithium response, while claim 2 proposes GRIN2A/glutamatergic signalling as a therapeutic target. They are related by topic but not duplicates, premises, or contradictions.",12694b8a-03de-462a-a0da-b8412687c380,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Both claims concern lithium's therapeutic effects but propose different, non-conflicting mechanisms: claim 1 links sphingomyelin metabolism and mediodorsal thalamus volume changes to depressive symptom improvement, while claim 2 implicates modulation/up-regulation of GRIN2A in bipolar disorder. They are topically related but not duplicates, premises of one another, or contradictory.",12694b8a-03de-462a-a0da-b8412687c380,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,contradiction,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Claim 1 asserts a specific molecular pathway (sphingomyelin metabolism, related to myelin) and a specific brain region (mediodorsal thalamus) mediating lithium's clinical effect. Claim 2 states lithium's molecular effects are systemic, not targeted to particular cell types/brain areas, and that myelination is not a central target. These statements directly oppose each other and cannot both be true as stated.",12694b8a-03de-462a-a0da-b8412687c380,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims concern biological mechanisms of lithium treatment but refer to different systems and mechanisms: claim 1 links sphingomyelin metabolism and mediodorsal thalamus volume changes to antidepressant response, while claim 2 describes lithium's regulation of immune-related signaling (B-cell, T-cell, chemokine). They do not duplicate, contradict, or serve as premises for one another, so they are related but distinct (variant).",12694b8a-03de-462a-a0da-b8412687c380,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Both claims concern biological mechanisms related to depression, but they describe different, non-conflicting mechanisms (sphingomyelin metabolism and thalamic volume mediation versus mitochondrial dysfunction). They are related in topic but not the same claim, not premises of one another, and not contradictory.",12694b8a-03de-462a-a0da-b8412687c380,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","Both claims address biological mechanisms related to depressive symptoms but describe different, non-overlapping pathways: Claim 1 implicates sphingomyelin metabolism and thalamic volume changes in lithium-associated symptom improvement, while Claim 2 implicates mitochondrial dysfunction, oxidative stress, and apoptosis as antecedents to depression. They relate to the same broad topic but do not duplicate, contradict, or serve as direct premises for one another.",12694b8a-03de-462a-a0da-b8412687c380,703e323f-781d-49a1-9b29-a076270691a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Both claims concern biological mechanisms related to depression, but they describe different, non-overlapping pathways: Claim 1 links sphingomyelin metabolism and mediodorsal thalamic volume changes to lithium-associated symptom improvement, while Claim 2 describes mitochondrial dysfunction leading to cellular stress, inflammation, and apoptosis in depression pathogenesis. They do not contradict or serve as premises for one another.",12694b8a-03de-462a-a0da-b8412687c380,e2a99bc5-1b56-47bf-8fe6-dc5063fe7060
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern biological mechanisms influencing mood symptoms in bipolar disorder (particularly depressive symptoms), but they implicate different pathways: sphingomyelin metabolism (linked to lithium response and mediodorsal thalamus volume changes) versus PKC modulation (affecting manic and depressive facets). They do not duplicate, contradict, or serve as a clear logical premise for one another.",12694b8a-03de-462a-a0da-b8412687c380,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological mechanisms affecting mood and bipolar disorder, but they describe different pathways: claim 1 implicates sphingomyelin metabolism and thalamic volume changes in lithium-related improvement of depressive symptoms, while claim 2 asserts a role for PKC in mood regulation and bipolar states. There is no direct equivalence, contradiction, or stated causal premise between the two.",12694b8a-03de-462a-a0da-b8412687c380,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims address biological mechanisms related to depressive behavior, but they concern different molecular pathways, brain regions, interventions, and experimental contexts (sphingomyelin metabolism and mediodorsal thalamus changes during lithium treatment versus PKC inhibition effects on hippocampal proliferation in rats). They do not contradict or directly support one another, so they are related but distinct.",12694b8a-03de-462a-a0da-b8412687c380,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims relate to mood regulation and depressive/bipolar states but describe different mechanisms: Claim 1 implicates sphingomyelin metabolism and thalamic volume changes during lithium treatment, while Claim 2 attributes mood regulation to PKC. They overlap topically but do not duplicate, contradict, or logically entail one another.",12694b8a-03de-462a-a0da-b8412687c380,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern biological mechanisms influencing mood-related states and treatment effects (antidepressant/antimanic outcomes), but they involve different pathways and contexts: Claim 1 links sphingomyelin metabolism and mediodorsal thalamus volume changes to lithium-associated improvement in depressive symptoms, while Claim 2 attributes manic- and antidepressant-like behaviors to PKC activation in experimental models. They are related by topic but not equivalent, contradictory, or a direct premise of one another.",12694b8a-03de-462a-a0da-b8412687c380,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern biological mechanisms affecting mood in bipolar disorder (depressive symptoms vs manic/depressive facets), but they describe different molecular pathways (sphingomyelin metabolism and thalamic-volume mediation vs PKC regulation). There is no direct entailment, duplication, or contradiction between them.",12694b8a-03de-462a-a0da-b8412687c380,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims address mechanisms of antidepressant effects but refer to different treatments (lithium vs ketamine) and distinct biological mechanisms (sphingomyelin metabolism and mediodorsal thalamus volume changes vs prefrontal synaptogenesis and enhanced serotonergic descending input). They overlap in topic but do not duplicate, contradict, or serve as premises for one another.",12694b8a-03de-462a-a0da-b8412687c380,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims address molecular mechanisms related to depression/antidepressant response, but they involve different entities and pathways (sphingomyelin metabolism and thalamic volume changes in Claim 1 vs miR-135 targeting genes in Claim 2). They do not duplicate, contradict, or serve as direct premises for one another.",12694b8a-03de-462a-a0da-b8412687c380,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern biological mediators of antidepressant effects, but they describe different mechanisms, molecules, brain regions, and treatments (sphingomyelin metabolism and mediodorsal thalamus with lithium vs. Homer1a in medial prefrontal cortex for sleep deprivation/imipramine/ketamine). They address the same general topic without duplicating or contradicting each other, and neither serves as a direct premise for the other.",12694b8a-03de-462a-a0da-b8412687c380,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern biological effects of lithium in the brain, but they differ in scope and content: Claim 1 reports a specific association (sphingomyelin metabolism linked to depressive improvement via mediodorsal thalamus volume changes), while Claim 2 is a broad summary of diverse cellular pathways lithium regulates. They are related but not equivalent, not contradictory, and neither serves as a direct logical premise for the other.",12694b8a-03de-462a-a0da-b8412687c380,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims address mechanisms of lithium action but propose different, non-conflicting mechanisms: claim 1 implicates sphingomyelin metabolism and thalamic volume changes in clinical improvement, while claim 2 highlights inhibition of GSK3 and IMPase as broader intracellular targets. They discuss the same topic (lithium mechanisms) with different emphases, so they are related but not equivalent or contradictory.",12694b8a-03de-462a-a0da-b8412687c380,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The sphingomyelin metabolism pathway is associated with depressive symptom improvement during lithium treatment, and this effect is mediated through volume changes in the mediodorsal thalamus.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern biological effects of lithium but describe different mechanisms and outcomes. Claim 1 links sphingomyelin metabolism and mediodorsal thalamus volume changes to depressive symptom improvement; Claim 2 describes lithium-enhanced autophagy via an IP3, mTOR-independent pathway. They do not contradict or directly entail one another, so they are related but distinct (variant).",12694b8a-03de-462a-a0da-b8412687c380,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Claim 2 describes the observed correlation between lithium-induced structural brain changes and gene expression in neurotrophic and cell-modeling pathways; this correlation serves as supporting evidence for Claim 1's conclusion that integrating structural and peripheral gene-expression effects indicates lithium acts via several neurotrophic molecular pathways.,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Claim 2 provides a specific molecular mechanism (lithium up-regulates GRIN2A, which is down-regulated in bipolar disorder) that supports the general assertion in Claim 1 that lithium acts via multiple neurotrophic molecular pathways; thus Claim 2 serves as a premise/evidence for Claim 1.",1a142c2f-a016-4716-8019-a883e04a6b5f,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims address lithium's molecular mechanisms but focus on different, non-conflicting aspects: claim 1 highlights multiple neurotrophic pathways, while claim 2 emphasizes systemic (not cell-type- or region-specific) effects and downplays myelination as a central target. They are related and complementary rather than identical or contradictory.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims describe molecular pathways modulated by lithium but refer to different systems: Claim 1 emphasizes neurotrophic pathways affecting brain structure and gene expression, while Claim 2 highlights immune-related (B-cell, T-cell, chemokine) pathways. They address related mechanisms without contradicting or restating the same specific claim.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"Both claims concern neurotrophic factors/neurotrophic pathways but address different points: Claim 1 makes a specific finding about lithium acting via neurotrophic molecular pathways, while Claim 2 is a general statement that neurotrophins are incompletely understood and promising for future discovery. They are related by topic but not duplicate, premise, or contradictory.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern molecular regulation of brain structure/neurogenesis and mood-related biology (neurotrophic pathways, hippocampal cell proliferation), but they address different interventions and specific pathways (lithium acting via neurotrophic pathways vs. PKC inhibition causing depressive-like effects). They are related in topic but not duplicates, premises, or contradictions.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern molecular/neurotrophic pathways affecting brain structure/function (e.g., hippocampal proliferation and mood). Claim 1 states lithium acts via several neurotrophic pathways, while Claim 2 reports effects of PKC inhibition in rats. They address related biological themes but involve different interventions and specific mechanisms and neither entails nor contradicts the other.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,Claim 2 establishes that BDNF is a key neurotrophic factor important for CNS development and neuronal plasticity. Claim 1 states lithium acts via neurotrophic molecular pathways; the role of BDNF provides foundational background about the importance of such pathways and thus serves as a premise supporting the relevance of Claim 1.,5d2a635d-4bc1-47e6-8418-e59d0ea7c895,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern neurotrophic mechanisms in the brain, but they make different, non-conflicting points: claim 1 says lithium acts via several neurotrophic molecular pathways, while claim 2 asserts BDNF (a specific neurotrophic factor) has a key role in many psychiatric disorders. Claim 1 does not specifically assert or entail the broad role of BDNF, nor does claim 2 depend on lithium's mechanisms, so they are related but not duplicates, premises, or contradictions.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern neurotrophic mechanisms in psychiatric drug action (claim 1: lithium acts via neurotrophic pathways; claim 2: BDNF, a neurotrophic factor, is involved in antidepressant/antipsychotic mechanisms). They are related topic-wise but do not state the same fact, nor does one logically entail the other.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern molecular mechanisms relevant to antidepressant actions/mood disorders, but they describe different, non-contradictory mechanisms: claim 1 focuses on lithium acting via neurotrophic pathways, while claim 2 describes miR-135 targeting genes linked to antidepressant actions and MDD.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern neurotrophic mechanisms affecting brain structure/behavior, but they address different specifics: Claim 1 broadly states lithium acts via multiple neurotrophic pathways, while Claim 2 reports a specific effect of BDNF loss in the dentate gyrus on neurogenesis and depressive-like behavior. They are related but not equivalent, not contradictory, and one does not logically entail the other.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims state that lithium influences neurotrophic-related mechanisms in the brain. Claim 2 is broader and enumerates many additional cellular pathways (ER stress, UPR, autophagy, oxidative stress, mitochondrial function, inflammation) beyond the neurotrophic pathways highlighted in Claim 1, so they discuss the same topic with different scope/detail rather than being identical or contradictory.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.",Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Claim 2 identifies inhibition of GSK3 and IMPase as key molecular effects that can drive lithium's intracellular responses; this offers a mechanistic basis that could explain Claim 1's finding that lithium acts through multiple neurotrophic molecular pathways. The statements are compatible, with Claim 2 serving as a plausible premise for Claim 1.",bc544bb8-5c5d-4d1e-9c34-b51e2f339464,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims address lithium's molecular mechanisms but make different, non-equivalent claims: claim 1 states lithium acts via several neurotrophic pathways (a broad, multi-pathway statement), while claim 2 singles out autophagy promotion as the primary mechanism in neurodegenerative disease. They are related and potentially compatible in different contexts but not duplicates, direct premises, or outright contradictions.",4ca80348-cbf0-476a-9ece-9ec40dc89dc2,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,Integration of lithium's effects on brain structure and peripheral gene expression reveals that lithium acts through several neurotrophic molecular pathways.,"Claim 2 specifies a concrete molecular mechanism (mTOR-independent, IP3-mediated autophagy enhancement) by which lithium acts. This specific pathway plausibly constitutes one of the 'several neurotrophic molecular pathways' asserted in Claim 1, so Claim 2 supports and helps substantiate Claim 1 rather than contradicting it.",88027d82-ef95-4b58-ad6b-ef7f74e5cb4d,4ca80348-cbf0-476a-9ece-9ec40dc89dc2
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.",Both claims concern lithium-induced gene expression changes in the brain and their functional relevance. Claim 1 is a broad statement linking lithium-driven structural brain changes to altered expression in neurotrophic/cell-remodeling pathways; Claim 2 is a specific instance (GRIN2A up-regulation and its relevance to bipolar disorder). They are consistent and related but not duplicates or a direct premise-conclusion pair.,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,1a142c2f-a016-4716-8019-a883e04a6b5f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Both claims address lithium's effects on the brain but focus on different, non-conflicting aspects. Claim 1 links lithium to structural changes correlated with gene-expression changes in neurotrophic and cell‑modeling pathways; Claim 2 emphasizes that lithium's molecular effects are broad/systemic and that myelination is not a primary target. These statements are compatible but not equivalent or causal, so they are variants rather than duplicates, contradictions, or premises.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims describe biological effects of lithium but on different systems: claim 1 links lithium to neurotrophic/cell-modeling gene expression correlated with brain structural changes, while claim 2 describes regulation of immune-related signaling pathways. They address related but distinct mechanisms and do not contradict or premise one another.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern effects on brain cellular/neurotrophic processes (structural changes, gene expression in neurotrophic/cell-modeling pathways, and hippocampal cell proliferation), but they describe different interventions (lithium vs PKC inhibition), different specific outcomes and mechanisms, and are not equivalent, contradictory, or a direct premise of one another.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern treatment-induced changes in brain biology related to neurotrophic function or cell proliferation, but they describe different interventions (lithium vs PKC inhibition), different specific outcomes (structural changes correlated with gene expression vs depressive-like behavior and reduced hippocampal proliferation), and there is no direct logical entailment or contradiction between them.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"Both claims concern neurotrophic mechanisms in the brain: Claim 1 links lithium-induced structural changes to gene expression in neurotrophic pathways, while Claim 2 states a general role for BDNF (a neurotrophic factor) in CNS development and plasticity. They are related in topic but do not restate the same claim, contradict one another, or serve as a clear logical premise for the other.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,5d2a635d-4bc1-47e6-8418-e59d0ea7c895
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern neurotrophic-related biology in the brain, but they address different specific points: Claim 1 links lithium-induced structural changes to gene-expression shifts in neurotrophic/cell‑modeling pathways, while Claim 2 states BDNF (a neurotrophic factor) is important across many psychiatric/neurodevelopmental disorders. Claim 1 does not explicitly mention BDNF or make Claim 2’s broader clinical assertion, nor do they contradict or entail each other.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims relate to neurotrophic mechanisms in psychiatric treatment: claim 1 links lithium to gene expression changes in neurotrophic pathways (broadly implicating factors like BDNF), while claim 2 specifically states BDNF is involved in antidepressant/antipsychotic mechanisms. They overlap conceptually but make different, non-identical claims and neither logically entails the other.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.",Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Claim 1 links lithium-induced structural brain changes to gene expression alterations in neurotrophic pathways. Claim 2 states that BDNF is a key neurotrophic factor important for development, synaptic plasticity, and neuronal health. Thus Claim 2 provides biological background/rationale (a premise) explaining why changes in neurotrophic pathways would be relevant to structural brain changes described in Claim 1.",1e7f51f6-eaca-4408-ae8b-756c1531362e,9ed653c6-b9bf-45f1-aa0c-0e81fe511c50
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims address molecular/neurobiological mechanisms underlying treatment effects on the brain, but they focus on different treatments, targets, and levels of description. Claim 1 links lithium-induced structural changes with gene expression in neurotrophic/cell‑modeling pathways broadly, while Claim 2 identifies Homer1a expression in mPFC as a specific final common pathway for several antidepressant interventions. They are thematically related but not equivalent, contradictory, or a direct premise of one another.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern neurotrophic pathways and structural/neurogenic brain changes, but they report different, non-conflicting findings: claim 1 links lithium treatment to correlated gene-expression changes in neurotrophic/cell‑modeling pathways, while claim 2 describes a causal effect of localized BDNF reduction in the dentate gyrus on neurogenesis and depressive-like behavior. There is no direct entailment or contradiction.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern lithium's effects on brain cellular pathways and neuroplasticity. Claim 1 reports a specific correlation between lithium-induced structural brain changes and gene-expression changes in neurotrophic and cell-modeling pathways; Claim 2 makes a broader claim that lithium regulates many cellular pathways (including neurotrophic response) involved in neuroplasticity and neuroprotection. They overlap but differ in scope and detail, and do not contradict.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern biological effects of lithium but at different levels: claim 1 reports structural brain changes correlated with gene expression in neurotrophic/cell‑modeling pathways, while claim 2 proposes broad intracellular mechanisms (GSK3 and IMPase inhibition). They are complementary and related but do not restate the same claim, directly contradict each other, or explicitly establish a premise→conclusion relationship.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims address molecular mechanisms of lithium's effects on the brain but propose different primary mechanisms. Claim 1 links structural brain changes to gene expression in neurotrophic and cell‑modeling pathways, while Claim 2 asserts promotion of autophagy as the primary protective mechanism. These are related (same topic) but not duplicates or direct contradictions, so they are variants.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Structural brain changes induced by lithium treatment correlate with gene expression changes in pathways involved in neurotrophic function and cell modeling.,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern biological effects of lithium but address different mechanisms/outcomes. Claim 1 links lithium to structural brain changes and gene-expression in neurotrophic and cell-remodeling pathways; Claim 2 describes a specific signaling mechanism (mTOR-independent, IP3-mediated) by which lithium enhances autophagy. They do not duplicate or contradict each other, nor is one clearly a direct premise for the other.",9ed653c6-b9bf-45f1-aa0c-0e81fe511c50,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Claim 2 provides mechanistic/therapeutic evidence (lithium up-regulates GRIN2A while GRIN2A is down-regulated in bipolar patients), which supports Claim 1’s conclusion that GRIN2A is a promising therapeutic target for bipolar disorder.",1a142c2f-a016-4716-8019-a883e04a6b5f,8c60294a-ff96-4ed1-8774-69b5ec363317
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Both claims concern biological mechanisms of affective disorders (depression/bipolar) but focus on different, non-conflicting mechanisms: Claim 1 proposes GRIN2A as a therapeutic target for affective disorders including bipolar disorder, while Claim 2 implicates mitochondrial dysfunction in depression. They are related in topic but are neither equivalent nor one a premise of the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","Both claims concern biological factors in affective disorders but focus on different mechanisms: Claim 1 proposes GRIN2A (a glutamatergic receptor subunit) as a therapeutic target, while Claim 2 implicates mitochondrial dysfunction preceding depressive symptoms. They do not restate or directly support/contradict each other, nor is one a clear logical premise for the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,703e323f-781d-49a1-9b29-a076270691a6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"Both claims concern biological mechanisms relevant to affective disorders but describe different, non-overlapping mechanisms: Claim 1 proposes GRIN2A/glutamatergic modulation as a therapeutic target (noting bipolar disorder), while Claim 2 implicates stress-induced mitochondrial electron transport inhibition in depression pathophysiology. They do not duplicate, contradict, or serve as premises for one another.",8c60294a-ff96-4ed1-8774-69b5ec363317,ffdad4fb-9055-44ab-99f8-e87b94a53af3
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Both claims relate to mechanisms underlying affective disorders but describe different, non-conflicting biological targets: Claim 1 identifies GRIN2A/glutamatergic signaling as a therapeutic target (esp. bipolar disorder), while Claim 2 implicates mitochondrial dysfunction and downstream effects in depression pathogenesis. They address the same broad topic (mood/affective disorders) via distinct mechanisms, so they are variants rather than duplicates, premises, or contradictions.",8c60294a-ff96-4ed1-8774-69b5ec363317,e2a99bc5-1b56-47bf-8fe6-dc5063fe7060
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Both claims propose therapeutic targets for mood/affective disorders but focus on different, non-conflicting mechanisms: Claim 1 targets the glutamatergic receptor subunit GRIN2A (including bipolar disorder), while Claim 2 targets early mitochondrial dysfunction in depression. They address the same general topic without duplicating, contradicting, or providing a premise relationship.",8c60294a-ff96-4ed1-8774-69b5ec363317,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern biological mechanisms relevant to bipolar disorder and potential therapeutic targets, but they refer to different molecular systems (GRIN2A/glutamatergic signaling vs PKC signaling). They do not duplicate or contradict each other, nor does one serve as a direct logical premise for the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern molecular components implicated in mood regulation and bipolar disorder but refer to different proteins (GRIN2A vs PKC) and make distinct, non-contradictory claims about therapeutic relevance; neither claim is a premise of the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern neurobiological mechanisms relevant to affective disorders but focus on different molecular targets (GRIN2A/NMDA receptor subunit vs PKC activation). They are related by topic but do not duplicate, contradict, or serve as direct premises for one another.",8c60294a-ff96-4ed1-8774-69b5ec363317,bfdfd15f-1d66-4cb0-bef9-66b87c492ad1
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern molecular mechanisms and therapeutic targets for bipolar disorder but refer to different proteins/systems (GRIN2A, an NMDA receptor subunit, vs PKC). They address the same topic without duplicating, supporting, or contradicting each other.",8c60294a-ff96-4ed1-8774-69b5ec363317,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern biological mechanisms relevant to affective disorders (potential therapeutic targets/effects) but refer to different molecular pathways—GRIN2A (glutamatergic) vs PKC activation. They do not duplicate or contradict each other, nor does one serve as a clear logical premise for the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern molecular mechanisms relevant to bipolar disorder and potential therapeutic modulation, but they refer to different targets and mechanisms (GRIN2A/NMDA receptor vs PKC). They are related in topic but do not duplicate, contradict, or serve as direct premises for one another.",8c60294a-ff96-4ed1-8774-69b5ec363317,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern molecular factors implicated in psychiatric disorders including bipolar disorder, but they refer to different molecules and roles (GRIN2A as a proposed therapeutic target vs. BDNF as a pathophysiological factor). They are related on topic but are not the same claim, do not contradict, and one is not a clear premise for the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern glutamatergic mechanisms for treating affective disorders but make different points: Claim 1 proposes GRIN2A (an NMDA receptor subunit) as a therapeutic target, while Claim 2 attributes ketamine's antidepressant effects mainly to AMPA activation by HNK and mTOR signaling rather than NMDA antagonism alone. Claim 2 offers an alternative/mechanistic emphasis but does not directly refute GRIN2A as a potential target.",8c60294a-ff96-4ed1-8774-69b5ec363317,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern glutamatergic-based approaches to affective disorders, but they make different, non-conflicting points: Claim 1 proposes GRIN2A as a therapeutic target, while Claim 2 describes ketamine's antidepressant mechanisms (synaptogenesis in PFC and increased serotonergic drive). They are related thematically but not equivalent or premises of one another.",8c60294a-ff96-4ed1-8774-69b5ec363317,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern biological mechanisms relevant to affective disorders but refer to different molecular targets and findings (GRIN2A as an NMDA subunit therapeutic target vs miR-135 regulating genes linked to antidepressant action and MDD). They address the same broad topic without duplicating, contradicting, or one serving as a direct premise for the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,"Both claims propose therapeutic approaches for affective disorders but focus on different mechanisms and modalities: Claim 1 highlights GRIN2A/glutamatergic targeting, while Claim 2 describes intranasal sertraline-conjugated siRNAs against 5-HT1A and SERT. They address the same general topic without contradicting or serving as premises for one another.",8c60294a-ff96-4ed1-8774-69b5ec363317,54c4e069-99aa-4b45-9a6b-a1c75b1af627
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern molecular mechanisms relevant to affective/antidepressant treatments but propose different specific targets/pathways (GRIN2A vs Homer1a in mPFC). They do not duplicate, contradict, or serve as direct premises for one another.",8c60294a-ff96-4ed1-8774-69b5ec363317,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.",Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern non-monoaminergic/glutamatergic approaches to treating affective disorders, but they make different points: claim 1 proposes GRIN2A as a specific therapeutic target (including bipolar disorder), while claim 2 highlights ketamine as proof that rapid-acting, non-monoaminergic antidepressants can be developed. They are related on topic but not equivalent or directly premise/consequence.",8c60294a-ff96-4ed1-8774-69b5ec363317,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims propose therapeutic approaches for affective disorders/depression, but they involve distinct targets and modalities (GRIN2A/glutamatergic targeting vs SSRI-conjugated siRNA delivery to serotonergic neurons). They are related by topic but neither duplicate nor contradict nor serve as a premise for the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"GRIN2A, a central component of the glutamatergic system, represents a warranted and promising therapeutic target for affective disorders including bipolar disorder.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern molecular targets/mechanisms relevant to affective or neuropsychiatric conditions, but they refer to different targets (GRIN2A/glutamatergic system vs lithium acting via GSK3 and IMPase). They do not duplicate or contradict each other and neither is a direct premise of the other.",8c60294a-ff96-4ed1-8774-69b5ec363317,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,contradiction,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Claim 1 proposes a specific, brain-targeted molecular mechanism (lithium up-regulates GRIN2A in the brain as part of its therapeutic effect). Claim 2 asserts lithium's molecular effects are systemic and not targeted to specific cell types or brain areas (and downplays targeted mechanisms such as effects on myelination). These positions conflict because one claims a specific brain/gene-targeted action while the other denies targeted regional or cell-type mechanisms.",1a142c2f-a016-4716-8019-a883e04a6b5f,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Both claims describe biological effects of lithium but on different systems: claim 1 concerns up-regulation of the neuronal gene GRIN2A as a possible therapeutic mechanism in bipolar disorder, while claim 2 concerns lithium's regulation of immune-related signaling pathways. They address the same general topic (lithium's mechanisms) without duplicating, implying, or contradicting each other.",1a142c2f-a016-4716-8019-a883e04a6b5f,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern molecular mechanisms relevant to bipolar disorder and its treatment, but they refer to different pathways (lithium-mediated upregulation of GRIN2A vs PKC modulation affecting mood dimensions). They do not contradict or provide a direct premise-to-conclusion relationship.",1a142c2f-a016-4716-8019-a883e04a6b5f,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims address molecular mechanisms relevant to bipolar disorder but focus on different targets (GRIN2A regulation by lithium vs PKC involvement). They do not duplicate, contradict, or serve as premises for one another and no direct causal or evidential link is stated.",1a142c2f-a016-4716-8019-a883e04a6b5f,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern biological mechanisms that may produce antimanic effects, but they refer to different molecular targets and lines of evidence (lithium up-regulating GRIN2A in the brain vs PKC inhibition producing antimanic-like behavior in rats). They do not duplicate, contradict, or serve as direct premises for one another, so they are related but different (variant).",1a142c2f-a016-4716-8019-a883e04a6b5f,ae3c78a3-aaea-4b95-88c9-0997465c58c7
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims address molecular mechanisms relevant to bipolar disorder but focus on different targets and claims: claim 1 posits lithium’s therapeutic effect involves up-regulation of GRIN2A, while claim 2 asserts a role for PKC in mood regulation and bipolar states. They are related by topic but do not duplicate, contradict, or serve as premises for one another.",1a142c2f-a016-4716-8019-a883e04a6b5f,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern mechanisms producing antimanic effects, but they describe different targets and evidence: claim 1 links lithium's therapeutic effect to upregulation of GRIN2A in bipolar disorder, while claim 2 describes PKC inhibition producing antimanic-like behaviors in rats. They address the same general topic without restating, supporting, or contradicting each other.",1a142c2f-a016-4716-8019-a883e04a6b5f,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims state that lithium regulates molecular targets in the brain relevant to neuroplasticity/neuroprotection. Claim 1 is a specific mechanistic example (up-regulation of GRIN2A and its relevance to bipolar disorder), while Claim 2 is a broad summary of many pathways lithium affects. They are related but not equivalent or strictly premise/consequence.",1a142c2f-a016-4716-8019-a883e04a6b5f,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims address mechanisms by which lithium may exert effects in the brain but propose different specific molecular targets: Claim 1 implicates up-regulation of GRIN2A in bipolar disorder, while Claim 2 attributes lithium's intracellular responses to inhibition of GSK3 and IMPase. They are related (same topic) but not equivalent, not contradictory, and neither is presented as a direct premise for the other.",1a142c2f-a016-4716-8019-a883e04a6b5f,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims concern possible molecular mechanisms of lithium's effects but in different contexts and via different pathways: Claim 1 links lithium to GRIN2A modulation in bipolar disorder, while Claim 2 attributes lithium's protective effects in neurodegenerative diseases to autophagy. They address related high-level topic (lithium mechanisms) without duplicating, supporting, or contradicting one another.",1a142c2f-a016-4716-8019-a883e04a6b5f,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Modulation of GRIN2A expression may be part of lithium's therapeutic effect in bipolar disorder, as lithium significantly up-regulates GRIN2A in the brain while GRIN2A is down-regulated in bipolar disorder patients.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims concern molecular effects of lithium but describe different, non-overlapping mechanisms: Claim 1 implicates lithium-induced up-regulation of GRIN2A in bipolar disorder therapeutic effects, while Claim 2 describes lithium-enhanced autophagy via an mTOR-independent IP3 pathway. They are related by topic (lithium mechanisms) but neither duplicates, contradicts, nor provides a clear logical premise for the other.",1a142c2f-a016-4716-8019-a883e04a6b5f,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Claim 2 reports lithium's regulation of immune pathways (B-cell, T-cell, chemokine signaling), which indicates effects on peripheral/immune cell types rather than a brain‑specific target; this supports Claim 1's assertion that lithium's molecular effects are systemic and not centered on myelination (though Claim 2 does not directly address myelination).",5930f19c-a19e-4fee-ab43-352f872aa7ad,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Claim 2 describes lithium regulating many diverse cellular pathways across the brain (neurotrophic signaling, ER stress/UPR, autophagy, oxidative stress, mitochondrial function, inflammation), which implies broad, system-level effects rather than action restricted to a particular cell type or region. This supports Claim 1's assertion that lithium's molecular effects are systemic and that myelination is not necessarily a central, singular target.",0ccc686b-5be5-4aa5-9360-6c97d148920d,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.","Claim 2 proposes that inhibition of broadly expressed enzymes (GSK3 and IMPase) underlies lithium's diverse intracellular responses; that mechanism would produce widespread, system-level effects across cell types and brain regions and thus supports Claim 1's assertion that lithium acts systemically rather than in a cell-type- or region-specific manner (and is consistent with myelination not being a central target).",bc544bb8-5c5d-4d1e-9c34-b51e2f339464,27a93479-31ed-49b7-950e-3cf4b7671182
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims address lithium's molecular mechanisms but focus on different aspects. Claim 1 emphasizes that lithium acts systemically and downplays myelination as a central target, while Claim 2 asserts autophagy promotion as the primary protective mechanism in neurodegeneration. These are not directly contradictory (autophagy could be a broadly acting/systemic mechanism) but they differ in emphasis and specificity, so they are variants rather than duplicates or premises of one another.",27a93479-31ed-49b7-950e-3cf4b7671182,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"The molecular effects of lithium are systemic rather than targeted to specific cell types or brain areas, with myelination not being a central target of lithium's mechanisms of action in the brain.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims address lithium's molecular actions but at different levels. Claim 1 makes a broad claim that lithium's effects are systemic and that myelination is not a central target, while Claim 2 describes a specific cellular signaling mechanism (mTOR-independent, IP3-mediated autophagy enhancement). These statements are compatible and concern the same topic without being duplicates or direct premises/contradictions.",27a93479-31ed-49b7-950e-3cf4b7671182,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Both claims concern immune/inflammatory processes but address different mechanisms and conclusions: Claim 1 describes lithium's regulation of immune signaling pathways, while Claim 2 describes how mitochondrial dysfunction drives oxidative stress, inflammation, and apoptosis in depression. They are related thematically but neither duplicates, contradicts, nor serves as a direct premise for the other.",5930f19c-a19e-4fee-ab43-352f872aa7ad,e2a99bc5-1b56-47bf-8fe6-dc5063fe7060
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims describe lithium’s regulatory effects on biological pathways but in different contexts: Claim 1 focuses on immune signaling (B-cell/T-cell/chemokine pathways), while Claim 2 focuses on brain cellular pathways related to neuroplasticity and neuroprotection (ER stress, autophagy, mitochondrial function, inflammation). They overlap only partially (inflammation) and do not contradict or serve as direct premises for one another.",5930f19c-a19e-4fee-ab43-352f872aa7ad,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.","Claim 2 identifies inhibition of GSK3 and IMPase as core molecular actions by which lithium produces broad intracellular effects. Those molecular effects can plausibly drive changes in signaling pathways (including B‑cell, T‑cell and chemokine pathways) described in Claim 1, so Claim 2 provides a mechanistic premise supporting Claim 1.",bc544bb8-5c5d-4d1e-9c34-b51e2f339464,5930f19c-a19e-4fee-ab43-352f872aa7ad
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims concern mechanisms of action of lithium but address different pathways and outcomes: Claim 1 describes immunoregulatory effects via B‑ and T‑cell and chemokine signaling, while Claim 2 attributes neuroprotective effects to autophagy promotion. They are not the same claim nor contradictory and could both be true.",5930f19c-a19e-4fee-ab43-352f872aa7ad,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium regulates several immune-related pathways including B-cell receptor, T-cell receptor, and chemokine signaling pathways, supporting lithium's immunoregulatory effects.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Both claims describe different biological effects and signaling mechanisms of lithium: Claim 1 concerns immunoregulatory effects via B- and T-cell receptor and chemokine pathways, while Claim 2 describes lithium-driven autophagy via an mTOR-independent, IP3-related mechanism. They address the same broader topic (lithium's cellular signaling) but refer to distinct, non-conflicting mechanisms, so they are variants.",5930f19c-a19e-4fee-ab43-352f872aa7ad,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Purified Aβ*56 from impaired transgenic mouse brains disrupts memory when administered to young rats, demonstrating a direct causal relationship between this protein assembly and cognitive impairment.","A specific 56-kDa soluble amyloid-beta assembly, termed Aβ*56, causes memory impairment independently of amyloid plaques or neuronal loss.","Claim 2 reports an experiment where purified Aβ*56 from affected transgenic mice causes memory disruption when given to young rats, providing direct causal evidence that supports Claim 1's assertion that Aβ*56 causes memory impairment (independent of plaques or neuronal loss).",339a5afb-fcce-4a86-8db0-61c5b7820889,acf52d27-7c31-4096-af22-9f53124e5954
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"A specific 56-kDa soluble amyloid-beta assembly, termed Aβ*56, causes memory impairment independently of amyloid plaques or neuronal loss.",Aβ*56 may contribute to cognitive deficits in early-stage Alzheimer's disease before the development of plaques or significant neuronal loss.,"Claim 1 asserts that Aβ*56 causes memory impairment independently of plaques or neuronal loss; this causal, plaque-independent effect provides direct support for Claim 2's weaker, conditional statement that Aβ*56 may contribute to early cognitive deficits before plaque formation or significant neuronal loss.",acf52d27-7c31-4096-af22-9f53124e5954,981409ae-f92e-4784-9066-87b4decde650
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Soluble amyloid-beta assemblies form a stable ladder of oligomers comprised of trimers and multiples of trimers, with trimers being the fundamental assembly unit in vivo.","A specific 56-kDa soluble amyloid-beta assembly, termed Aβ*56, causes memory impairment independently of amyloid plaques or neuronal loss.","Claim 2 provides a structural description of soluble Aβ oligomers (trimers and multiples of trimers), which supports the existence/identification of a discrete ~56-kDa oligomer (Aβ*56) described in Claim 1. Claim 2 supplies a biochemical basis for that species but does not itself make the toxic/memory-impairment claim.",b859f853-c1b7-4bae-afcc-1d8552492731,acf52d27-7c31-4096-af22-9f53124e5954
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"A specific 56-kDa soluble amyloid-beta assembly, termed Aβ*56, causes memory impairment independently of amyloid plaques or neuronal loss.",Aβ*56 impairs memory by inducing transient physiological alterations rather than permanent neuropathological changes in the brain.,"Claim 1 states Aβ*56 causes memory impairment independently of plaques or neuronal loss (i.e., not due to permanent neuropathology). Claim 2 provides a mechanism — transient physiological alterations rather than permanent neuropathological changes — which builds on that independence. Thus Claim 1 is a premise supporting Claim 2.",acf52d27-7c31-4096-af22-9f53124e5954,9f159ba9-7ed1-4c2b-9d87-f770d8888d11
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Purified Aβ*56 from impaired transgenic mouse brains disrupts memory when administered to young rats, demonstrating a direct causal relationship between this protein assembly and cognitive impairment.",Aβ*56 may contribute to cognitive deficits in early-stage Alzheimer's disease before the development of plaques or significant neuronal loss.,"Claim 1 presents experimental causal evidence that purified Aβ*56 induces memory disruption in an animal model in the absence of plaques, which directly supports Claim 2's hypothesis that Aβ*56 may contribute to cognitive deficits in early-stage Alzheimer’s disease before plaque formation or major neuronal loss.",339a5afb-fcce-4a86-8db0-61c5b7820889,981409ae-f92e-4784-9066-87b4decde650
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Purified Aβ*56 from impaired transgenic mouse brains disrupts memory when administered to young rats, demonstrating a direct causal relationship between this protein assembly and cognitive impairment.","Soluble amyloid-beta assemblies form a stable ladder of oligomers comprised of trimers and multiples of trimers, with trimers being the fundamental assembly unit in vivo.","Both claims concern soluble amyloid-β assemblies but address different aspects: Claim 1 asserts a functional/causal effect of a specific assembly (Aβ*56) on memory, while Claim 2 describes the structural organization (trimers and multiples) of soluble oligomers. They do not duplicate or contradict one another, nor does either serve as a direct logical premise for the other, so they are related variants on the same topic.",339a5afb-fcce-4a86-8db0-61c5b7820889,b859f853-c1b7-4bae-afcc-1d8552492731
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Purified Aβ*56 from impaired transgenic mouse brains disrupts memory when administered to young rats, demonstrating a direct causal relationship between this protein assembly and cognitive impairment.",Aβ*56 impairs memory by inducing transient physiological alterations rather than permanent neuropathological changes in the brain.,Claim 1 provides experimental evidence that Aβ*56 causally disrupts memory (administration to rats causes impairment). Claim 2 proposes a specific mechanism (transient physiological alterations rather than permanent neuropathology). Claim 1 does not establish the mechanism but serves as a foundational demonstration of causation that supports Claim 2.,339a5afb-fcce-4a86-8db0-61c5b7820889,9f159ba9-7ed1-4c2b-9d87-f770d8888d11
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Aβ*56 may contribute to cognitive deficits in early-stage Alzheimer's disease before the development of plaques or significant neuronal loss.,"Soluble amyloid-beta assemblies form a stable ladder of oligomers comprised of trimers and multiples of trimers, with trimers being the fundamental assembly unit in vivo.","Both claims concern soluble Aβ oligomers but address different aspects: claim 1 posits a functional/toxic role for a specific oligomer (Aβ*56) in early AD, while claim 2 describes the structural organization of soluble Aβ as trimer-based oligomeric ladders. Claim 2 does not directly support, contradict, or serve as a clear logical premise for claim 1, so they are related but not equivalent.",981409ae-f92e-4784-9066-87b4decde650,b859f853-c1b7-4bae-afcc-1d8552492731
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Aβ*56 impairs memory by inducing transient physiological alterations rather than permanent neuropathological changes in the brain.,Aβ*56 may contribute to cognitive deficits in early-stage Alzheimer's disease before the development of plaques or significant neuronal loss.,Claim 2 provides a mechanistic explanation — Aβ*56 causes transient physiological (not permanent neuropathological) changes that impair memory — which supports Claim 1's assertion that Aβ*56 can contribute to cognitive deficits in early-stage Alzheimer's before plaques or neuronal loss.,9f159ba9-7ed1-4c2b-9d87-f770d8888d11,981409ae-f92e-4784-9066-87b4decde650
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Soluble amyloid-beta assemblies form a stable ladder of oligomers comprised of trimers and multiples of trimers, with trimers being the fundamental assembly unit in vivo.",Aβ*56 impairs memory by inducing transient physiological alterations rather than permanent neuropathological changes in the brain.,"Both claims concern soluble Aβ oligomers but address different, non-conflicting aspects: claim 1 describes oligomer structural organization (trimers as fundamental units), while claim 2 asserts a functional effect of a specific oligomer (Aβ*56) on memory via transient physiological changes. They relate by topic but do not duplicate, contradict, or serve as direct premises for one another.",b859f853-c1b7-4bae-afcc-1d8552492731,9f159ba9-7ed1-4c2b-9d87-f770d8888d11
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Neurotrophins activate multiple signaling pathways by binding to two distinct receptor types: Trk receptor tyrosine kinases and the p75 NTR receptor.,"While Trk receptor signaling pathways are well-characterized, p75 NTR signaling is more complex and its in vivo significance remains incompletely determined.","Both claims address neurotrophin receptor signaling. Claim 1 states that neurotrophins signal via Trk and p75NTR receptors; Claim 2 provides additional nuance that Trk pathways are well characterized while p75NTR signaling is more complex and less well understood in vivo. The statements are complementary (same topic, different emphasis), not duplicate, premise, or contradictory.",32039099-7adb-448e-9ab9-b51dbee4866b,e39212d2-772a-428b-a2fa-5e5f17b75391
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Neurotrophins activate multiple signaling pathways by binding to two distinct receptor types: Trk receptor tyrosine kinases and the p75 NTR receptor.,"p75 NTR can bind pro-neurotrophins as ligands and form different complexes with other transmembrane proteins, expanding understanding of its signaling capabilities.","Both claims concern p75NTR's role in neurotrophin signaling but provide different, complementary information. Claim 1 states the general fact that neurotrophins signal via Trk receptors and p75NTR; Claim 2 adds specific details (binding of pro-neurotrophins and complex formation with other transmembrane proteins) that expand understanding of p75NTR signaling. The two do not contradict and one does not strictly entail the other.",32039099-7adb-448e-9ab9-b51dbee4866b,4f2c7d9b-21a1-4c57-bf10-bdc5fe88cf6f
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Neurotrophins activate multiple signaling pathways by binding to two distinct receptor types: Trk receptor tyrosine kinases and the p75 NTR receptor.,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"Both claims concern neurotrophin biology: Claim 1 describes the general receptor-mediated signaling mechanisms of neurotrophins (Trk and p75NTR), while Claim 2 makes a functional claim about a specific neurotrophin (BDNF) being essential for CNS development and plasticity. They are related but address different aspects (mechanism vs. specific biological role) and neither logically entails nor contradicts the other.",32039099-7adb-448e-9ab9-b51dbee4866b,5d2a635d-4bc1-47e6-8418-e59d0ea7c895
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Neurotrophins activate multiple signaling pathways by binding to two distinct receptor types: Trk receptor tyrosine kinases and the p75 NTR receptor.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern neurotrophins/BDNF but address different aspects: Claim 1 describes general receptor-mediated signaling by neurotrophins, while Claim 2 asserts a role for BDNF in the mechanisms of psychiatric drugs. They are related topical variants rather than duplicates, premises, or contradictions.",32039099-7adb-448e-9ab9-b51dbee4866b,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Neurotrophins activate multiple signaling pathways by binding to two distinct receptor types: Trk receptor tyrosine kinases and the p75 NTR receptor.,"BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.","Claim 1 describes a general mechanism by which neurotrophins signal (via Trk receptor tyrosine kinases and p75NTR). BDNF is a neurotrophin that signals through TrkB/p75, and those signaling pathways underlie its roles in brain development, synaptic plasticity, and neuronal health, so Claim 1 serves as a mechanistic premise supporting Claim 2.",32039099-7adb-448e-9ab9-b51dbee4866b,1e7f51f6-eaca-4408-ae8b-756c1531362e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"p75 NTR can bind pro-neurotrophins as ligands and form different complexes with other transmembrane proteins, expanding understanding of its signaling capabilities.","While Trk receptor signaling pathways are well-characterized, p75 NTR signaling is more complex and its in vivo significance remains incompletely determined.",Claim 2 gives mechanistic details (binding pro-neurotrophins and forming complexes with other transmembrane proteins) that explain the complexity of p75NTR signaling and thereby support Claim 1's point that p75NTR signaling is more complex and not fully characterized in vivo.,4f2c7d9b-21a1-4c57-bf10-bdc5fe88cf6f,e39212d2-772a-428b-a2fa-5e5f17b75391
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"While Trk receptor signaling pathways are well-characterized, p75 NTR signaling is more complex and its in vivo significance remains incompletely determined.",Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,Claim 1 gives a specific example (uncertain in vivo significance of p75NTR signaling) that supports the general claim in Claim 2 that neurotrophins are incompletely understood; thus Claim 1 can be a premise for Claim 2.,e39212d2-772a-428b-a2fa-5e5f17b75391,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"p75 NTR can bind pro-neurotrophins as ligands and form different complexes with other transmembrane proteins, expanding understanding of its signaling capabilities.",Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"Both statements concern neurotrophins/p75NTR but at different levels: Claim 1 is a specific mechanistic finding about p75NTR binding pro-neurotrophins and forming complexes, while Claim 2 is a broad, high-level claim that neurotrophins remain incompletely understood and promising for future discoveries. They relate topically without duplicating, contradicting, or serving as strict premises for one another.",4f2c7d9b-21a1-4c57-bf10-bdc5fe88cf6f,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"p75 NTR can bind pro-neurotrophins as ligands and form different complexes with other transmembrane proteins, expanding understanding of its signaling capabilities.",Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"Both statements concern neurotrophin biology but address different points: claim 1 describes p75NTR binding pro-neurotrophins and receptor complexing (signaling mechanisms), while claim 2 states a functional role for BDNF in CNS development and plasticity. They are related topics but not equivalent, not premises of one another, and do not contradict.",4f2c7d9b-21a1-4c57-bf10-bdc5fe88cf6f,5d2a635d-4bc1-47e6-8418-e59d0ea7c895
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"p75 NTR can bind pro-neurotrophins as ligands and form different complexes with other transmembrane proteins, expanding understanding of its signaling capabilities.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern neurotrophin biology and signaling (p75NTR binds pro-neurotrophins; BDNF is a neurotrophin implicated in psychiatric disorders), so they are related but make different, nonredundant points and neither implies nor contradicts the other.",4f2c7d9b-21a1-4c57-bf10-bdc5fe88cf6f,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"p75 NTR can bind pro-neurotrophins as ligands and form different complexes with other transmembrane proteins, expanding understanding of its signaling capabilities.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern neurotrophin signaling, but they address different aspects: Claim 1 describes p75NTR binding pro-neurotrophins and forming receptor complexes (receptor-level signaling mechanisms), while Claim 2 states that BDNF (a neurotrophin) is involved in the mechanism of action of psychiatric drugs. They are related topicaly but are neither equivalent, contradictory, nor a direct premise of one another.",4f2c7d9b-21a1-4c57-bf10-bdc5fe88cf6f,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"Claim 2 states that BDNF, a neurotrophin, is essential for CNS development and plasticity. This specific established role supports Claim 1's general point that neurotrophins are important and promising targets for future discoveries (i.e., Claim 2 serves as evidence/premise for Claim 1), though Claim 2 does not address the ‘incompletely understood’ aspect directly.",5d2a635d-4bc1-47e6-8418-e59d0ea7c895,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Claim 1 is a general statement about neurotrophins being incompletely understood and promising for future discoveries. Claim 2 is a specific factual claim about BDNF (a neurotrophin) and its role in psychiatric/neurodevelopmental disorders. They are topically related but not equivalent, not contradictory, and one is not a direct logical premise for the other.",e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.",Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"BDNF is a neurotrophin; its established vital roles in brain development, synaptic plasticity, and neuronal health illustrate the importance of neurotrophins and thereby support the broader claim that neurotrophins are incompletely understood growth factors with potential to yield significant discoveries. Claim 2 therefore serves as a premise for Claim 1.",1e7f51f6-eaca-4408-ae8b-756c1531362e,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.",Claim 1 is a broad general statement about neurotrophins as a class; Claim 2 is a specific empirical finding about BDNF (a neurotrophin) in the dentate gyrus. They address the same topic at different levels of specificity and do not contradict or serve as direct premises for one another.,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Neurotrophins remain incompletely understood growth factors with the potential to yield many significant discoveries in future research.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",Both claims concern neurotrophic biology (claim 1 about neurotrophins broadly; claim 2 about lithium affecting neurotrophic response among other pathways). They address related topics without restating the same assertion or contradicting one another.,e72c54de-dd47-4c36-8aab-ce6c0f7f7fd4,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Claim 2 describes specific mitochondrial alterations (impaired oxidative phosphorylation, loss of membrane polarity) that increase oxidative stress and apoptosis and may precede depressive symptoms, providing mechanistic and temporal support for the broader claim (Claim 1) that mitochondrial dysfunction plays an important role in depression.",703e323f-781d-49a1-9b29-a076270691a6,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Claim 2 gives a specific mechanism (chronic stress–induced inhibition of mitochondrial electron transport chain complexes) that would produce mitochondrial dysfunction implicated in depression, thereby serving as a premise supporting the broader Claim 1.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.",Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Claim 2 supplies mechanistic explanations (reduced ATP, impaired neuronal circuit activity, altered mitochondrial dynamics, increased oxidative stress/inflammation/apoptosis) that explain how mitochondrial dysfunction can cause or contribute to depression, so it serves as a premise/supporting foundation for Claim 1.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,ee17cb0b-702d-46ca-bfed-fc7e1a1da63a
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Claim 1 states that mitochondrial dysfunction contributes to depression; Claim 2 proposes that reversing early mitochondrial dysfunction could be a therapeutic strategy. Claim 1 provides the logical basis for Claim 2, so Claim 1 is a premise supporting Claim 2.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological contributors to mood disorders and depressive states but assert different mechanisms (mitochondrial dysfunction vs PKC signaling). They overlap in topic but do not duplicate, contradict, or provide a direct premise-conclusion relationship.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern biological mechanisms related to depression, but they address different pathways: Claim 1 posits a role for mitochondrial dysfunction generally, while Claim 2 reports that PKC inhibition produces depressive-like behavior and reduces hippocampal cell proliferation in rats. There is no direct entailment or contradiction between them.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological mechanisms underlying mood disorders and specifically depressive states, but they describe different mechanisms (mitochondrial dysfunction vs. PKC signaling) and different diagnostic contexts (depression vs. bipolar disorder including depression). They do not duplicate, contradict, or provide a clear logical premise–conclusion relationship.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern mechanisms related to depression but refer to different specific mechanisms. Claim 1 posits a role for mitochondrial dysfunction in depression generally; Claim 2 reports that chronic PKC inhibition induces depressive-like behavior and reduced hippocampal proliferation in rats. They are topic-related but neither duplicates, directly contradicts, nor serves as a clear premise for the other.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern mechanisms implicated in major depressive disorder, but they assert different biological factors (mitochondrial dysfunction vs BDNF). They address the same topic without duplicating, contradicting, or providing a clear premise–conclusion relationship.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern biological mechanisms relevant to psychiatric disorders and antidepressant effects, but they refer to different non-conflicting pathways (mitochondrial dysfunction vs BDNF-mediated mechanisms). They are related in topic but not equivalent, contradictory, or a direct premise of one another.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both statements concern depression mechanisms/treatment but describe different, non-overlapping mechanisms: Claim 1 implicates mitochondrial dysfunction in depression pathophysiology, while Claim 2 describes ketamine’s synaptogenic and serotonergic actions as its antidepressant mechanism. They do not contradict or serve as premises for one another.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern biological factors linked to depression but refer to different mechanisms: Claim 1 implicates mitochondrial dysfunction in depression pathophysiology, while Claim 2 implicates miR-135 regulation of genes related to antidepressant actions and association with major depressive disorder. They are related topics but not duplicates, contradictions, or premises of one another.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims concern mechanisms affecting depressive-like behavior but address different, non-overlapping mechanisms. Claim 1 implicates mitochondrial dysfunction broadly in depression; Claim 2 reports that prodynorphin knockdown in the rat nucleus accumbens reduces depressive-like behavior. They do not state the same thing, do not contradict one another, and neither serves as a direct logical premise for the other.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern biological mechanisms related to depression but address different pathways: Claim 1 implicates mitochondrial dysfunction in depression pathophysiology, while Claim 2 identifies Homer1a expression in medial prefrontal cortex as a common mediator of antidepressant actions. They do not duplicate, entail, or contradict each other, but discuss distinct, non-conflicting mechanisms.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims address mechanisms contributing to depression but focus on different, non-overlapping pathways: Claim 1 implicates mitochondrial dysfunction broadly in depression, while Claim 2 specifies BDNF reduction in the dentate gyrus reducing neurogenesis and producing depressive-like behaviors. They are related by topic but neither restates, contradicts, nor provides a direct premise for the other.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Mitochondrial dysfunction plays an important role in the pathophysiology of depression.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern mitochondrial function in the brain but make different assertions: Claim 1 states mitochondrial dysfunction contributes to depression, while Claim 2 states lithium modulates mitochondrial function (among other pathways). They are related on topic but neither duplicates nor contradicts the other, and one does not logically entail the other.",ee17cb0b-702d-46ca-bfed-fc7e1a1da63a,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"Both claims attribute a role for mitochondrial dysfunction (impaired oxidative phosphorylation/ETC activity) in depression, but they differ in specificity and emphasis: Claim 2 names chronic stress–induced inhibition of ETC complexes as a contributing factor, while Claim 1 more broadly links alterations in oxidative phosphorylation and membrane polarity (leading to oxidative stress and apoptosis) as preceding depressive symptoms. They are compatible but not identical.",703e323f-781d-49a1-9b29-a076270691a6,ffdad4fb-9055-44ab-99f8-e87b94a53af3
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Both claims link mitochondrial dysfunction to increased oxidative stress and apoptosis in depression. Claim 1 offers a general temporal/causal premise (mitochondrial alterations may precede depressive symptoms), while Claim 2 provides a more detailed mechanistic pathway (reduced ATP → dampened circuits, disrupted mitochondrial dynamics → oxidative stress, inflammation, proapoptotic events) that explains how mitochondrial dysfunction contributes to depression. Thus Claim 1 serves as a premise supporting Claim 2.",703e323f-781d-49a1-9b29-a076270691a6,e2a99bc5-1b56-47bf-8fe6-dc5063fe7060
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Claim 1 states that early mitochondrial dysfunction may precede depression (a causal/temporal precursor). Claim 2 builds on that idea by proposing that reversing those early dysfunctions could be a therapeutic target, so Claim 1 serves as a logical premise for Claim 2.",703e323f-781d-49a1-9b29-a076270691a6,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern biological mechanisms that influence mood symptoms/depression, but they refer to different processes and contexts: claim 1 implicates mitochondrial dysfunction preceding depressive symptoms, while claim 2 implicates PKC modulation affecting manic and depressive dimensions in bipolar disorder. They address the same broad topic without duplicating, contradicting, or serving as direct premises for one another.",703e323f-781d-49a1-9b29-a076270691a6,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological mechanisms relevant to mood disorders (depression/bipolar) but propose different, non-overlapping molecular pathways—mitochondrial dysfunction versus PKC signaling—so they are related topic-wise without duplicating, contradicting, or serving as a direct premise for one another.",703e323f-781d-49a1-9b29-a076270691a6,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims address biological causes of depressive-like symptoms but invoke different mechanisms. Claim 1 proposes mitochondrial dysfunction (oxidative phosphorylation, membrane polarity, oxidative stress, apoptosis) may precede depression, while Claim 2 implicates chronic PKC inhibition causing depressive-like behavior and reduced hippocampal cell proliferation in rats. They are related by topic but not equivalent, contradictory, or a direct premise for one another.",703e323f-781d-49a1-9b29-a076270691a6,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological mechanisms implicated in mood disorders (depressive states), but they describe different, non-conflicting pathways: Claim 1 implicates mitochondrial dysfunction and oxidative stress in depression onset, while Claim 2 implicates PKC signalling in mood regulation and bipolar disorder. They are related topically but are not duplicates, premises, or contradictions.",703e323f-781d-49a1-9b29-a076270691a6,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims relate to biological mechanisms that can lead to depressive symptoms, but they describe different pathways and evidence: claim 1 implicates mitochondrial dysfunction (oxidative phosphorylation, membrane polarity, oxidative stress, apoptosis) as a possible precursor, while claim 2 reports that chronic PKC inhibition produces depressive-like behavior and reduced hippocampal cell proliferation in rats. They do not duplicate or contradict one another, nor is one clearly a direct premise for the other.",703e323f-781d-49a1-9b29-a076270691a6,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern biological mechanisms implicated in psychiatric disorders (including depression) but refer to different mechanisms—mitochondrial dysfunction versus BDNF signaling. They address the same broad topic without duplicating, implying, or contradicting each other.",703e323f-781d-49a1-9b29-a076270691a6,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern biological factors linked to depression but describe different mechanisms (mitochondrial dysfunction vs. miR-135 regulation of antidepressant-related genes). They address the same topic area without duplicating, contradicting, or serving as direct premises for one another.",703e323f-781d-49a1-9b29-a076270691a6,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.",Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims concern factors that influence depressive-like behavior but describe different mechanisms and evidence: Claim 1 posits mitochondrial dysfunction as a possible precursor to depression, while Claim 2 reports that reducing prodynorphin in the rat nucleus accumbens lessens depressive-like behavior. They do not duplicate or contradict each other, nor does one serve as a direct premise for the other.",703e323f-781d-49a1-9b29-a076270691a6,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern mechanisms related to depression but address different, non-conflicting biological processes: Claim 1 proposes mitochondrial dysfunction (oxidative phosphorylation, membrane polarity) as a precursor to depressive symptoms, while Claim 2 identifies Homer1a expression in medial prefrontal cortex as a common mediator of antidepressant effects. There is no direct logical dependency or contradiction between them.",703e323f-781d-49a1-9b29-a076270691a6,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern biological mechanisms that can lead to depressive symptoms (mitochondrial dysfunction increasing oxidative stress/apoptosis vs region-specific BDNF reduction decreasing neurogenesis). They address the same general topic (depression pathophysiology) but describe different, non-overlapping mechanisms; they do not duplicate, directly contradict, or serve as a clear premise for one another.",703e323f-781d-49a1-9b29-a076270691a6,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Alterations in mitochondrial functions such as oxidative phosphorylation and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims address mitochondrial function and oxidative stress in the brain, but they make different points: Claim 1 proposes mitochondrial alterations may precede depressive symptoms (a pathogenic hypothesis), while Claim 2 states lithium regulates mitochondrial function and other protective pathways. They are related on topic but do not duplicate, directly contradict, or serve as a clear logical premise for one another.",703e323f-781d-49a1-9b29-a076270691a6,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Claim 1 identifies a specific cause of mitochondrial dysfunction (stress-induced inhibition of electron transport chain complexes). Claim 2 describes the downstream consequences of mitochondrial dysfunction (reduced ATP, dampened neuronal activity, oxidative stress, inflammation, proapoptotic events) that contribute to depression. Thus Claim 1 can serve as a mechanistic premise supporting the processes outlined in Claim 2.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,e2a99bc5-1b56-47bf-8fe6-dc5063fe7060
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,Claim 1 asserts that mitochondrial electron transport inhibition contributes to depression; Claim 2 proposes that reversing early mitochondrial dysfunction could be a therapeutic target. Therefore Claim 1 provides a causal premise supporting Claim 2's therapeutic inference.,ffdad4fb-9055-44ab-99f8-e87b94a53af3,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological mechanisms affecting mood/depressive states, but they refer to different specific mechanisms and disorders: Claim 1 implicates chronic-stress–induced mitochondrial electron-transport inhibition in depression, while Claim 2 implicates PKC signaling in mood regulation and bipolar disorder. They are related topical variants, not duplicates, premises, or contradictions.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims propose biological contributors to depressive-like states but involve different mechanisms and levels of explanation: Claim 1 implicates stress-induced inhibition of mitochondrial electron transport chain complexes, while Claim 2 implicates PKC inhibition leading to depressive-like behavior and reduced hippocampal proliferation in rats. They do not duplicate, contradict, or provide a clear premise–conclusion relationship, so they are related but distinct variants.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological contributors to mood disorders/depressive states but describe different, non-conflicting mechanisms. Claim 1 implicates chronic stress–induced inhibition of mitochondrial electron transport chain complexes in depression, while Claim 2 implicates PKC signaling in mood regulation and bipolar disorder. They overlap thematically but are neither duplicates, contradictions, nor clear premises for one another.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims propose biological contributors to depressive phenotypes but describe different mechanisms and evidence. Claim 1 implicates chronic stress–induced inhibition of mitochondrial electron transport complexes in depression pathophysiology, while Claim 2 reports that chronic PKC inhibition produces depressive-like behavior and reduced hippocampal cell proliferation in rats. They are related topical variants (different pathways/models) rather than duplicates, direct contradictions, or premises for one another.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern biological contributors to the pathophysiology of depression (and psychiatric disorders) but describe different, non-overlapping mechanisms: Claim 1 implicates mitochondrial electron transport chain inhibition from chronic stress, while Claim 2 implicates BDNF across multiple disorders. They do not duplicate, contradict, or logically entail one another.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern molecular contributors to major depressive disorder but describe different mechanisms (mitochondrial electron transport chain inhibition due to chronic stress vs miR-135 regulation of genes linked to antidepressant actions). They are related by topic but do not duplicate, contradict, or serve as direct premises for one another.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims concern biological mechanisms influencing depression, but they describe different, non-overlapping mechanisms and experimental contexts: Claim 1 implicates chronic-stress–induced inhibition of mitochondrial electron transport in depression pathophysiology, while Claim 2 reports that prodynorphin knockdown in the rat nucleus accumbens reduces depressive-like behavior. They do not restate the same claim, do not contradict each other, and neither serves as a direct logical premise for the other.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims address biological mechanisms that can contribute to depression but describe distinct, non-overlapping pathways: claim 1 implicates chronic stress–induced mitochondrial electron transport chain inhibition, while claim 2 implicates region-specific BDNF reduction affecting neurogenesis in the dentate gyrus. They are related by topic (mechanisms of depression) but are neither duplicates, direct premises, nor contradictions.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic stress-induced inhibition of electron transport chain complexes in the inner membrane of mitochondria is a contributing factor in the pathophysiology of depression.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern mitochondrial function in brain pathology: claim 1 asserts stress-induced inhibition of mitochondrial electron transport contributes to depression, while claim 2 states lithium regulates mitochondrial function (among other pathways) for neuroprotection. They are related but make different, non-identical claims and do not directly premise or contradict one another.",ffdad4fb-9055-44ab-99f8-e87b94a53af3,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.",Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Claim 1 describes how mitochondrial dysfunction contributes causally to depression (reduced ATP, increased oxidative stress, inflammation, apoptosis). That mechanistic role provides the rationale that reversing early mitochondrial dysfunction could be a therapeutic intervention, so Claim 1 is a premise for Claim 2.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern biological factors contributing to mood disorders (depression/bipolar) but describe different mechanisms: Claim 1 links mitochondrial dysfunction to depression pathogenesis, while Claim 2 implicates PKC signaling in mood regulation and bipolar disorder. They address the same broad topic without asserting the same fact, contradicting each other, or providing a direct premise relationship.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern factors implicated in depression pathogenesis but describe different mechanisms: Claim 1 focuses on mitochondrial dysfunction leading to oxidative stress, inflammation, and proapoptotic events, while Claim 2 implicates chronic PKC inhibition and reduced hippocampal cell proliferation in depressive-like behavior in rats. There is no direct entailment, contradiction, or clear premise relationship between them.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims address biological mechanisms relevant to mood disorders/depressive states but focus on different, non-identical mechanisms (mitochondrial dysfunction in depression vs PKC signaling in bipolar disorder). They do not duplicate or contradict each other, nor does one serve as a clear logical premise for the other.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern biological mechanisms contributing to depression but focus on different factors: Claim 1 implicates mitochondrial dysfunction, oxidative stress, inflammation, and apoptosis, while Claim 2 reports that chronic PKC inhibition produces depressive-like behavior and reduces hippocampal cell proliferation in rats. They do not directly contradict or entail one another, nor does one serve as a clear premise for the other.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern biological mechanisms implicated in major depressive disorder but focus on different factors—mitochondrial dysfunction (Claim 1) versus BDNF signaling (Claim 2). They do not restate the same claim, do not contradict each other, and neither claim serves as a direct logical premise for the other.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern neurobiological mechanisms related to depression but describe different, non-conflicting processes. Claim 1 implicates mitochondrial dysfunction and downstream oxidative/inflammatory/apoptotic effects in depression pathogenesis, while Claim 2 describes ketamine's antidepressant actions via synaptogenesis and enhanced serotonergic transmission; they are related topical variants rather than duplicates, contradictions, or premises of one another.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.",MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims relate to biological mechanisms linked to depression but describe different, non-overlapping pathways (mitochondrial dysfunction vs miR-135 targeting genes). They do not duplicate, contradict, or serve as premises for one another.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern mechanisms contributing to depression but describe different, non-overlapping pathways. Claim 1 implicates mitochondrial dysfunction (reduced ATP, oxidative stress, inflammation, apoptosis) in depression pathogenesis; Claim 2 implicates region-specific BDNF reduction in the dentate gyrus causing reduced neurogenesis and depressive-like behaviors. They are related by topic (depression mechanisms) but do not duplicate, contradict, or serve as direct premises for one another.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Dysfunctional mitochondria decrease available ATP, which dampens neuronal circuit activity and interferes with mitochondrial dynamics, ultimately increasing oxidative stress, inflammatory responses, and proapoptotic events involved in depression pathogenesis.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern mitochondrial function, oxidative stress and inflammation in the brain, but they make different points: Claim 1 describes how mitochondrial dysfunction contributes to depression-related pathology; Claim 2 states that lithium regulates those same pathways. They are related but not duplicates, contradictions, or direct premises of one another.",e2a99bc5-1b56-47bf-8fe6-dc5063fe7060,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern mood disorders and depressive states but focus on different biological mechanisms: Claim 1 proposes reversing mitochondrial dysfunction as a therapeutic target for depression, while Claim 2 implicates PKC in mood regulation and bipolar disorder. They do not duplicate or contradict each other, nor does one serve as a clear premise for the other.",07787c05-d861-4709-ab6b-53fbbf35ae62,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern molecular mechanisms relevant to mood disorders and potential therapeutic targets, but they focus on different mechanisms (mitochondrial dysfunction in depression vs PKC involvement in bipolar disorder and mood regulation). They do not duplicate or contradict each other, nor is one a clear logical premise for the other.",07787c05-d861-4709-ab6b-53fbbf35ae62,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern biological mechanisms relevant to depression, but they address different mechanisms (mitochondrial dysfunction as a therapeutic target vs chronic PKC inhibition causing depressive-like behavior and reduced hippocampal proliferation in rats). They do not duplicate, contradict, or serve as direct premises for one another.",07787c05-d861-4709-ab6b-53fbbf35ae62,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern biological factors relevant to depression but address different mechanisms: Claim 1 proposes targeting mitochondrial dysfunction as a treatment approach for depression, while Claim 2 states that BDNF is important across psychiatric disorders including depression. They discuss the same topic without duplicating, contradicting, or serving as direct premises for one another.",07787c05-d861-4709-ab6b-53fbbf35ae62,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern biological mechanisms relevant to psychiatric treatment, but they refer to different pathways: claim 1 proposes targeting mitochondrial dysfunction in depression, while claim 2 states BDNF is involved in the action of antidepressants/antipsychotics. They address related topics without duplicating, contradicting, or logically implying one another.",07787c05-d861-4709-ab6b-53fbbf35ae62,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims propose different biological mechanisms as targets for antidepressant action (mitochondrial dysfunction reversal versus AMPA/HNK-driven mTOR signaling). They address the same broad topic (therapeutic mechanisms in depression) but make different, non-contradictory proposals and neither claim serves as a premise for the other.",07787c05-d861-4709-ab6b-53fbbf35ae62,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern mechanisms relevant to antidepressant therapy but describe different, non-overlapping mechanisms: claim 1 proposes targeting early mitochondrial dysfunction as a therapeutic approach, while claim 2 attributes ketamine's effects to increased synaptogenesis in prefrontal pyramidal neurons and enhanced serotonergic output to the raphe. They do not duplicate, contradict, or logically premise one another.",07787c05-d861-4709-ab6b-53fbbf35ae62,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both statements concern molecular mechanisms relevant to depression and potential therapeutic targets, but they refer to different specific mechanisms: claim 1 focuses on mitochondrial dysfunction, while claim 2 concerns miR-135 and its gene targets. They do not duplicate, contradict, or serve as direct premises for one another.",07787c05-d861-4709-ab6b-53fbbf35ae62,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,"Both claims relate to therapeutic interventions for depression but propose different mechanisms/approaches: Claim 1 suggests targeting mitochondrial dysfunction, while Claim 2 describes an intranasal sertraline-conjugated siRNA strategy targeting 5-HT1A and SERT. They address the same general topic without duplicating, supporting, or contradicting each other.",07787c05-d861-4709-ab6b-53fbbf35ae62,54c4e069-99aa-4b45-9a6b-a1c75b1af627
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims concern potential therapeutic approaches for depression, but they refer to different mechanisms and levels of evidence. Claim 1 proposes mitochondrial dysfunction reversal as a general therapeutic target, while Claim 2 reports a specific experimental intervention (prodynorphin knockdown in rat nucleus accumbens) that reduces depressive-like behavior. They do not duplicate, contradict, or serve as premises for one another, but are related variants on treatment strategies.",07787c05-d861-4709-ab6b-53fbbf35ae62,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"Both claims concern novel antidepressant mechanisms. Claim 2 shows that non-monoaminergic approaches (ketamine) can yield effective, rapid antidepressants, which supports the plausibility of investigating other non-monoaminergic targets—such as reversing mitochondrial dysfunction—as therapeutic interventions for depression (i.e., Claim 2 provides a supporting premise for Claim 1).",0ff4b45b-d46b-405d-8744-56b371122414,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,"SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims propose therapeutic approaches for depression but address different mechanisms and interventions: Claim 1 suggests targeting mitochondrial dysfunction, while Claim 2 describes SSRI-conjugated siRNA delivery to serotonergic neurons. They do not duplicate, contradict, or serve as premises for one another.",07787c05-d861-4709-ab6b-53fbbf35ae62,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",Reversing early stages of mitochondrial dysfunction could provide a novel target for therapeutic intervention in depression.,Claim 2 indicates that lithium modulates mitochondrial function and other neuroprotective/neuroplastic pathways implicated in depression. This provides a mechanistic basis supporting Claim 1's proposition that targeting/reversing mitochondrial dysfunction could be a therapeutic strategy for depression.,0ccc686b-5be5-4aa5-9360-6c97d148920d,07787c05-d861-4709-ab6b-53fbbf35ae62
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",Both claims state the same idea: PKC regulates mood/bipolar disorder and affects both manic and depressive facets. Claim 2 is a rephrasing of Claim 1.,38c47f6f-9f2f-4c59-95e5-89c32b7e6241,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 2 provides experimental evidence (PKC inhibition produces antimanic-like effects in rats) that supports Claim 1's assertion that PKC modulation affects the manic dimension of bipolar disorder. It does not address the depressive facet, so it is partial evidence rather than a full equivalence.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 2 provides experimental evidence that PKC inhibition produces depressive-like behavior (and reduced hippocampal proliferation) in rats, which supports Claim 1's assertion that PKC modulation affects the depressive dimension of bipolar disorder. Claim 2 is preclinical and addresses only the depressive side (not manic effects), so it serves as a premise/evidence for Claim 1 rather than a duplicate or contradiction.",9ccfdc45-aa16-4546-abcf-7333a5b07623,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 2 provides experimental evidence that PKC activation produces both manic-like (enhanced risk-taking) and antidepressant-like (reduced forced-swim immobility) effects. Those specific opposing effects support Claim 1's general statement that PKC modulation affects both manic and depressive facets of bipolar disorder, so Claim 2 is a premise for Claim 1.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",Both claims state the same idea: protein kinase C (PKC) is involved in regulating mood and affects both manic and depressive facets of bipolar disorder; the second is a rewording of the first.,38c47f6f-9f2f-4c59-95e5-89c32b7e6241,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 2 provides experimental evidence that PKC inhibition produces antimanic-like effects in rats (reduced amphetamine-induced hyperlocomotion and risk-taking), which supports Claim 1's assertion that PKC modulation affects the manic dimension of bipolar disorder. Claim 2 does not address the depressive facet, so it is partial support rather than a full equivalence.",c989f22f-aa0e-401c-81e7-044a608fa580,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 2 provides experimental evidence that chronic PKC inhibition induces depressive-like behavior and reduces hippocampal cell proliferation in rats, which supports Claim 1's assertion that PKC modulation affects the depressive dimension of mood illness. It does not address manic effects or directly demonstrate the phenomenon in humans, so it functions as supporting premise rather than a complete confirmation.",982b4346-2957-418d-8cf9-da662ceb1b52,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",Claim 2 provides specific experimental observations (PKC activation produces manic-like behavior and antidepressant-like effects such as increased risk-taking and reduced forced-swim immobility) that support the broader Claim 1 that PKC modulation affects both manic and depressive dimensions of bipolar disorder. Therefore Claim 2 serves as a premise/evidence for Claim 1.,8558ce87-1df5-4a7f-88b6-63efb39b40e9,38c47f6f-9f2f-4c59-95e5-89c32b7e6241
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern PKC but describe different, nonconflicting effects in distinct domains: Claim 1 links PKC modulation to manic and depressive aspects of bipolar disorder, while Claim 2 links PKC activity to adult hippocampal cell proliferation (chronic inhibition reduces proliferation). They are related by topic but neither duplicates, directly contradicts, nor serves as a clear logical premise for the other.",38c47f6f-9f2f-4c59-95e5-89c32b7e6241,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",The two claims are verbatim identical and convey the same meaning: PKC modulation affects both manic and depressive facets of bipolar disorder.,38c47f6f-9f2f-4c59-95e5-89c32b7e6241,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern molecular contributors to psychiatric disorders and both mention bipolar disorder, but they refer to different molecules (PKC vs BDNF) and make distinct, noncontradictory assertions. They are related topically but not duplicates or premises of one another.",38c47f6f-9f2f-4c59-95e5-89c32b7e6241,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 reports experimental evidence that PKC inhibition reduces manic-like behaviors in rats, which supports Claim 1's broader assertion that PKC is involved in regulating mood and contributes to manic states in bipolar disorder. (Claim 2 addresses the manic aspect specifically and does not by itself cover depressive states.)",ae3c78a3-aaea-4b95-88c9-0997465c58c7,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 reports experimental evidence that chronic PKC inhibition produces depressive-like behavior and reduced hippocampal cell proliferation in rats, which supports Claim 1's assertion that PKC regulates mood and is involved in depressive aspects of bipolar disorder. The statements are not identical (animal experimental evidence vs. broad clinical claim) but Claim 2 serves as a supporting premise for Claim 1.",9ccfdc45-aa16-4546-abcf-7333a5b07623,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 provides experimental evidence that PKC activation produces manic-like (enhanced risk taking) and antidepressant-like (reduced immobility) effects in models, which supports Claim 1's assertion that PKC regulates mood and is involved in both manic and depressive facets of bipolar disorder.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern PKC's roles in the brain but describe different phenomena: Claim 1 links PKC to mood regulation and bipolar disorder, while Claim 2 addresses PKC's role in adult hippocampal cell proliferation and effects of chronic inhibition. They are related by topic but do not duplicate, contradict, or strictly serve as a necessary premise for one another (though Claim 2 could be a potential mechanistic contributor to Claim 1).",679feb8f-e96a-4b0e-a6bc-f3447c3b774b,f46b86ed-7e0f-49ea-a715-326d1b9e3bf5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",The two claims are identical in wording and meaning: both state that PKC critically regulates mood and is involved in both manic and depressive aspects of bipolar disorder.,679feb8f-e96a-4b0e-a6bc-f3447c3b774b,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 reports experimental evidence that inhibiting PKC produces antimanic-like effects in an animal model (reduced amphetamine-induced hyperlocomotion and risk-taking). This supports Claim 1's assertion that PKC plays a critical role in mood regulation and is involved in bipolar disorder (particularly manic states). Claim 2 thus acts as a supporting premise for Claim 1, though it addresses the manic aspect specifically rather than depressive states.",c989f22f-aa0e-401c-81e7-044a608fa580,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 provides specific experimental evidence (in rats) that inhibiting PKC produces depressive-like behavior and reduces hippocampal proliferation, which supports Claim 1's assertion that PKC regulates mood and is involved in depressive aspects of bipolar disorder. Claim 2 addresses the depressive side specifically and thus can serve as a premise for the broader claim.",982b4346-2957-418d-8cf9-da662ceb1b52,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",Claim 2 gives specific experimental effects of PKC activation (manic-like increased risk-taking and antidepressant-like reduced immobility in the forced swim test) that directly support the broader claim 1 that PKC regulates mood and is involved in manic and depressive states. This is supportive evidence rather than a contradiction or mere restatement.,8558ce87-1df5-4a7f-88b6-63efb39b40e9,679feb8f-e96a-4b0e-a6bc-f3447c3b774b
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern functions of PKC but address different phenomena: Claim 1 links PKC to mood regulation and bipolar disorder, while Claim 2 describes PKC's role in adult hippocampal cell proliferation. They do not contradict or duplicate each other, and Claim 2 is not explicitly presented as a direct mechanistic premise for Claim 1.",679feb8f-e96a-4b0e-a6bc-f3447c3b774b,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",Both claims state that PKC is involved in and modulates both manic and depressive aspects of bipolar disorder; Claim 2 is a rephrasing emphasizing ‘opposite facets’ but conveys the same core assertion as Claim 1.,679feb8f-e96a-4b0e-a6bc-f3447c3b774b,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims implicate molecular factors in bipolar disorder/psychiatric conditions, but they reference different molecules (PKC vs BDNF). They relate to the same general topic without repeating, supporting, or contradicting each other.",679feb8f-e96a-4b0e-a6bc-f3447c3b774b,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern molecular mechanisms related to mood disorders (depressive states), but they refer to different biological factors and contexts: Claim 1 implicates PKC in bipolar disorder (mania and depression), while Claim 2 implicates miR-135 in major depressive disorder and antidepressant responses. They are related topically but neither duplicates, entails, nor contradicts the other.",679feb8f-e96a-4b0e-a6bc-f3447c3b774b,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern molecular regulators of mood/affective states but describe different mechanisms and specifics: Claim 1 implicates PKC broadly in mood regulation and bipolar disorder, while Claim 2 implicates BDNF reduction in the dentate gyrus (not CA3) in reduced neurogenesis and depressive-like behavior. They do not duplicate, contradict, or serve as premises for one another, but are related by topic.",679feb8f-e96a-4b0e-a6bc-f3447c3b774b,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims address molecular mechanisms relevant to mood regulation and bipolar disorder but refer to different targets and mechanisms: Claim 1 implicates PKC in mood and bipolar states, while Claim 2 attributes lithium effects to inhibition of GSK3 and IMPase. They are related topical variants rather than duplicates, contradictions, or premises of one another.",679feb8f-e96a-4b0e-a6bc-f3447c3b774b,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern effects of PKC inhibition in rats but report different outcomes under different conditions: Claim 1 describes antimanic-like effects (reduced amphetamine-induced hyperlocomotion and risk-taking), whereas Claim 2 describes depressive-like behavior and decreased hippocampal cell proliferation after chronic inhibition. These are related and potentially compatible findings that differ by outcome and experimental conditions (e.g., acute vs. chronic), so they are variants rather than duplicates or direct contradictions.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,9ccfdc45-aa16-4546-abcf-7333a5b07623
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern behavioral effects of PKC modulation but describe opposite manipulations: Claim 1 reports that PKC inhibition produces antimanic-like effects (reduced amphetamine-induced hyperlocomotion and decreased risk-taking), while Claim 2 reports that PKC activation produces manic-like (enhanced risk-taking) and antidepressant-like (reduced forced-swim immobility) effects. These are complementary/opposite findings about activation versus inhibition and are not direct contradictions, so they differ without contradicting.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,bfdfd15f-1d66-4cb0-bef9-66b87c492ad1
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern effects of PKC inhibition but on different outcomes: Claim 1 describes behavioral (antimanic-like) effects in rats, while Claim 2 describes effects on adult hippocampal cell proliferation. They are related and compatible but not the same claim, not mutually exclusive, and neither serves as a clear logical premise for the other.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,f46b86ed-7e0f-49ea-a715-326d1b9e3bf5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 1 reports experimental (rat) evidence that inhibiting PKC reduces mania-like behaviors, which supports the broader claim 2 that PKC regulates mood and is involved in bipolar disorder (including manic states). Thus Claim 1 serves as a premise/evidence for Claim 2.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","The two claims are identical in wording and content: both state that PKC inhibition produces antimanic-like effects in rats, evidenced by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern behavioral effects of PKC inhibition in rats but describe different outcomes: Claim 1 reports antimanic-like effects (reduced amphetamine-induced hyperactivity and risk-taking), whereas Claim 2 reports depressive-like behavior and reduced hippocampal cell proliferation with chronic inhibition. These findings can reflect different protocols (acute vs. chronic treatment), measures, or doses rather than a direct contradiction, so they are related variants.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern PKC modulation but describe different manipulations and outcomes: Claim 1 reports that PKC inhibition yields antimanic-like effects (reduced amphetamine hyperlocomotion, decreased risk-taking), while Claim 2 reports that PKC activation produces manic-like effects (enhanced risk-taking) and antidepressant-like effects (reduced forced-swim immobility). They are related and report opposite/complementary effects of PKC manipulation rather than asserting mutually exclusive facts, so they differ without directly contradicting one another.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern effects of PKC inhibition but on different outcomes: Claim 1 describes acute antimanic-like behavioral effects in rats, while Claim 2 describes chronic PKC inhibition reducing adult hippocampal cell proliferation. They address distinct endpoints and are neither equivalent nor directly contradictory.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 1 provides experimental evidence that PKC inhibition alters manic-like behavior (reduced amphetamine-induced hyperlocomotion and risk-taking in rats), which supports Claim 2's assertion that PKC modulation affects the manic facet of bipolar disorder. Claim 1 does not address depressive effects, so it only partially underpins the broader claim that PKC regulates both manic and depressive dimensions.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern mechanisms related to mood/antimanic effects, but they refer to different molecular targets and findings. Claim 1 reports that PKC inhibition yields antimanic-like behavioral effects in rats. Claim 2 proposes lithium acts mainly via inhibition of GSK3 and IMPase. The claims do not duplicate, contradict, or serve as direct premises for one another, but they discuss the same broad topic (mechanisms of antimanic/mood-stabilizing actions) with different targets—hence a variant relationship.",ae3c78a3-aaea-4b95-88c9-0997465c58c7,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims address how manipulating PKC affects mood-related behaviors in rodents. Claim 1 reports that PKC inhibition produces depressive-like effects and reduced hippocampal proliferation; claim 2 reports that PKC activation produces manic-like and antidepressant-like effects. These are opposite effects of PKC modulation on related outcomes and are consistent rather than mutually exclusive, so they are related variants of the same phenomenon.",9ccfdc45-aa16-4546-abcf-7333a5b07623,bfdfd15f-1d66-4cb0-bef9-66b87c492ad1
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims report that chronic PKC inhibition reduces hippocampal cell proliferation. Claim 1 additionally states it causes depressive-like behavior in rats, while Claim 2 emphasizes PKC's role in adult hippocampal proliferation and specifically mentions newly proliferating cells. They overlap in the proliferation finding but are not identical, so they are variants.",9ccfdc45-aa16-4546-abcf-7333a5b07623,f46b86ed-7e0f-49ea-a715-326d1b9e3bf5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 1 reports experimental evidence that inhibiting PKC produces depressive-like behavior and reduces hippocampal cell proliferation in rats; this supports the broader assertion in Claim 2 that PKC helps regulate mood and can be involved in mood disorders. (Note: Claim 1 is an animal/inhibition-specific result and does not by itself prove PKC's role across all facets of bipolar disorder, but it constitutes supporting premises.)",9ccfdc45-aa16-4546-abcf-7333a5b07623,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern effects of PKC inhibition in rats but describe different, non-identical outcomes: one reports chronic PKC inhibition produces depressive-like behavior and reduced hippocampal cell proliferation, while the other reports antimanic-like effects (reduced amphetamine-induced hyperlocomotion and risk-taking). These are different aspects/assays and can coexist under different protocols (dose, duration, models), so they are related but not duplicates or direct contradictions.",9ccfdc45-aa16-4546-abcf-7333a5b07623,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,The two claims are identical in wording and meaning: both state that chronic PKC inhibition induces depressive-like behavior and reduces hippocampal cell proliferation in rats.,9ccfdc45-aa16-4546-abcf-7333a5b07623,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims address how manipulating PKC affects mood-related behaviors in rodents: Claim 1 reports that PKC inhibition produces depressive-like effects and reduced hippocampal proliferation, while Claim 2 reports that PKC activation produces manic-like and antidepressant-like effects. They are complementary/opposite findings about the same mechanism rather than duplicates or direct contradictions, and neither claim is strictly a logical premise for the other.",9ccfdc45-aa16-4546-abcf-7333a5b07623,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims report that chronic PKC inhibition reduces hippocampal cell proliferation (claim 2 frames PKC's role and specifies fewer newly proliferating cells). Claim 1 adds that chronic PKC inhibition also causes depressive-like behavior in rats. They overlap on the proliferation finding without contradicting, but are not duplicates because claim 1 includes an additional outcome.",9ccfdc45-aa16-4546-abcf-7333a5b07623,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 1 provides experimental evidence that modulating PKC (specifically inhibiting it) produces depressive-like behavior and reduced hippocampal proliferation in rats. This supports Claim 2's general assertion that PKC modulation affects the depressive dimension of mood disorders. It does not address manic effects or clinical translation to human bipolar disorder, so it is a partial premise rather than a full equivalence.",9ccfdc45-aa16-4546-abcf-7333a5b07623,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern biological mechanisms related to psychiatric disorders (including depression) but address different factors and levels of evidence: claim 1 reports an effect of PKC inhibition on depressive-like behavior and hippocampal proliferation in rats, while claim 2 states a broad role for BDNF across many disorders. They are related but not equivalent, not contradictory, and neither is a direct premise for the other.",9ccfdc45-aa16-4546-abcf-7333a5b07623,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims concern depressive-like behavior in rats but describe different interventions and outcomes: chronic PKC inhibition is reported to cause depressive-like behavior and reduce hippocampal proliferation, whereas prodynorphin knockdown in the nucleus accumbens is reported to reduce depressive-like behavior. They address the same topic without being duplicates, premises, or direct contradictions.",9ccfdc45-aa16-4546-abcf-7333a5b07623,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims link reduced hippocampal neurogenesis to depressive-like behavior, but they describe different manipulations and levels of specificity: claim 1 attributes effects to chronic PKC inhibition (broadly reducing hippocampal cell proliferation), while claim 2 attributes effects to localized BDNF reduction in the dentate gyrus (not CA3). They are related but not equivalent or logically dependent.",9ccfdc45-aa16-4546-abcf-7333a5b07623,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern molecular mechanisms affecting brain neuroplasticity/neuroprotection, but they describe different interventions and findings. Claim 1 reports effects of chronic PKC inhibition on depressive-like behavior and hippocampal proliferation in rats; Claim 2 describes lithium's broad regulatory effects on many cellular pathways. They are thematically related but not duplicate, contradictory, or a direct premise of one another.",9ccfdc45-aa16-4546-abcf-7333a5b07623,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern roles of PKC in the brain but describe different, non-conflicting effects: Claim 1 reports behavioral outcomes of PKC activation, while Claim 2 reports effects of PKC inhibition on adult hippocampal cell proliferation. They are related by topic and potentially complementary mechanistically but neither duplicates nor logically entails the other.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,f46b86ed-7e0f-49ea-a715-326d1b9e3bf5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 1 reports experimental effects where PKC activation produces both manic-like (increased risk-taking) and antidepressant-like (reduced forced-swim immobility) behaviors. Those observations provide direct supportive evidence that PKC regulates mood and is involved in both manic and depressive facets, so Claim 1 functions as a premise/evidence for Claim 2.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern PKC modulation. Claim 1 states that PKC activation produces manic-like effects (including increased risk-taking); Claim 2 states that PKC inhibition produces antimanic-like effects (reduced hyperlocomotion and risk-taking). These statements are consistent and Claim 1 (activation causes mania-like behavior) provides a logical basis for Claim 2 (inhibition produces the opposite, antimanic effects).",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims describe opposite manipulations of PKC with reciprocal behavioral outcomes in rodents. Chronic PKC inhibition producing depressive-like behavior (and reduced hippocampal proliferation) supports the interpretation that PKC activation would produce antidepressant-like (and opposing) effects, so Claim 2 serves as a supporting premise for Claim 1.",982b4346-2957-418d-8cf9-da662ceb1b52,bfdfd15f-1d66-4cb0-bef9-66b87c492ad1
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","The two claims are identical in wording and meaning: both state that PKC activation produces manic-like and antidepressant-like effects, including increased risk-taking behavior and reduced immobility in the forced swim test.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern PKC but address different outcomes: Claim 1 describes behavioral effects of PKC activation, while Claim 2 describes PKC's role in adult hippocampal cell proliferation and effects of its inhibition. They do not restate each other, contradict, or provide a clear premise-conclusion relationship.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 1 reports that PKC activation produces both manic-like (increased risk-taking) and antidepressant-like (reduced forced‑swim immobility) effects. That empirical statement supports Claim 2's broader assertion that PKC modulation affects both manic and depressive dimensions, so Claim 1 serves as a premise for Claim 2.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern molecular mechanisms related to antidepressant or psychiatric effects, but they refer to different factors and do not duplicate or contradict one another. Claim 1 attributes antidepressant-like and manic-like behavioral effects to PKC activation; Claim 2 states BDNF is involved in mechanisms of antidepressants/antipsychotics. There is no explicit causal or equivalence link between PKC and BDNF in these claims.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern mechanisms producing antidepressant-like effects but propose different, non-conflicting mechanisms: Claim 1 attributes effects to PKC activation (including manic-like behaviors), while Claim 2 attributes ketamine’s antidepressant action to HNK-driven AMPA receptor activation and mTOR signaling. They address the same topic without duplication, contradiction, or a clear premise relationship.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern antidepressant-like effects but refer to different interventions and mechanisms: Claim 1 attributes behavioral (manic- and antidepressant-like) effects to PKC activation, while Claim 2 attributes ketamine's antidepressant action to increased prefrontal synaptogenesis and enhanced descending serotonergic drive. They address the same general topic without duplicating, contradicting, or providing a direct premise relationship.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims report interventions that reduce depressive-like behavior in rodents (antidepressant-like effects / reduced depressive-like behavior), but they involve different mechanisms and outcomes: PKC activation produces both antidepressant-like and manic-like (increased risk-taking) effects, whereas prodynorphin knockdown in nucleus accumbens reduces depressive-like behavior without changing anxiety. They are related on the general topic (antidepressant-like effects) but are not duplicates, premises of one another, or contradictory.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern molecular mechanisms producing antidepressant-like effects, but they invoke different pathways (PKC activation vs Homer1a expression in mPFC). They are related by topic but do not duplicate, contradict, or serve as direct premises for one another.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern neurobiological mechanisms that affect mood-related behaviors, but they involve different pathways and findings (PKC activation producing manic- and antidepressant-like effects versus BDNF reduction in the dentate gyrus causing decreased neurogenesis and depressive-like behavior). They address the same general topic (neural control of affect) without directly contradicting or logically entailing one another.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern antidepressant mechanisms outside classical monoamine reuptake: claim 1 reports that PKC activation produces antidepressant-like (and manic-like) behaviors in animal tests, while claim 2 argues ketamine exemplifies a paradigm shift toward rapid, non-monoaminergic antidepressants. They address the same broader topic but make different, non-equivalent assertions and do not contradict or directly premise one another.",bfdfd15f-1d66-4cb0-bef9-66b87c492ad1,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Both claims concern roles of PKC but in different domains: claim 1 describes PKC’s role in adult hippocampal cell proliferation, while claim 2 describes PKC’s involvement in mood regulation and bipolar disorder. They address related biological functions of the same protein without duplicating, contradicting, or directly serving as a logical premise for one another.",f46b86ed-7e0f-49ea-a715-326d1b9e3bf5,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Both claims concern effects of PKC inhibition but on different endpoints: Claim 1 concerns adult hippocampal cell proliferation (a cellular/neurogenesis outcome) while Claim 2 concerns behavioral antimanic-like effects in rats. They are related by topic (PKC inhibition) but neither duplicates nor contradicts the other, nor does one logically entail the other based on the provided text.",f46b86ed-7e0f-49ea-a715-326d1b9e3bf5,c989f22f-aa0e-401c-81e7-044a608fa580
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims state that chronic PKC inhibition reduces hippocampal cell proliferation. Claim 2 additionally reports that this inhibition causes depressive-like behavior in rats. They address the same phenomenon without contradiction but differ in scope/details, so they are variants.",f46b86ed-7e0f-49ea-a715-326d1b9e3bf5,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims concern PKC activity but refer to different outcomes: Claim 1 describes effects of PKC inhibition on adult hippocampal cell proliferation, while Claim 2 describes behavioral effects of PKC activation. They do not restate the same claim, do not contradict one another, and neither is clearly a direct premise for the other, so they are related but different (variant).",f46b86ed-7e0f-49ea-a715-326d1b9e3bf5,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.",The two claims are identical in wording and meaning: both state that PKC is implicated in adult hippocampal cell proliferation and that chronic PKC inhibition reduces the number of newly proliferating hippocampal cells.,f46b86ed-7e0f-49ea-a715-326d1b9e3bf5,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern the role of PKC, but they describe different effects in different domains: Claim 1 concerns PKC's role in adult hippocampal cell proliferation, while Claim 2 concerns PKC's modulation of clinical features of bipolar disorder. They are related by topic but are not equivalent, contradictory, or a clear logical premise for one another.",f46b86ed-7e0f-49ea-a715-326d1b9e3bf5,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern regulation of adult hippocampal neurogenesis but describe different mechanisms and specificity: Claim 1 implicates PKC (broadly reducing proliferating cells when inhibited), while Claim 2 implicates region-specific (dentate gyrus) BDNF reduction and links it to depressive-like behavior. They address the same topic without asserting the same fact, contradicting each other, or providing a direct logical premise.",f46b86ed-7e0f-49ea-a715-326d1b9e3bf5,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 reports that PKC inhibition produces antimanic-like effects in rats (reduced amphetamine-induced hyperlocomotion and decreased risk-taking), providing experimental evidence that PKC activity contributes to manic states. This supports Claim 1's assertion that PKC is involved in regulating mood and plays a role in bipolar disorder (specifically the manic facet). Note: the evidence is from an animal model and does not directly address the depressive aspect of Claim 1.",c989f22f-aa0e-401c-81e7-044a608fa580,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 presents experimental evidence (in rats) that inhibiting PKC produces depressive-like behavior and reduces hippocampal cell proliferation, which supports the assertion in Claim 1 that PKC activity regulates mood and is involved in depressive aspects of bipolar disorder. (Limitation: Claim 2 is an animal study and is supportive but not definitive for humans.)",982b4346-2957-418d-8cf9-da662ceb1b52,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Claim 2 gives specific experimental effects of PKC activation (manic-like increased risk-taking and antidepressant-like reduced immobility) that provide mechanistic/causal support for Claim 1's general assertion that PKC regulates mood and is involved in manic and depressive facets of bipolar disorder, so Claim 2 is a premise supporting Claim 1.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims involve PKC but address different phenomena: Claim 1 concerns PKC's role in mood and bipolar disorder, while Claim 2 concerns PKC's role in adult hippocampal cell proliferation. They do not duplicate or contradict each other, nor does Claim 2 directly serve as a stated logical premise for Claim 1 (though it could be a possible mechanistic link).",44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.",Both claims state that PKC influences both manic and depressive facets of bipolar disorder; claim 2 is a rephrasing ('opposite facets' / 'modulation affecting both manic and depressive dimensions') of claim 1 without changing the meaning.,44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern molecular contributors to psychiatric disorders and each specifically implicates bipolar disorder, but they refer to different molecules (PKC vs BDNF) and do not restate, contradict, or serve as logical premises for one another.",44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern molecular mechanisms relevant to psychiatric disorders but involve different molecules and specific claims (PKC in mood/bipolar; BDNF in actions of antidepressants/antipsychotics). They are related by topic but are not the same, not contradictory, and neither serves as a direct premise for the other.",44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.",MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern molecular contributors to mood disorders/depression but describe distinct factors and mechanisms (PKC in bipolar mood regulation vs. miR-135 affecting antidepressant-related genes and MDD). They are related by topic but are neither equivalent, contradictory, nor a direct premise for one another.",44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both statements address neurobiological contributors to mood/depressive states but refer to different molecules, brain regions, and disorders/mechanisms: claim 1 implicates PKC in bipolar mood regulation, while claim 2 describes BDNF reduction in the dentate gyrus reducing neurogenesis and producing depressive-like behavior. They are related by topic but are neither duplicates, premises for one another, nor contradictory.",44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Protein kinase C (PKC) plays a critical role in regulating mood and is involved in different facets of bipolar disorder, including both manic and depressive states.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern intracellular signaling mechanisms relevant to psychiatric/neuropathological conditions (mood regulation/bipolar and lithium's cellular targets), but they refer to different molecular targets (PKC versus GSK3 and IMPase) and do not duplicate, contradict, or serve as premises for one another.",44d9d6c3-956a-4cda-9524-e2ff9c9eeb31,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.",Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"Both claims concern effects of PKC inhibition in rats but report different outcomes: Claim 1 describes antimanic-like effects (reduced amphetamine-induced hyperlocomotion and risk-taking), whereas Claim 2 reports depressive-like behavior and reduced hippocampal cell proliferation after chronic inhibition. These can both be true under different experimental conditions (e.g., acute vs chronic treatment, different doses or assays), so they are related but not equivalent or directly contradictory.",c989f22f-aa0e-401c-81e7-044a608fa580,982b4346-2957-418d-8cf9-da662ceb1b52
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Both claims concern PKC modulation but describe opposite manipulations (inhibition vs activation) with opposite behavioral outcomes (antimanic-like vs manic-like). They are not duplicates and not mutually contradictory because inhibition and activation can produce opposing effects; claim 2 also adds antidepressant-like effects not mentioned in claim 1.,c989f22f-aa0e-401c-81e7-044a608fa580,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims involve effects of PKC inhibition but describe different outcomes: Claim 1 reports behavioral (antimanic-like) effects in rats, while Claim 2 reports reduced adult hippocampal cell proliferation with chronic PKC inhibition. They do not duplicate or contradict each other, nor does either explicitly serve as a premise for the other.",c989f22f-aa0e-401c-81e7-044a608fa580,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 1 provides experimental evidence that PKC inhibition reduces mania-like behaviors in rats (reduced amphetamine-induced hyperlocomotion and risk-taking), which supports Claim 2's assertion that PKC modulation affects the manic dimension of bipolar disorder. Claim 1 does not directly address depressive effects, so it is a partial premise supporting Claim 2 rather than a full equivalence.",c989f22f-aa0e-401c-81e7-044a608fa580,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC inhibition produces antimanic-like effects in rats, as demonstrated by reduced amphetamine-induced hyperlocomotion and decreased risk-taking behavior.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern molecular mechanisms relevant to antimanic/mood-stabilizing effects, but they describe different targets and interventions: Claim 1 reports antimanic-like effects from PKC inhibition in rats, while Claim 2 attributes lithium's effects to inhibition of GSK3 and IMPase. They are related by topic but not equivalent, contradictory, or a premise of one another.",c989f22f-aa0e-401c-81e7-044a608fa580,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Both claims address effects of PKC modulation on rodent mood-related behavior but describe opposite directions of manipulation: Claim 1 reports that PKC inhibition produces depressive-like effects and reduced hippocampal proliferation, while Claim 2 reports that PKC activation produces antidepressant- and manic-like effects (increased risk-taking, reduced forced-swim immobility). These are complementary/opposite findings about the same mechanism rather than duplicates, direct contradictions, or a clear premise relation.",982b4346-2957-418d-8cf9-da662ceb1b52,8558ce87-1df5-4a7f-88b6-63efb39b40e9
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims report that chronic PKC inhibition reduces hippocampal cell proliferation, but Claim 1 additionally asserts it causes depressive-like behavior while Claim 2 focuses on PKC's role in adult hippocampal proliferation and reduction in newly proliferating cells; they overlap on the proliferation finding but are not identical.",982b4346-2957-418d-8cf9-da662ceb1b52,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 1 reports experimental evidence that inhibiting PKC produces depressive-like behavior and reduced hippocampal cell proliferation in rats. This provides empirical support (a premise) for Claim 2's broader assertion that PKC modulation affects depressive dimensions of mood disorders and thus contributes to PKC regulating opposite facets (manic vs depressive), though Claim 1 addresses only the depressive side and is from an animal model.",982b4346-2957-418d-8cf9-da662ceb1b52,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims address neurobiological mechanisms related to depression/antidepressant effects but describe different, non-conflicting mechanisms and interventions (chronic PKC inhibition affecting hippocampal proliferation and depressive-like behavior vs ketamine-induced PFC synaptogenesis and enhanced serotonergic output). They are related in topic but not duplicates, contradictions, or premises of one another.",982b4346-2957-418d-8cf9-da662ceb1b52,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims relate to molecular mechanisms tied to depression/antidepressant effects but describe different pathways and contexts. Claim 1 reports that chronic PKC inhibition induces depressive-like behavior and lowers hippocampal cell proliferation in rats; Claim 2 states that miR-135 targets genes involved in antidepressant actions and is associated with major depressive disorder. They do not duplicate, contradict, or logically entail one another.",982b4346-2957-418d-8cf9-da662ceb1b52,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,Both claims concern depressive-like behavior in rats but involve different interventions and brain regions: chronic PKC inhibition (causing increased depressive-like behavior and reduced hippocampal proliferation) versus prodynorphin knockdown in the nucleus accumbens (reducing depressive-like behavior). They address the same phenotype through different mechanisms and are not direct contradictions or duplicates.,982b4346-2957-418d-8cf9-da662ceb1b52,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Chronic PKC inhibition causes depressive-like behavior and reduces hippocampal cell proliferation in rats.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims link reduced hippocampal neurogenesis to depressive-like behavior, but they describe different experimental manipulations and specificity: claim 1 implicates chronic PKC inhibition causing reduced hippocampal cell proliferation broadly, while claim 2 attributes these effects to BDNF reduction specifically in the dentate gyrus (not CA3). They are related but not duplicate, contradictory, or a direct premise of one another.",982b4346-2957-418d-8cf9-da662ceb1b52,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","Both claims concern PKC's role but address different outcomes: Claim 1 reports behavioral effects of PKC activation, while Claim 2 reports effects of PKC inhibition on adult hippocampal cell proliferation. They are related by topic (PKC function) but are not equivalent, contradictory, or a direct logical premise for one another.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,250087d7-a16f-41a4-a719-305cb8574ec4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Claim 1 reports specific effects of PKC activation (both manic-like and antidepressant-like behaviors), which supports the broader Claim 2 that PKC modulation affects both manic and depressive facets of bipolar disorder. Thus Claim 1 serves as a premise/evidence for Claim 2.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern molecular mechanisms underlying psychiatric drug effects (antidepressant-like actions), but they reference different molecules (PKC activation vs BDNF) and do not restate, directly support, or contradict each other. They are related topics without a direct logical dependency.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern mechanisms producing antidepressant-like behavioral effects, but they posit different, nonoverlapping molecular pathways (PKC activation in claim 1 versus HNK→AMPA receptor activation and mTOR signaling for ketamine in claim 2). They do not duplicate, contradict, or serve as premises for one another.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern antidepressant-like effects but refer to different agents and mechanisms. Claim 1 attributes behavioral (manic- and antidepressant-like) effects to PKC activation, while Claim 2 attributes ketamine’s antidepressant effects to increased synaptogenesis in prefrontal pyramidal neurons and enhanced serotonergic descending input to the raphe. They address the same broad topic without duplicating, contradicting, or serving as direct premises for one another.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims concern interventions that alter depression-related behaviors in rodents, but they involve different biological targets and distinct effects: PKC activation produces manic- and antidepressant-like effects (including increased risk-taking), whereas prodynorphin knockdown in nucleus accumbens specifically reduces depressive-like behavior without affecting anxiety. They are related topic-wise but not equivalent, premises, or contradictory.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims address mechanisms producing antidepressant-like effects but invoke different molecular mediators (PKC activation vs. Homer1a expression in mPFC). They do not state the same claim, do not contradict one another, and there is no explicit premise relationship between them.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC activation induces manic-like and antidepressant-like effects, including enhanced risk-taking behavior and reduced immobility in the forced swim test.",Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern antidepressant mechanisms but address different specific findings: Claim 1 reports that PKC activation produces manic- and antidepressant-like behaviors in preclinical tests, while Claim 2 states that ketamine exemplifies a paradigm shift showing non-monoaminergic, rapid-acting antidepressants can be developed. They are related topically but do not duplicate, contradict, or directly premise one another.",8558ce87-1df5-4a7f-88b6-63efb39b40e9,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","Both claims concern roles of protein kinase C (PKC) in the brain but refer to different phenomena—one to adult hippocampal cell proliferation and the other to modulation of bipolar disorder symptoms—so they are related by topic but are neither duplicates, contradictions, nor logical premises of one another.",250087d7-a16f-41a4-a719-305cb8574ec4,1b1b68ed-d73c-418f-abed-03484f767103
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC is implicated in adult hippocampal cell proliferation, with chronic PKC inhibition reducing the number of newly proliferating cells in the hippocampus.","BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims address regulation of adult hippocampal neurogenesis but attribute effects to different factors and levels of specificity: Claim 1 implicates PKC activity (chronic inhibition reduces proliferating cells generally in the hippocampus), while Claim 2 implicates BDNF reduction specifically in the dentate gyrus (decreasing neurogenesis and producing depressive-like behaviors). They discuss the same phenomenon without repeating the same claim, contradicting each other, or providing a direct causal premise for one another.",250087d7-a16f-41a4-a719-305cb8574ec4,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"PKC regulates opposite facets of bipolar disorder, with its modulation affecting both manic and depressive dimensions of the illness.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Both claims concern molecular contributors to bipolar disorder but refer to different entities and scopes: claim 1 implicates PKC specifically in manic and depressive facets, while claim 2 states BDNF is involved broadly across multiple psychiatric disorders including bipolar. They are related by topic but neither duplicates, contradicts, nor serves as a direct premise for the other.",1b1b68ed-d73c-418f-abed-03484f767103,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Claim 1 states BDNF is essential for CNS development and neuronal plasticity. Claim 2 asserts BDNF contributes to the pathophysiology of various psychiatric and neurodevelopmental disorders. Because impairments in development and neural plasticity can underlie such disorders, Claim 1 provides a mechanistic foundation for Claim 2.",5d2a635d-4bc1-47e6-8418-e59d0ea7c895,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Claim 1 establishes BDNF's key role in CNS development and neuronal plasticity, which provides a mechanistic foundation for Claim 2's assertion that modulation of BDNF is involved in how antidepressants and antipsychotics act in psychiatric disorders.",5d2a635d-4bc1-47e6-8418-e59d0ea7c895,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,duplicate,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.",Both claims assert the same idea that BDNF is essential/vital for brain/CNS development and for neuronal/synaptic plasticity (and neuronal health); they restate the same claim in different words.,5d2a635d-4bc1-47e6-8418-e59d0ea7c895,1e7f51f6-eaca-4408-ae8b-756c1531362e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Claim 1 states a general role for BDNF in CNS development and neuronal plasticity, which provides a conceptual foundation for Claim 2's specific experimental finding that reducing BDNF in the dentate gyrus (but not CA3) impairs neurogenesis and leads to depressive-like behaviors. Claim 2 is a region-specific application/implication of the general principle in Claim 1.",5d2a635d-4bc1-47e6-8418-e59d0ea7c895,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Brain-derived neurotrophic factor (BDNF) is essential for central nervous system development and neuronal plasticity.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern neuroplasticity and neurotrophic signaling: claim 1 states BDNF is essential for CNS development and neuronal plasticity, while claim 2 describes lithium's regulation of multiple pathways (including neurotrophic responses) relevant to neuroplasticity and neuroprotection. They address the same topic but focus on different entities and do not duplicate, entail, or contradict each other.",5d2a635d-4bc1-47e6-8418-e59d0ea7c895,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Both claims concern BDNF and psychiatric disorders but make different, non-contradictory points: claim 1 asserts BDNF's role in disease pathophysiology across several disorders, while claim 2 states BDNF is involved in how antidepressants and antipsychotics work. They are related but not equivalent or logically entailed.",f1026128-41d0-42c3-903f-91b85f829d75,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Claim 2 asserts that BDNF is essential for normal brain development, synaptic plasticity, and neuronal health; this provides a mechanistic foundation for Claim 1's assertion that BDNF dysfunction contributes to the pathophysiology of psychiatric and neurodevelopmental disorders. Therefore Claim 2 is a premise for Claim 1.",1e7f51f6-eaca-4408-ae8b-756c1531362e,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims concern neurobiological mechanisms relevant to psychiatric disorders (including major depressive disorder) but make different, non-contradictory points: Claim 1 states BDNF is implicated in various disorders, while Claim 2 describes proposed mechanisms for ketamine's antidepressant action (synaptogenesis in PFC pyramidal neurons and enhanced serotonergic output). Neither claim duplicates or logically entails the other.",f1026128-41d0-42c3-903f-91b85f829d75,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.",MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern major depressive disorder but focus on different molecular actors: Claim 1 implicates BDNF broadly in psychiatric/neurodevelopmental disorders including MDD, while Claim 2 implicates miR-135 in genes tied to antidepressant actions and MDD. They relate to the same topic without duplicating, contradicting, or providing a clear premise relationship.",f1026128-41d0-42c3-903f-91b85f829d75,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.",Claim 2 provides a specific experimental finding (BDNF reduction in the dentate gyrus causes decreased neurogenesis and depressive-like behaviors) that constitutes mechanistic evidence supporting the broader Claim 1 that BDNF plays a crucial role in the pathophysiology of psychiatric disorders including major depressive disorder.,1a636000-95d9-4c4f-8a2d-e203b07f0ad5,f1026128-41d0-42c3-903f-91b85f829d75
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims concern depression and neurobiology but address different aspects: claim 1 states BDNF’s broad role in the pathophysiology of psychiatric disorders (including major depressive disorder), while claim 2 describes a specific therapeutic delivery approach (SSRI-conjugated siRNAs to serotonergic neurons) producing antidepressant-like effects. They are related topicaly but neither duplicates, contradicts, nor directly premises the other.",f1026128-41d0-42c3-903f-91b85f829d75,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern neuroplasticity/neurotrophic mechanisms in brain disorders: Claim 1 highlights BDNF's role in psychiatric and neurodevelopmental disorders, while Claim 2 describes lithium's regulation of pathways (including neurotrophic responses) relevant to neuroplasticity and neuroprotection. They are related and address the same topic but make different, non-identical points (neither is a direct premise of the other nor do they contradict).",f1026128-41d0-42c3-903f-91b85f829d75,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF plays a crucial role in the pathophysiology of psychiatric and neurodevelopmental disorders including major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, addiction, Rett syndrome, and eating disorders.","Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern molecular mechanisms implicated in psychiatric and neurodevelopmental disorders, but they describe different factors: Claim 1 highlights BDNF's role, while Claim 2 focuses on lithium's actions via GSK3 and IMPase. They address related topics without entailing or contradicting one another.",f1026128-41d0-42c3-903f-91b85f829d75,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.","Both claims concern the role of BDNF but focus on different aspects: claim 2 states BDNF's fundamental roles in brain development and synaptic plasticity, while claim 1 asserts BDNF is involved in the mechanisms of psychiatric drugs. They are related and complementary but neither duplicates nor logically entails the other.",e637a57c-7d6e-4115-9772-d33043296384,1e7f51f6-eaca-4408-ae8b-756c1531362e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Both claims concern mechanisms of antidepressant action but focus on different aspects. Claim 1 states a general role for BDNF in antidepressant/antipsychotic mechanisms. Claim 2 gives a specific mechanism for ketamine (HNK → AMPA activation and mTOR signaling rather than NMDA antagonism). The claims are not contradictory and Claim 2 does not directly follow from Claim 1, though they can be complementary (mTOR/AMPA pathways can interact with BDNF signaling).",e637a57c-7d6e-4115-9772-d33043296384,7f20b8cb-7031-4eda-94a6-62bf085ad3a4
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Both claims address mechanisms of antidepressant action but at different specificity and with different factors: claim 1 asserts a general role for BDNF in antidepressant/antipsychotic mechanisms, while claim 2 specifies ketamine acts via increased synaptogenesis in prefrontal pyramidal neurons and enhanced descending serotonergic transmission. They are related but not equivalent, and do not contradict or serve as direct premises for one another.",e637a57c-7d6e-4115-9772-d33043296384,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both claims concern molecular factors implicated in antidepressant mechanisms, but they refer to different specific entities (BDNF vs miR-135). They are related in topic without being duplicates, direct contradictions, or a clear premise–conclusion relationship.",e637a57c-7d6e-4115-9772-d33043296384,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,"Both statements concern mechanisms of antidepressant action, but they address different aspects: claim 1 makes a broad claim about BDNF involvement in antidepressant/antipsychotic mechanisms, while claim 2 describes a specific intranasal sertraline-conjugated siRNA intervention targeting 5-HT1A and SERT that alters antidepressant markers faster than fluoxetine. They are related by topic but do not duplicate, contradict, or serve as direct premises for one another.",e637a57c-7d6e-4115-9772-d33043296384,54c4e069-99aa-4b45-9a6b-a1c75b1af627
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern molecular mechanisms of antidepressant effects but posit different specific mediators: Claim 1 names BDNF broadly for antidepressants and antipsychotics, while Claim 2 identifies Homer1a expression in mPFC as a final common pathway for certain antidepressant treatments. They are related and compatible but not equivalent or logically dependent.",e637a57c-7d6e-4115-9772-d33043296384,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.",BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Claim 2 provides experimental, region-specific evidence that reducing BDNF causes decreased neurogenesis and depressive-like behaviors, which supports the broader claim (Claim 1) that BDNF modulation is relevant to psychiatric treatment mechanisms. It is supportive evidence (a premise) for the idea that antidepressants/antipsychotics may act via BDNF, though it does not by itself prove the drugs’ mechanism.",1a636000-95d9-4c4f-8a2d-e203b07f0ad5,e637a57c-7d6e-4115-9772-d33043296384
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern mechanisms of antidepressant action but address different, non‑equivalent points. Claim 1 states that BDNF is involved in mechanisms of antidepressants/antipsychotics broadly; Claim 2 describes ketamine as a paradigm shift showing that rapid, non‑monoaminergic antidepressants can be developed and may be more efficacious. They are related and potentially complementary (ketamine’s effects have been linked to BDNF signaling), but neither duplicates, directly contradicts, nor serves as a clear logical premise for the other.",e637a57c-7d6e-4115-9772-d33043296384,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims concern treatments for depression/psychiatric disorders but make different, nonconflicting points: Claim 1 states BDNF is involved in mechanisms of antidepressants/antipsychotics; Claim 2 describes a specific SSRI-conjugated siRNA intranasal delivery approach that produces rapid antidepressant-like effects and addresses RNAi delivery—it does not assert or contradict the role of BDNF nor serve as a direct premise for Claim 1.",e637a57c-7d6e-4115-9772-d33043296384,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",Both claims address neuroplasticity/neurotrophic mechanisms in psychiatric treatment but focus on different specifics. Claim 1 highlights BDNF's role in antidepressant and antipsychotic mechanisms; Claim 2 describes lithium's regulation of multiple cellular pathways important for neuroplasticity (including the neurotrophic response). They are consistent and related but not equivalent or a direct premise/conclusion of one another.,e637a57c-7d6e-4115-9772-d33043296384,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,BDNF is involved in the mechanism of action of antidepressants and antipsychotics used to treat psychiatric disorders.,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Both claims concern molecular mechanisms of psychiatric drug effects but refer to different drugs and targets: Claim 1 implicates BDNF in antidepressant/antipsychotic action, while Claim 2 attributes lithium's effects to GSK3 and IMPase inhibition. They are related topical variants rather than duplicates, contradictions, or premises of one another.",e637a57c-7d6e-4115-9772-d33043296384,bc544bb8-5c5d-4d1e-9c34-b51e2f339464
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.",Claim 2 provides a specific experimental finding (that reducing BDNF in the dentate gyrus decreases neurogenesis and leads to depressive-like behaviors) which supports the general claim in Claim 1 that BDNF is vital for normal brain function. The statements are consistent; Claim 2 is a specific piece of evidence for Claim 1.,1a636000-95d9-4c4f-8a2d-e203b07f0ad5,1e7f51f6-eaca-4408-ae8b-756c1531362e
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF is a vital component to normal brain function due to its critical role in brain development, synaptic plasticity, and neuronal cell health.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern mechanisms of neuroplasticity/neuroprotection: Claim 1 states BDNF is essential for brain development and synaptic plasticity, while Claim 2 describes lithium's regulatory effects on multiple pathways (including neurotrophic response) that support neuroplasticity. They are related but not equivalent, contradictory, or a direct premise-conclusion pair.",1e7f51f6-eaca-4408-ae8b-756c1531362e,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.",Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Claim 1 describes upstream molecular mechanisms (HNK-driven AMPA receptor activation and mTOR signaling) that are known to promote protein synthesis and synaptogenesis; this provides a mechanistic basis for Claim 2's downstream observations of increased synaptogenesis in prefrontal pyramidal neurons and could contribute to enhanced descending serotonergic neurotransmission. The claims are complementary, not contradictory.",7f20b8cb-7031-4eda-94a6-62bf085ad3a4,574de708-d2c9-4a84-a3ab-666c829c2ca0
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims address mechanisms underlying ketamine's antidepressant effects but propose different (non-identical) molecular mediators. Claim 1 emphasizes HNK-driven AMPA receptor activation and mTOR signaling; Claim 2 proposes Homer1a expression in mPFC as a final common pathway for multiple treatments including ketamine. These are compatible or complementary hypotheses rather than duplicates or direct contradictions (Homer1a could be downstream, parallel, or independent), so the relationship is 'variant'.",7f20b8cb-7031-4eda-94a6-62bf085ad3a4,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.",Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Claim 1 provides a specific non‑monoaminergic mechanism (HNK-mediated AMPA activation and mTOR signaling) for ketamine's rapid antidepressant effects. That mechanistic evidence supports Claim 2's broader claim that ketamine demonstrates the feasibility of developing rapid-acting, non-monoaminergic antidepressants more efficacious than monoamine reuptake blockers.",7f20b8cb-7031-4eda-94a6-62bf085ad3a4,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Ketamine's antidepressant properties result from activation of AMPA receptors by its metabolite hydroxynorketamine (HNK) and mTOR signaling, rather than NMDA receptor antagonism alone.","SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims concern antidepressant interventions/mechanisms but describe entirely different approaches: Claim 1 attributes ketamine's effects to HNK-activated AMPA receptors and mTOR signaling, while Claim 2 proposes intranasal SSRI-conjugated siRNAs targeting serotonergic neurons for RNAi delivery. They address the same general topic (antidepressant strategies) without entailing or contradicting each other.",7f20b8cb-7031-4eda-94a6-62bf085ad3a4,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Both statements relate to antidepressant mechanisms but address different elements: Claim 1 describes ketamine's synaptogenic and serotonergic mechanisms, while Claim 2 concerns miR-135 regulating genes linked to antidepressant actions and association with MDD. They overlap thematically but do not duplicate, contradict, or serve as direct premises for one another.",574de708-d2c9-4a84-a3ab-666c829c2ca0,d3692f18-f6e0-43f6-8900-8c465cb99821
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,"Both claims concern antidepressant effects and involve serotonergic modulation, but they describe different interventions and mechanisms (ketamine-induced synaptogenesis and descending serotonergic enhancement vs intranasal sertraline-conjugated siRNAs targeting 5-HT1A and SERT) and do not duplicate, contradict, or serve as a direct premise for one another.",574de708-d2c9-4a84-a3ab-666c829c2ca0,54c4e069-99aa-4b45-9a6b-a1c75b1af627
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims address mechanisms that reduce depressive-like behavior (antidepressant effects) but describe different interventions, brain regions, and molecular targets (ketamine acting via PFC synaptogenesis and descending serotonergic inputs vs. prodynorphin knockdown in nucleus accumbens). They do not duplicate, contradict, or serve as premises for one another.",574de708-d2c9-4a84-a3ab-666c829c2ca0,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims address mechanisms of antidepressant action (including ketamine) in the medial/prefrontal cortex but propose different, non-conflicting mechanisms. Claim 1 emphasizes synaptogenesis in PFC pyramidal neurons and enhanced serotonergic descending input to the raphe, while Claim 2 identifies Homer1a expression in mPFC as a common downstream mediator for several treatments. They are related and potentially complementary but not duplicates, contradictions, or clear logical premises for one another.",574de708-d2c9-4a84-a3ab-666c829c2ca0,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern neurobiological mechanisms relevant to depression, but they describe different, non-overlapping mechanisms and brain regions: Claim 1 attributes ketamine's antidepressant effects to increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic drive to the raphe, while Claim 2 implicates dentate gyrus-specific BDNF reduction leading to decreased neurogenesis and depressive-like behavior. They do not duplicate, contradict, or serve as direct premises for one another.",574de708-d2c9-4a84-a3ab-666c829c2ca0,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Claim 1 gives a specific mechanistic explanation for ketamine's antidepressant effects (non-monoaminergic synaptogenesis in PFC, with downstream serotonergic modulation), which provides empirical/theoretical support for Claim 2's broader assertion that ketamine exemplifies development of rapid-acting, non-monoaminergic antidepressants that can outperform monoamine reuptake blockers.",574de708-d2c9-4a84-a3ab-666c829c2ca0,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Claim 1 provides mechanistic support that enhancing serotonergic neurotransmission contributes to antidepressant effects (in the context of ketamine). That mechanistic point makes the approach in Claim 2—directly targeting serotonergic neurons—to elicit antidepressant-like effects more plausible. However, Claim 1 does not by itself validate the specific delivery method, siRNA strategy, or the claimed rapidity/robustness of effects in Claim 2.",574de708-d2c9-4a84-a3ab-666c829c2ca0,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Ketamine's antidepressant effects are mediated through increased synaptogenesis in prefrontal cortical pyramidal neurons and enhanced serotonergic neurotransmission via descending inputs to the raphe nuclei.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern how psychotropic drugs influence neuroplasticity/neuroprotection in the brain, but they focus on different drugs and distinct mechanisms: ketamine via synaptogenesis in PFC pyramidal neurons and enhanced descending serotonergic transmission, versus lithium acting on intracellular pathways (neurotrophic signaling, ER stress/UPR, autophagy, mitochondrial function, inflammation). They are thematically related but not duplicates, contradictions, or premises for one another.",574de708-d2c9-4a84-a3ab-666c829c2ca0,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,"Both claims concern molecular interventions related to antidepressant mechanisms, but they refer to different agents and targets (miR-135 targeting genes associated with MDD versus sertraline-conjugated siRNAs targeting 5-HT1A and SERT) and do not duplicate, contradict, or serve as direct logical premises for one another.",d3692f18-f6e0-43f6-8900-8c465cb99821,54c4e069-99aa-4b45-9a6b-a1c75b1af627
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern molecular mechanisms underlying antidepressant effects, but they refer to different specific molecules/pathways (miR-135 versus Homer1a in mPFC). They are related in topic but do not duplicate, imply, or contradict each other.",d3692f18-f6e0-43f6-8900-8c465cb99821,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims concern RNA-based mechanisms/therapies related to depression, but they address different specific topics: Claim 1 reports a role for miR-135 in antidepressant actions and association with major depressive disorder, while Claim 2 describes an SSRI-conjugated siRNA delivery method to serotonergic neurons producing antidepressant-like effects. They do not duplicate each other, do not contradict, and neither claim serves as a direct logical premise for the other.",d3692f18-f6e0-43f6-8900-8c465cb99821,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,MicroRNA-135 (miR-135) targets genes involved in antidepressant actions and is associated with major depressive disorder.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern molecular mechanisms relevant to antidepressant effects and neuroplasticity, but they address different specific entities and mechanisms (miR-135 and its gene targets vs. lithium's regulation of broad cellular pathways). They do not duplicate, contradict, or serve as direct premises for one another.",d3692f18-f6e0-43f6-8900-8c465cb99821,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Both claims concern interventions that produce antidepressant-related effects in preclinical models, but they describe different targets and methods (intranasal sertraline-conjugated siRNAs targeting 5-HT1A/SERT vs. prodynorphin knockdown in nucleus accumbens) and do not duplicate, contradict, or serve as premises for one another.",54c4e069-99aa-4b45-9a6b-a1c75b1af627,e4e083c6-321d-43d1-a9e2-8cde729e53f8
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern rapid-acting antidepressant effects versus traditional SSRIs, but they describe different approaches and emphases. Claim 2 is a broad claim about ketamine establishing that non-monoaminergic, rapid-acting antidepressants can be developed; Claim 1 reports a specific intranasal, sertraline-conjugated siRNA approach targeting 5-HT1A and SERT that yields faster biomarker changes than fluoxetine. They relate to the same topic but are different, non-contradictory claims (neither is a direct premise for the other).",54c4e069-99aa-4b45-9a6b-a1c75b1af627,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Intranasal application of sertraline-conjugated siRNAs targeting 5-HT1A receptors and SERT produces faster changes in antidepressant markers than traditional SSRI treatment with fluoxetine.,"SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Claim 1 reports a specific experimental result — intranasal sertraline-conjugated siRNAs targeting 5-HT1A and SERT produce faster changes in antidepressant markers than fluoxetine — which directly supports the general assertion in Claim 2 that intranasal SSRI-conjugated siRNAs can elicit rapid, robust antidepressant-like effects and overcome delivery/targeting challenges. Claim 2 is a broader claim about efficacy and solution to delivery issues; Claim 1 provides concrete supporting evidence rather than repeating or contradicting it.",54c4e069-99aa-4b45-9a6b-a1c75b1af627,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Both claims concern molecular mechanisms underlying antidepressant-like effects in rodents, but they involve different genes (prodynorphin vs Homer1a), different brain regions (nucleus accumbens vs medial prefrontal cortex), and different manipulations; they are related in topic but neither duplicates, entails, nor contradicts the other.",e4e083c6-321d-43d1-a9e2-8cde729e53f8,c22169ca-25d4-454c-83d7-dc34195e21f6
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Both claims concern neural manipulations that alter depressive-like behavior, but they involve different molecules (prodynorphin vs BDNF), different brain regions (nucleus accumbens vs dentate gyrus/hippocampus), and report different directions/effects. They are related by topic but are not duplicates, contradictions, or premises for one another.",e4e083c6-321d-43d1-a9e2-8cde729e53f8,1a636000-95d9-4c4f-8a2d-e203b07f0ad5
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern non-monoaminergic approaches to producing antidepressant effects, but they are different in scope and content: Claim 1 is a specific preclinical finding about prodynorphin knockdown in the rat nucleus accumbens reducing depressive-like behavior, while Claim 2 is a broad statement that ketamine exemplifies a paradigm shift toward rapid-acting, non-monoaminergic antidepressants. They are related/topically similar but not duplicates, contradictions, or direct premises of one another.",e4e083c6-321d-43d1-a9e2-8cde729e53f8,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Knockdown of prodynorphin in the rat nucleus accumbens reduces depressive-like behavior without affecting anxiety-like behavior.,"SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims concern producing antidepressant-like effects via genetic knockdown/RNAi approaches in preclinical models, but they describe different targets and methods: claim 1 reports prodynorphin knockdown in the nucleus accumbens, while claim 2 proposes SSRI-conjugated siRNA delivery to serotonergic neurons intranasally to solve delivery/targeting. They are related but not the same and do not contradict.",e4e083c6-321d-43d1-a9e2-8cde729e53f8,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.",Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"Both claims concern antidepressant mechanisms and mention ketamine, but they make different, non-contradictory points. Claim 1 proposes Homer1a expression in medial PFC as a shared molecular mediator of several treatments (including ketamine). Claim 2 makes a broader claim about ketamine’s impact on antidepressant drug development and non-monoaminergic rapid-acting therapies. They are related but not duplicates, premises, or contradictions.",c22169ca-25d4-454c-83d7-dc34195e21f6,0ff4b45b-d46b-405d-8744-56b371122414
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims concern interventions that produce antidepressant-like effects, but they describe different mechanisms and approaches: claim 1 posits Homer1a expression in mPFC as a common downstream pathway for several treatments, while claim 2 describes an intranasal SSRI-conjugated siRNA delivery targeting serotonergic neurons to elicit rapid effects. They do not duplicate, contradict, or provide a clear logical premise for one another.",c22169ca-25d4-454c-83d7-dc34195e21f6,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Homer1a expression in the medial prefrontal cortex represents a final common pathway mediating the antidepressant effects of various treatments including sleep deprivation, imipramine, and ketamine.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims address molecular mechanisms underlying treatments' effects on brain function (antidepressant/neuroplasticity), but they focus on different agents and pathways: Claim 1 implicates Homer1a in the mPFC as a common pathway for several antidepressant treatments, whereas Claim 2 describes lithium's regulation of diverse cellular pathways (neurotrophic responses, ER stress/UPR, autophagy, oxidative stress, mitochondria, inflammation). They are related in topic but not duplicate, contradictory, or a premise of one another.",c22169ca-25d4-454c-83d7-dc34195e21f6,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"BDNF reduction specifically in the dentate gyrus, but not the CA3 subfield of the hippocampus, decreases neurogenesis and causes depressive-like behaviors.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Both claims concern neuroplasticity/neurotrophic mechanisms in the brain, but they make different, noncontradictory points. Claim 1 is a specific causal finding about BDNF reduction in the dentate gyrus (not CA3) reducing neurogenesis and producing depressive-like behavior; Claim 2 states that lithium broadly regulates multiple pathways (including neurotrophic responses) relevant to neuroplasticity and neuroprotection. They overlap in topic but do not restate, contradict, or serve as direct premises for one another.",1a636000-95d9-4c4f-8a2d-e203b07f0ad5,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,Ketamine represents a paradigm shift in antidepressant drug development by demonstrating that rapid-acting antidepressants more efficacious than monoamine reuptake blockers can be developed through non-monoaminergic mechanisms.,"SSRI-conjugated siRNAs delivered intranasally to serotonergic neurons can elicit rapid and robust antidepressant-like effects, solving the delivery and targeting challenges of RNA interference strategies for depression treatment.","Both claims concern development of rapid-acting antidepressants but propose different mechanisms/approaches. Claim 1 highlights a ketamine-driven, non-monoaminergic paradigm, while Claim 2 proposes a monoaminergic-targeted (serotonergic) siRNA delivery method; they address the same goal without directly contradicting or one being a premise for the other.",0ff4b45b-d46b-405d-8744-56b371122414,7edf49c1-fbb0-4c33-9108-69565003a47c
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.","Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Claim 2 offers a mechanistic explanation (inhibition of GSK3 and IMPase) that could underlie the diverse intracellular regulatory effects listed in Claim 1. Thus Claim 2 functions as a supporting premise for Claim 1 (not contradictory), albeit presented as a proposed mechanism.",bc544bb8-5c5d-4d1e-9c34-b51e2f339464,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Claim 1 states lithium modulates multiple neuroprotective pathways, explicitly including autophagy. That supports Claim 2's focus on autophagy as a mechanism, but Claim 1 does not establish that autophagy is the primary mechanism, so it functions as a supporting premise for Claim 2 rather than a duplicate or direct entailment.",0ccc686b-5be5-4aa5-9360-6c97d148920d,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,"Lithium exerts regulatory effects on diverse cellular pathways within the brain that are crucial for neuroplasticity and neuroprotection, including neurotrophic response, ER stress, UPR, autophagy, oxidative stress, mitochondrial function, and inflammation.","Claim 1 asserts lithium regulates multiple pathways including autophagy. Claim 2 provides a specific mechanism for lithium's autophagy-enhancing effect (an mTOR-independent, IP3-mediated pathway). Thus Claim 2 serves as a mechanistic premise supporting the autophagy component of Claim 1.",88027d82-ef95-4b58-ad6b-ef7f74e5cb4d,0ccc686b-5be5-4aa5-9360-6c97d148920d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,variant,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.",The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Both claims concern molecular mechanisms for lithium's neuroprotective effects but propose different primary explanations: Claim 1 cites inhibition of GSK3 and IMPase as the key effects, while Claim 2 asserts promotion of autophagy is the primary mechanism. These hypotheses are related and could be compatible (IMPase inhibition can induce autophagy), but they are not equivalent or directly supporting one another as stated, so they are variants rather than duplicates, contradictions, or a clear premise relationship.",bc544bb8-5c5d-4d1e-9c34-b51e2f339464,49494958-ed3e-4d55-9ca1-fb94f2be3929
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,"Lithium's wide range of intracellular responses may be secondary to two key effects: inhibition of GSK3 and IMPase, dysregulation of which has been implicated in diverse neuropathological conditions.",Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,Claim 1 identifies inhibition of IMPase (and GSK3) as a key effect of lithium; IMPase inhibition reduces inositol/IP3 signaling. Claim 2 states lithium enhances autophagy via an mTOR-independent pathway involving IP3. Thus Claim 1 provides a mechanistic premise (IMPase → altered IP3 signaling) that supports Claim 2.,bc544bb8-5c5d-4d1e-9c34-b51e2f339464,88027d82-ef95-4b58-ad6b-ef7f74e5cb4d
pairwise,b0b8ed2c-bcb1-4fd8-bb37-471becf9d253,premise,Lithium's signaling pathway as an autophagy enhancer operates through an mTOR-independent pathway involving IP3 signaling.,The promotion of autophagy is the primary molecular mechanism explaining lithium's protective effects in neurodegenerative diseases.,"Claim 2 specifies a mechanism by which lithium enhances autophagy (an mTOR-independent, IP3-related pathway). That mechanistic detail supports Claim 1's assertion that promotion of autophagy is the primary molecular basis for lithium's neuroprotective effects; Claim 2 does not contradict Claim 1 nor claim primacy itself, so it functions as a premise for Claim 1.",88027d82-ef95-4b58-ad6b-ef7f74e5cb4d,49494958-ed3e-4d55-9ca1-fb94f2be3929
